fluorouracil has been researched along with Nausea in 367 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Nausea: An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk." | 9.41 | Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. ( Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF, 2021) |
| "To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen)." | 9.34 | A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham ( Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020) |
| "Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis." | 9.27 | Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018) |
| "The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy." | 9.20 | A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. ( Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ, 2015) |
| "The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen." | 9.20 | Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015) |
| "The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma." | 9.19 | Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. ( Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 9.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients." | 9.17 | One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. ( Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB, 2013) |
| "The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment." | 9.17 | A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. ( Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K, 2013) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 9.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 9.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 9.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 9.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 9.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted." | 9.11 | A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 9.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 9.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 9.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| "The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer." | 9.09 | [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 9.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 9.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 9.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas." | 9.08 | [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 9.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 9.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 9.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 9.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer." | 9.08 | [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. ( Fujishima, H; Hisano, C; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Okuma, K, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 9.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan." | 9.08 | [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 9.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC)." | 9.07 | A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. ( Bauernhofer, T; Derstvenscheg, E; Kuss, I; Moser, R; Ploner, F; Samonigg, H; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 9.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 9.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 9.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| " 97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study (76 had previously received an adjuvant treatment); tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration." | 9.07 | Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer. ( Bastit, P; Bonneterre, J; Cappelaere, P; Chevrier, A; Fargeot, P; Geyer, G; Kerbrat, P; Metz, R; Roche, H; Tubiana-Hulin, M, 1991) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 9.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 9.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 9.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 9.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 9.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 9.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 9.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "To determine the incidence of anticipatory vomiting (AV) and postchemotherapy nausea and vomiting (PCNV) in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma, we studied 52 women randomized to two regimens (standard-dose and low-dose) of CMF." | 9.05 | Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. ( Abeloff, MD; Fetting, JH; Nettesheim, KM; Wilcox, PM, 1982) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 9.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide." | 9.04 | Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 8.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 8.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| "Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients." | 8.80 | Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 8.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| " We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations." | 7.91 | Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. ( Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019) |
| "The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF)." | 7.85 | [Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF]. ( Asoda, S; Iwabuchi, H; Kasazaki, S; Shiiba, Y; Suga, K; Uchiyama, K; Uehara, K; Yamada, M, 2017) |
| "Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin." | 7.80 | Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy. ( Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N, 2014) |
| "To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer." | 7.79 | Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer. ( Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E, 2013) |
| "Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)." | 7.79 | Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013) |
| " In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer." | 7.78 | [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012) |
| "We retrospectively analyzed the efficacy and safety of aprepitant in breast cancer patients who were treated with FEC(5- fluorouracil, epirubicin, cyclophosphamide)or EC(epirubicin, cyclophosphamide)." | 7.77 | [Efficacy and safety of aprepitant in patients with breast cancer]. ( Aogi, K; Eguchi, H; Hara, F; Kiyoto, S; Matsuhisa, T; Osumi, S; Oze, I; Tagashira, H; Takabatake, D; Takahashi, M; Takashima, S, 2011) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 7.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 7.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 7.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 7.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 7.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 7.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated." | 7.69 | [Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation]. ( Hatano, Y; Kato, N; Okuyama, N; Park, Y; Sasamoto, S; Yamazaki, S, 1997) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 7.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 7.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 7.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 7.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 7.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 7.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 7.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer." | 7.66 | Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 6.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 6.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation." | 6.73 | [Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007) |
| "3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0." | 6.71 | [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | 6.68 | Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997) |
| " From the above results, THP in combination with cyclophosphamide and 5-Fluorouracil is comparable to ADR in efficacy and can be regarded as having better safety than ADR for the treatment of breast cancer." | 6.66 | [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer]. ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tanaka, T; Tominaga, T, 1986) |
| "To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings." | 6.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects." | 5.62 | NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021) |
| "To evaluate whether adding aprepitant to palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI (fluorouracil, leucovorin, and irinotecan) or FOLFOX (fluorouracil, leucovorin, and oxaliplatin) chemotherapy regimens among women with gastrointestinal cancer at higher risk." | 5.41 | Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial. ( Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF, 2021) |
| "Irinotecan, a topoisomerase inhibitor, is a common cytotoxic agent prescribed for metastatic colorectal cancer (mCRC) patients." | 5.41 | A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab. ( Chang, TK; Chen, PJ; Chen, YC; Cheng, TL; Chuang, KH; Huang, CW; Li, CC; Ma, CJ; Su, WC; Tsai, HL; Wang, JY; Yin, TC, 2021) |
| "Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen." | 5.36 | [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010) |
| "Biweekly schedule of XELOX-2 (capecitabine plus oxaliplatin) showed interesting results in first-line therapy of patients with metastatic colorectal cancer (mCRC)." | 5.34 | Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802). ( Aieta, M; Bordonaro, R; Cinieri, S; Colucci, G; Cordio, S; Di Maggio, G; Di Maio, M; Febbraro, A; Giuliani, F; Latiano, TP; Maiello, E; Pisconti, S; Rinaldi, A; Rizzi, D; Rossi, A, 2020) |
| "To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen)." | 5.34 | A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham ( Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K, 2020) |
| "Chemotherapy-induced nausea and vomiting (CINV) causes significant morbidity among colorectal cancer patients, receiving fluorouracil, oxaliplatin, and leucovorin (FOLFOX) chemotherapy even with standard antiemetic prophylaxis." | 5.27 | Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer. ( Blanke, C; Bubalo, JS; Chen, E; Edwards, MS; Fisher, A; Herrington, JD; Lopez, CD; Palumbo, A; Takemoto, M; Williams, C; Willman, P, 2018) |
| "Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy." | 5.27 | [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 5.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| "The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer." | 5.22 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016) |
| "The granisetron transdermal system (GTS) showed non-inferior efficacy to oral granisetron to control chemotherapy-induced nausea and vomiting (CINV) during multiday chemotherapy." | 5.20 | A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. ( Ahn, JS; Hong, YS; Kim, JE; Kim, KP; Kim, TW; Lee, J; Lee, JL; Park, SJ; Park, YS; Shin, DB; Sym, SJ, 2015) |
| "The aprepitant therapy was more effective than the control therapy for prevention of CINV in colorectal cancer patients receiving an oxaliplatin-based regimen." | 5.20 | Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. ( Doki, Y; Fukunaga, M; Fukuzaki, T; Hata, T; Ide, Y; Kudo, T; Miyake, Y; Mizushima, T; Mori, M; Morita, S; Nakata, K; Nezu, R; Nishimura, J; Ohno, Y; Sakai, D; Satoh, T; Sekimoto, M; Takemasa, I; Takemoto, H; Uemura, M; Yamamoto, H; Yasui, M, 2015) |
| "The present study aimed to evaluate efficacy and adverse effects of Nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in the treatment of advanced oral carcinoma." | 5.19 | Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma. ( Gu, QP; Guo, W; Li, ZP; Meng, J; Meng, QF; Si, YM; Zhang, J; Zhuang, QW, 2014) |
| "The purpose of this phase I study was to determine the safety, toxicity, maximum tolerated dose, and pharmacokinetics of capecitabine when administered concurrently with radiotherapy in patients with localised, inoperable pancreatic adenocarcinoma." | 5.19 | A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. ( Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L, 2014) |
| "Adverse events associated with 5-fluorouracil (5FU) based adjuvant therapy in colorectal cancer (CRC) patients may predict survival." | 5.19 | Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity? ( André, T; Bono, P; de Gramont, A; Hermunen, K; Österlund, P; Poussa, T; Quinaux, E; Soveri, LM, 2014) |
| "The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs." | 5.19 | Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014) |
| "We report the long-term results of a randomised trial comparing tamoxifen with tamoxifen plus cyclophosphamide, methotrexate and fluorouracil (CMF) in postmenopausal high-risk breast cancer patients." | 5.17 | One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. ( Andersen, J; Andersson, M; Cold, S; Ejlertsen, B; Elversang, J; Jensen, MB; Mouridsen, HT; Nielsen, DL; Rasmussen, BB, 2013) |
| "The safety and efficacy of neratinib monotherapy were compared with that of lapatinib plus capecitabine in patients with human epidermal growth factor receptor-2-positive (HER2+), locally advanced/metastatic breast cancer and prior trastuzumab treatment." | 5.17 | A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer. ( Awada, A; Bonneterre, J; Germa, C; Geyer, CE; Ito, Y; Kim, SB; Lang, I; Martin, M; Ro, J; Vermette, J; Wang, K, 2013) |
| "For moderately emetogenic chemotherapy, palonosetron (PALO) is reported to provide complete control of chemotherapy-induced nausea and vomiting (CINV) in 69% of patients." | 5.16 | Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study. ( Bekaii-Saab, T; Blazer, M; Efries, D; Griffith, N; Juergens, K; Phillips, G; Reardon, J; Rose, J; Smith, Y; Weatherby, L, 2012) |
| "Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC)." | 5.14 | Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. ( Hlebanja, Z; Ocvirk, J; Rebersek, M; Skof, E, 2009) |
| "A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer." | 5.12 | Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. ( Arun, B; Broglio, K; Buchholz, T; Francis, D; Groves, M; Hortobagyi, GN; Meyers, C; Rivera, E; Valero, V; Yin, G, 2006) |
| "Gastric cancer patients with cytologically confirmed malignant ascites were treated with cycles of oxaliplatin at 85 mg/m(2) plus leucovorin 20 mg/m(2) on the first day of treatment, followed by 5-fluorouracil (5-FU) via a 400 mg/m(2) bolus and a 22 h continuous infusion of 600 mg/m(2) 5-FU on Days 1-2 at 2-week intervals." | 5.12 | A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites. ( Jang, JS; Jeong, JS; Kim, HJ; Kim, MC; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY; Yoo, HS, 2007) |
| "Ninety patients with breast cancer were included; 70 patients received single agent paclitaxel either weekly or every 3 weeks and 20 received FAC (5-FU, doxorubicin, cyclophosphamide) chemotherapy." | 5.11 | Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. ( Arun, B; Booser, D; Bruera, E; Cleeland, CS; Fritsche, HA; Hortobagyi, GN; Ibrahim, N; Lara, J; Martinez, MM; Mendoza, TR; Pusztai, L; Reuben, JM; Rivera, E; Royce, M; Syed, A; Valero, V; Willey, JS, 2004) |
| "The purpose is to determine the plasma pharmacokinetics, the maximum-tolerable dose and to preliminary evaluate the antitumor activity of irinotecan administered as a 7-day continuous infusion every 21 days in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed." | 5.11 | A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed. ( Allegrini, G; Barbara, C; Cupini, S; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Masi, G, 2004) |
| "This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer." | 5.11 | Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004) |
| "Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer." | 5.11 | Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004) |
| "To verify the effectiveness of oral 1-hexylcarbamoyl-5-fluorouracil (HCFU) in improving the surgical cure rate in advanced colorectal cancer, a multicenter randomized comparative study was conducted." | 5.11 | A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer. ( Kodaira, S; Kotake, K; Koyama, Y; Ohashi, Y, 2005) |
| "Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin." | 5.11 | Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005) |
| "To assess the feasibility and activity of a combination schedule with irinotecan (CPT-11), oxaliplatin (L-OHP), brief infusional fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer (MCC) patients." | 5.11 | An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial. ( Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Pasinetti, N; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L, 2005) |
| "To assess the activity and safety of combined folinic acid (FA), 5-fluorouracil (5-FU) and mitomycin C (MMC) in metastatic breast cancer patients previously treated with at least two chemotherapy regimens." | 5.10 | Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens. ( Correale, P; Fiaschi, AI; Francini, G; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M, 2002) |
| "To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)." | 5.10 | Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002) |
| " Chemotherapy naive women with stage I or II breast cancer scheduled to intravenous cyclophosphamide, fluorouracil and methotrexate or cyclophosphamide, epirubicin and fluorouracil every 3 weeks were included." | 5.09 | Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. ( Andersen, LJ; Dombernowsky, P; Havsteen, H; Herrstedt, J; Kjaer, M; Kjaerbøl, AG; Langer, SW; Lund, H; Sigsgaard, T, 1999) |
| "The inhibitory effect of ramosetron hydrochloride (Ram), a 5-HT3 receptor antagonist, on nausea and vomiting occurring in CMF or CEF therapy as a pre- or postoperative adjuvant chemotherapy or chemotherapy for recurrent cancer was evaluated in 34 patients with breast cancer." | 5.09 | [Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer]. ( Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K, 1999) |
| "To compare the response rate, efficacy parameters, and toxicity profile of oral capecitabine with bolus intravenous (IV) fluorouracil plus leucovorin (5-FU/LV) as first-line treatment in patients with metastatic colorectal cancer." | 5.09 | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. ( Ansari, R; Batist, G; Burger, HU; Cox, J; Harrison, E; Hoff, PM; Kocha, W; Kuperminc, M; Maroun, J; Osterwalder, B; Walde, D; Weaver, C; Wong, AO; Wong, R, 2001) |
| "We have reported that an alternating regimen of bolus and continuous infusion 5-fluorouracil (FU) was superior to bolus FU in terms of response rate and progression-free survival in advanced colorectal cancer." | 5.09 | 5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer. ( Aschele, C; Caroti, C; Cirillo, M; Cortesi, E; Frassineti, GL; Gallo, L; Grossi, F; Guglielmi, A; Labianca, R; Pessi, MA; Ravaioli, A; Recaldin, E; Sobrero, A; Testore, P; Turci, D, 2001) |
| "The purpose of this study was to evaluate the activity and safety of oxaliplatin and protracted venous infusion of 5-fluorouracil (PVI 5-FU) in patients with advanced or relapsed 5-FU pretreated colorectal cancer." | 5.09 | Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. ( Chau, I; Cunningham, D; Hill, M; Massey, A; Norman, A; Waters, JS; Webb, A, 2001) |
| "The comparative study among granisetron alone and granisetron combined with hydroxyzine hydrochloride or dexamethasone was undertaken for the prevention of nausea and vomiting during chemotherapy including cisplatin in patients with advanced head and neck carcinomas." | 5.08 | [Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin]. ( Enomoto, H; Furukawa, M; Ikema, Y; Kawai, S; Kohno, H; Kubota, A; Makino, Y; Matsuda, H; Tsukuda, M; Yago, T, 1995) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 5.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 5.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "To determine whether a combination chemotherapy regimen that contains epirubicin (fluorouracil, epirubicin, and cyclophosphamide [FEC]) is superior to the standard cyclophosphamide, methotrexate, and fluorouracil (CMF) combination in premenopausal women with axillary node-positive operable breast cancer." | 5.08 | Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab ( Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM, 1996) |
| "Both the biochemical modulation and the continuous administration of 5-fluorouracil (5-FU) have achieved promising results in patients with gastric carcinoma." | 5.08 | Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group. ( Belón, J; Blanco, E; Espinosa, E; Feliu, J; García-Alfonso, P; García-Girón, C; Garrido, P; Gómez-Navarro, J; González Barón, M; Ordónez, A; Zamora, P, 1996) |
| "A crossover clinical trial between granisetron alone and granisetron combined with methylprednisolone (MPL) was undertaken for the prevention of nausea and vomiting during chemotherapy, including cisplatin, in 12 patients with advanced primary and metastatic lung cancer." | 5.08 | [Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy]. ( Fujishima, H; Hisano, C; Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Okuma, K, 1996) |
| "The aim of this open, nonrandomized, monocentric study was to evaluate the efficacy of a single daily dose of 8 mg oral ondansetron in the prophylaxis of acute nausea and vomiting in chemotherapy-naive breast cancer patients receiving their first cycle of chemotherapy with 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)." | 5.08 | Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting. ( Bosnjak, SM; Jovanovic-Micic, DJ; Mitrovic, LB; Neskovic-Konstantinovic, ZB; Radulovic, SS, 1996) |
| "Azasetron, a selective 5-HT3 receptor antagonist, has been previously shown to be highly effective in the prophylaxis of nausea and vomiting induced by anticancer drugs, and is widely used in the clinical setting in Japan." | 5.08 | [Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP]. ( Kimura, E; Niimi, S; Tanaka, T; Watanabe, A, 1997) |
| " The combination chemotherapy with CDDP and 5-fluorouracil (5-FU), which has great efficacy for head and neck cancer, induces nausea and vomiting as side effects." | 5.08 | [Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer]. ( Fujii, M; Imanishi, Y; Kanke, M; Kanzaki, J; Ohno, Y; Tokumaru, Y, 1997) |
| "Efficacy of combination of ondansetron injection and tablet on CAF (cyclophosphamide, adriamycin, 5-fluorouracil) induced emesis were investigated in 10 breast cancer patients (33 courses)." | 5.08 | [Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients]. ( Furukawa, T; Kurihara, N; Machimura, T; Nemoto, Y; Nishihori, H; Shinohara, H; Urakami, H; Yonekawa, H, 1998) |
| "The antiemetic efficacy of dexamethasone (Dexaven) was examined in patients with breast cancer during chemotherapy CMF (cyclophosphamide, methotrexate and 5-fluorouracil) in comparison with patients treated identically but without dexamethasone." | 5.07 | [Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen]. ( Domaradzka-Woźniak, A; Dziewulska-Bokiniec, A; Wojtacki, J, 1994) |
| "A total of 50 patients were treated weekly with 5-fluorouracil (FU), leucovorin (LV), and 4'-O-tetrahydropyranyl-doxorubicin (THP) as first-line chemotherapy for advanced breast cancer (ABC)." | 5.07 | A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients. ( Bauernhofer, T; Derstvenscheg, E; Kuss, I; Moser, R; Ploner, F; Samonigg, H; Schmid, M; Steindorfer, P; Stöger, H; Wilders-Truschnig, M, 1994) |
| " A sample of 43 patients with breast cancer was accrued from September to November 1992 in a phase II study to assess the efficacy of granisetron in patients receiving FEC (5-FU, epirubicin, cyclophosphamide)." | 5.07 | Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide. ( Ang, PT; Khoo, KS; Tan, EH, 1994) |
| "The combination of cyclophosphamide, methotrexate and 5-fluorouracil (CMF) is a widely used chemotherapy regimen in breast cancer patients." | 5.07 | Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study. ( Aapro, MS; Bauer, J; Brunner, KW; Buser, KS; Cavalli, F; Haefliger, JM; Joss, RA; Jungi, WF; Obrist, R; Piquet, D, 1993) |
| " To address its use with a widely used but less emetogenic regimen, we performed a double-blind, randomized clinical trial comparing ondansetron with dexamethasone and metoclopramide in patients with breast cancer receiving chemotherapy with cyclophosphamide, methotrexate, and fluorouracil." | 5.07 | Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil. ( Latreille, J; Levitt, M; Lofters, WS; Perrault, DJ; Potvin, M; Rayner, HL; Warner, E; Warr, D; Wilson, KS; Yelle, L, 1993) |
| "The antiemetic response and side effects resulting from treatment with methylprednisolone (MPA) given on two different dose schedules were evaluated in 20 women with breast cancer who were undergoing chemotherapy consisting of cyclophosphamide, methotrexate and 5-fluorouracil (CMF)." | 5.07 | Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules. ( Cass, Y; Edelmann, DZ; Gez, E; Strauss, N; Vitzhaki, N, 1992) |
| " 97 female breast cancer patients who received their first two FEC courses (epirubicin 50-75 mg/m2, 5-fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2) entered this randomised crossover study (76 had previously received an adjuvant treatment); tetracosactrin was administered intramuscularly and methylprednisolone intravenously immediately before chemotherapy administration." | 5.07 | Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer. ( Bastit, P; Bonneterre, J; Cappelaere, P; Chevrier, A; Fargeot, P; Geyer, G; Kerbrat, P; Metz, R; Roche, H; Tubiana-Hulin, M, 1991) |
| "The French Epirubicin Study Group carried out a randomized trial comparing epirubicin alone 75 mg/m2 with fluorouracil (5FU) 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 50 mg/m2 (FEC 50) and 5FU 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 75 mg/m2 (FEC 75) as first treatment for advanced breast cancer patients." | 5.07 | A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group. ( , 1991) |
| "Seventy-five breast cancer patients scheduled to receive a first course (in a new cycle) of cyclophosphamide, fluorouracil, and doxorubicin (FAC) or epirubicin (FEC) participated in a double-blind crossover study to compare the antiemetic efficacy and safety of ondansetron (GR38032), a 5-hydroxytryptamine3 (5-HT3) receptor antagonist, and metoclopramide." | 5.06 | A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. ( Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M, 1990) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 5.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "Two hundred sixty-three patients with advanced breast cancer were randomized to two treatment regimens consisting of fluorouracil, 500 mg/m2; cyclophosphamide, 500 mg/m2; and either epirubicin (Farmorubicin, Farmitalia Carlo Erba SpA, Italy), 50 mg/m2 (FEC); or doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH), 50 mg/m2 (FAC), administered intravenously (IV) every 3 weeks." | 5.06 | A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group. ( , 1988) |
| "The antiemetic effectiveness of haloperidol plus dexamethasone was compared with that of prochlorperazine plus dexamethasone in a prospective study of patients receiving chemotherapy for breast cancer." | 5.06 | A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer. ( Carpenter, JT; Conolley, C; Lee, J; Silvey, L; Wheeler, RH, 1988) |
| " CMF were included in a double-blind comparative study aimed at evaluating the efficacy of 3 different drugs (methylprednisolone (MP), metoclopramide (MTC), and domperidone (DMP) in preventing chemotherapy-induced nausea and vomiting." | 5.06 | Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF. ( Ballatori, E; Basurto, C; del Favero, A; Minotti, V; Roila, F; Tonato, M, 1987) |
| "The antiemetic efficacy and toxicity of methylprednisolone (MP) and metoclopramide (MTC) in prevention of nausea and vomiting in breast cancer patients receiving intravenous cyclophosphamide methotrexate 5-fluorouracil (CMF) chemotherapy has been evaluated in a double-blind trial." | 5.06 | Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study. ( Ballatori, E; Basurto, C; Del Favero, A; Minotti, V; Roila, F; Tonato, M, 1988) |
| "Patients with visceral patterns of metastatic breast cancer were stratified according to dominant metastatic site and performance status and then randomized to therapy with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF) or CAF alternating with a "cell-cycle active" regimen including cytosine arabinoside, methotrexate with leucovorin rescue, and oncovin ( CAMELEON )." | 5.05 | Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project. ( Carpenter, J; Fishkin, E; Krauss, S; Moore, MR; Raab, S; Raney, M; Smalley, RV; Stagg, M; Velez-Garcia, E; Vogel, CL, 1984) |
| "One hundred twenty-one patients with advanced measurable adenocarcinoma of the colon were randomized for treatment with intravenous 5-fluorouracil (IV 5-FU) alone, 15 mg/kg/week vs." | 5.05 | Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. ( Bateman, JR; Chlebowski, RT; Kardinal, C; Pajak, T; Silverberg, I; Weiner, J, 1980) |
| "To determine the incidence of anticipatory vomiting (AV) and postchemotherapy nausea and vomiting (PCNV) in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma, we studied 52 women randomized to two regimens (standard-dose and low-dose) of CMF." | 5.05 | Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma. ( Abeloff, MD; Fetting, JH; Nettesheim, KM; Wilcox, PM, 1982) |
| "One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU." | 5.05 | Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. ( Barkin, J; Bateman, J; Brooks, J; Chaffey, J; Childs, DS; Corson, JM; Douglas, HO; Frytak, S; Hahn, RG; Holbrook, MA; Kalser, M; Knowlton, A; Lavin, PT; Lessner, H; Livstone, E; Lokich, J; Mann-Kaplan, R; Moertel, CG; Nave, H; Novak, JW; O'Connell, MJ; Ramming, K; Reitemeier, RJ; Rubin, J; Schutt, AJ; Spiro, H; Thomas, P; Weiland, LH; Zamcheck, N, 1981) |
| "As of August 1984, 115 women with advanced breast cancer have been randomized to receive a combination of either cyclophosphamide, Novantrone (mitoxantrone) and 5-fluorouracil (CNF) or cyclophosphamide, Adriamycin (doxorubicin) and 5-fluorouracil (CAF)." | 5.05 | A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer. ( Bennett, JM; Byrne, P; DeConti, R; Desai, A; Doroshow, J; Krementz, E; Muggia, F; Plotkin, D; Vogel, C; White, C, 1985) |
| "One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide." | 5.04 | Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977) |
| " The incidence of nausea and vomiting in benzquinamide-treated patients was equal to that in placebo-treated patients and significantly higher than that in patients treated with prochlorperazine, 10 mg 3 times daily." | 5.04 | Oral benzquinamide in the treatment of nausea and vomiting. ( Hahn, RG; Moertel, CG; O'Fallon, JR; Schutt, AJ, 1975) |
| "An electronic search was undertaken to identify randomized controlled trials comparing raltitrexed-based regimen to 5-fluorouracil-based regimen in patients with advanced colorectal cancer." | 4.90 | Raltitrexed-based chemotherapy for advanced colorectal cancer. ( Hong, W; Huang, Q; Liu, Y; Sun, X; Wu, J; Wu, W, 2014) |
| "We analyzed individual data on 6,284 patients from nine phase III trials of advanced colorectal cancer (aCRC) that used fluorouracil-based single-agent and combination chemotherapy." | 4.87 | Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials. ( Blanke, CD; Bleyer, A; Bot, BM; de Gramont, A; Goldberg, RM; Kohne, CH; Sargent, DJ; Seymour, MT; Thomas, DM, 2011) |
| " A phase III randomized trial, Xeloda in Adjuvant Colorectal Cancer Treatment, demonstrated that treatment with single-agent capecitabine was equivalent to bolus 5-fluorouracil with leucovorin with respect to disease-free survival and overall survival, with significantly less diarrhea, stomatitis, neutropenia, nausea and vomiting, and alopecia." | 4.83 | Capecitabine: a new adjuvant option for colorectal cancer. ( Berg, DT, 2006) |
| "Fluorouracil (5-FU) continuous infusion is superior to 5-FU bolus in patients with advanced colorectal cancer, but the survival difference between the two treatments is small and, therefore, the difference in toxicity profile is crucial in choosing a treatment for individual patients." | 4.80 | Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. ( Benedetti, J; Brufman, G; Buyse, M; Fryer, J; Hansen, R; Isacson, R; Laplanche, A; Leichman, C; Lévy, E; Lokich, J; Macdonald, J; Pater, J; Piedbois, P; Pignon, JP; Quinaux, E; Rougier, P; Ryan, L; Thirion, P; Weinerman, B; Zee, B, 1998) |
| " This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs." | 4.12 | Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022) |
| "The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma." | 4.02 | Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. ( Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D, 2021) |
| " We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations." | 3.91 | Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. ( Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019) |
| "To evaluate the impact of sex on toxicity and efficacy outcomes among patients with metastatic colorectal cancer receiving first-line 5-fluorouracil-based regimens." | 3.91 | Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. ( Abdel-Rahman, O, 2019) |
| "The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF)." | 3.85 | [Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF]. ( Asoda, S; Iwabuchi, H; Kasazaki, S; Shiiba, Y; Suga, K; Uchiyama, K; Uehara, K; Yamada, M, 2017) |
| "Although efficacy of aprepitant for suppressing emesis associated with single-dose cisplatin has been demonstrated, there are limited data on the antiemetic effect of this oral neurokinin-1 receptor antagonist during daily administration of cisplatin." | 3.80 | Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy. ( Ishimaru, K; Kaneko, K; Katsura, M; Takahashi, H; Takano, A; Yamaguchi, N, 2014) |
| "To evaluate the efficacy of reduction of dexamethasone with a single-dose of palonosetron in preventing acute and delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy (HEC) for early breast cancer." | 3.79 | Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer. ( Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E, 2013) |
| "Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)." | 3.79 | Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013) |
| ", drug-adverse event pairs, found in 1,644,220 AERs from 2004 to 2009, it was suggested that leukopenia, neutropenia, and thrombocytopenia were more frequently accompanied by the use of 5-FU than capecitabine, whereas diarrhea, nausea, vomiting, and hand-foot syndrome were more frequently associated with capecitabine." | 3.78 | Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations. ( Brown, JB; Kadoyama, K; Miki, I; Okuno, Y; Sakaeda, T; Tamura, T, 2012) |
| " In this retrospective study, we assessed the efficacy of palonosetron versus granisetron for the incidence of CINV induced by mFOLFOX6 and FOLFIRI in patients with advanced colorectal cancer." | 3.78 | [Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey]. ( Hayakawa, Y; Muro, K; Noma, H; Okamoto, H; Sato, Y; Tatematsu, M, 2012) |
| " The aim of the present report was to evaluate real-life drug adherence in a prospective cohort analysis of patients with gastrointestinal or breast cancer treated with capecitabine-based chemotherapy." | 3.77 | Self-reported compliance with capecitabine: findings from a prospective cohort analysis. ( Bressoud, A; Delmore, G; Hermann, F; Hoesli, P; Pederiva, S; von Moos, R; Winterhalder, R, 2011) |
| "We retrospectively analyzed the efficacy and safety of aprepitant in breast cancer patients who were treated with FEC(5- fluorouracil, epirubicin, cyclophosphamide)or EC(epirubicin, cyclophosphamide)." | 3.77 | [Efficacy and safety of aprepitant in patients with breast cancer]. ( Aogi, K; Eguchi, H; Hara, F; Kiyoto, S; Matsuhisa, T; Osumi, S; Oze, I; Tagashira, H; Takabatake, D; Takahashi, M; Takashima, S, 2011) |
| "The aim of the study was to evaluate the role of ramosetron for the prevention of chemoradiotherapy-induced nausea and vomiting (CRINV) in patients receiving upper abdominal irradiation with concurrent 5-fluorouracil chemotherapy." | 3.75 | Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer. ( Bang, YJ; Chie, EK; Ha, SW; Im, SA; Jang, JY; Kim, K; Kim, SW; Kim, TY; Oh, DY, 2009) |
| "We encountered a case of peritoneal dissemination of hepatocellular carcinoma, successfully treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil." | 3.74 | Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil. ( Iwasaki, Y; Miyake, Y; Sakaguchi, K; Shiraha, H; Shiratori, Y, 2007) |
| "Short-term infusion of 5-fluorouracil with leucovorin in combination with irinotecan or oxaliplatin has been considered as standard treatment for metastatic colorectal cancer." | 3.74 | Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan. ( Boku, N; Fukutomi, A; Hasuike, N; Hironaka, S; Machida, N; Ono, H; Onozawa, Y; Yamaguchi, Y; Yamazaki, K; Yoshino, T, 2007) |
| " We evaluated the toxicity and efficacy of a Hypofractionated and intensively Accelerated RT regimen supported with amifostine Cytoprotection (HypoARC) in a cohort of 72 high-risk breast cancer patients treated with modified mastectomy or conservative surgery and FEC (5-fluorouracil/epirubicin/cyclophosphamide) chemotherapy." | 3.71 | Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients. ( Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E, 2002) |
| "The incidence of nausea and vomiting was investigated for a maximum of 7 days in 32 breast cancer patients receiving CAF (cyclophosphamide, adriamycin, 5-fluorouracil) and CMF (cyclophosphamide, methotrexate, 5-fluorouracil) therapies." | 3.71 | [Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets]. ( Hayakawa, H; Ishida, T; Kusaba, T, 2002) |
| "The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy." | 3.70 | Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998) |
| "The incidence of nausea and vomiting or anorexia was investigated in 16 outpatients receiving oral antimetabolites such as 5-FU (fluorouracil) as chemotherapy, during a maximum observation period of 28 days." | 3.70 | [Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets]. ( Ishikawa, H; Ohya, M; Sasaki, K; Yanagida, T, 2000) |
| "The antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation was investigated." | 3.69 | [Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation]. ( Hatano, Y; Kato, N; Okuyama, N; Park, Y; Sasamoto, S; Yamazaki, S, 1997) |
| "Multiple studies have shown that leucovorin-fluorouracil regimens are modestly superior to fluorouracil alone in the treatment of advanced colorectal cancer." | 3.69 | Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine. ( DeLap, RJ; Marshall, JL; Richmond, E, 1996) |
| "Seventy-five female patients suffering from advanced breast cancer were treated with toilet mastectomy, radiotherapy and oophorectomy (if premenopausal) or tamoxifen therapy (if postmenopausal) as well as chemotherapy with cyclophosphamide, methotrexate, 5-fluorouracil and prednisone." | 3.68 | Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer. ( Dandapat, MC; Mohapatro, SK; Padhi, NC, 1992) |
| "A total of 60 patients with advanced breast cancer were treated with a combination of prednimustine (P: 110 mg/m2, days 1-5), mitoxantrone (M: 12 mg/m2, day 1) and 5-fluorouracil (F: 500 mg/m2, day 1) (PMF)." | 3.68 | Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer. ( Dusleag, J; Kasparek, AK; Lechner, P; Pfeiffer, K; Samonigg, H; Schmid, M; Smola, M; Steindorfer, P; Stöger, H, 1991) |
| "Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue." | 3.67 | Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. ( Aboud, A; Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Yap, HY, 1984) |
| "Thirty consecutive patients with metastatic breast cancer previously untreated by chemotherapy were given high-dose cyclophosphamide (Cytoxan) and high-dose 5-fluorouracil (5-FU) as first-line therapy." | 3.67 | High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer. ( Aguilera, J; Breau, JL; Israel, L, 1984) |
| "As adverse reactions to the combination treatment by the digestive system, we observed the occurrence of nausea and vomiting in 15% of the cases who received FTP treatment consisting of 5-FU, toyomicin and prednisone, 25% of the cases who received MFU treatment consisting of MMC, 5-FU and ACNU, and in 64% of the cases who received PPQ treatment consisting of CDDP, Carboquone (CQ) and prednisone." | 3.67 | [Adverse reactions to carcinostatics and countermeasures]. ( Nakao, I, 1989) |
| "Thirty patients with advanced breast cancer, not pretreated with chemotherapy, received a polychemotherapy regimen containing mitoxantrone, fluorouracil and cyclophosphamide at the dose of 10 mg/m2, 500 mg/m2 and 500 mg/m2 i." | 3.67 | Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer. ( Canova, N; Ercolino, L; Martoni, A; Pannuti, F; Rani, P, 1988) |
| "Forty-six outpatients with breast cancer who had experienced severe emesis as a result of chemotherapy were evaluated for the antiemetic efficacy of high-dose metoclopramide (HD-MCP) and dexamethasone (DXM)." | 3.67 | High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study. ( Ben-Baruch, N; Ben-Yosef, R; Biran, S; Brufman, G; Gez, E; Uziely, B; Warner-Efraty, E; Yitzhaki, N, 1987) |
| "We employed a structured interview to retrospectively study tastes and vomiting associated with the parenteral components of cyclophosphamide, methotrexate, and 5-FU in 45 patients with stage II-IV breast cancer." | 3.67 | Tastes associated with parenteral chemotherapy for breast cancer. ( Donehower, RC; Enterline, JP; Fetting, JH; Grochow, LB; Sheidler, VR; Wilcox, PM, 1985) |
| "In our wide experience of treating advanced breast carcinoma with chemotherapy, the combination of doxorubicin (DOX), vincristine (VCR), cyclophosphamide (CPM) and fluorouracil (FU) gave a complete plus partial response rate of over 60%, with 100% alopecia and frequent cardiac toxicity depending on total dose." | 3.67 | Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer. ( Armand, JP; Cappelaere, P; Delgado, M; Grimbert, J; Keiling, R; Mathe, G; Metz, R; Misset, JL; Prevot, G, 1985) |
| "A total of 65 patients with advanced colorectal or breast cancer were given oral tegafur in the phase I study." | 3.66 | Phase I-II studies of oral tegafur (ftorafur). ( Ansfield, FJ; Kallas, GJ; Singson, JP, 1983) |
| "Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)." | 3.66 | Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983) |
| "A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer." | 3.66 | Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981) |
| "A group of 47 patients with advanced breast cancer were treated with a combination of prednimustine, methotrexate, 5-FU, and tamoxifen." | 3.66 | Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study. ( Boesen, E; Mouridsen, HT, 1982) |
| "Overall, nausea was reported by 86% (n=129) of the patients during the ten-day period from the start of cancer treatment." | 3.30 | Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39). ( Andersson, BÅ; Åsenlund, U; Elinder, E; Fust, L; Lewin, F; Lewin, N; Nilsson, MP; Oliva, D; Schildt, EB; Sellerstam, G; Shamoun, L; Sharp, L, 2023) |
| " The studies demonstrated a significant benefit from the triplet at the price of an increased incidence of chemotherapy-related adverse events (AEs)." | 2.90 | Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies. ( Allegrini, G; Aprile, G; Bergamo, F; Boccaccino, A; Boni, L; Borelli, B; Buonadonna, A; Cordio, S; Cremolini, C; Dell'Aquila, E; Falcone, A; Latiano, TP; Libertini, M; Lonardi, S; Marmorino, F; Masi, G; Moretto, R; Passardi, A; Pella, N; Randon, G; Ratti, M; Ricci, V; Ronzoni, M; Rossini, D; Tamburini, E; Urbano, F; Zucchelli, G, 2019) |
| " Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284)." | 2.90 | Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP). ( Aparicio, J; Bordonaro, R; Bury, D; Chau, I; Cicin, I; Di Bartolomeo, M; Drea, E; Fedyanin, MY; García-Alfonso, P; Heinemann, V; Karthaus, M; Kavan, P; Ko, YJ; Maiello, E; Martos, CF; Peeters, M; Picard, P; Riechelmann, RP; Sobrero, A; Srimuninnimit, V; Ter-Ovanesov, M; Yalcin, S, 2019) |
| "vomiting, anorexia and infection) were recorded, and short-term effect of chemotherapy was evaluated regularly." | 2.84 | Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms. ( Deng, B; Jia, L; Li, X; Li, Y; Lou, Y; Tan, H; Yu, L, 2017) |
| "In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma." | 2.82 | A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016) |
| "7% of patients experienced grade 3 and 4 adverse events, respectively." | 2.80 | Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. ( Campone, M; Citron, ML; Dang, CT; Dirix, L; Gianni, L; Krop, IE; Romieu, G; Smitt, M; Suter, TM; Xu, N; Zamagni, C, 2015) |
| "Patients with advanced solid tumors received oral BKM120 daily combined with standard doses of mFOLFOX6 every 2 weeks of a 28 day cycle." | 2.80 | A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors. ( Carlson, C; Ivanova, A; McRee, AJ; O'Neil, BH; Sanoff, HK, 2015) |
| "Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI (bolus irinotecan, folinic acid, and fluorouracil followed by 46-hour fluorouracil infusion) followed by bevacizumab (5 mg/kg) in Cycle 1." | 2.79 | Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ( Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y, 2014) |
| "In 2594 patients with complete adverse event (AE) data, the incidence of grade 3 or greater 5FU-AEs in DPYD*2A, I560S, and D949V carriers were 22/25 (88." | 2.79 | DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). ( Alberts, SR; Berenberg, JL; Diasio, RB; Goldberg, RM; Lee, AM; Pavey, E; Sargent, DJ; Shi, Q; Sinicrope, FA, 2014) |
| " The experimental arm's dosage schedule was paclitaxel 60 mg/m2 (intravenous infusion) on days 1, 8 and 15 and S-1 80-120 mg/d (oral administration) on days 1-14." | 2.78 | A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013) |
| "To evaluate the efficacy and safety of trastuzumab in combination with chemotherapy versus chemotherapy alone in the first-line treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer." | 2.78 | [Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport]. ( Feng, FY; Guan, ZZ; Jiao, SC; Jin, YN; Li, J; Pan, LX; Qin, SK; Shen, L; Tao, M; Wang, JJ; Wang, LW; Wang, YJ; Xu, JM; Yu, SY; Zheng, LZ, 2013) |
| "Patients with stage II and III esophageal cancer were enrolled." | 2.77 | Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012) |
| " We designed a pilot study in order to explore the optimal dosing period for indisetron during modified FOLFOX6 (mFOLFOX6)." | 2.77 | Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study. ( Asaka, M; Kato, K; Komatsu, Y; Kudo, M; Meguro, T; Miyagishima, T; Muto, S; Nakatsumi, H; Oba, K; Sogabe, S; Tateyama, M; Uebayashi, M; Yuki, S, 2012) |
| "Survival time for metastatic breast cancer (MBC) can be substantially improved by combination chemotherapy in the adjuvant setting." | 2.75 | A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines. ( Alexopoulos, A; Ardavanis, A; Ioannidis, G; Kandylis, C; Malliou, S; Orphanos, G; Rigatos, G; Stavrakakis, J, 2010) |
| "To explore the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of paclitaxel liposome versus paclitaxel combined with 5-fluorouracil (5-Fu) for patients with advanced gastric cancer." | 2.75 | [Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer]. ( Chen, SC; Lu, ZH; Wu, F; Xiong, JP, 2010) |
| "5, or 50 mg) was administered orally once daily on three dosing schedules: 4 weeks on treatment, 2 weeks off treatment (Schedule 4/2); 2 weeks on treatment, 1 week off treatment (Schedule 2/1); and continuous daily dosing (CDD schedule)." | 2.75 | A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. ( Bello, A; Burris, HA; Chao, R; Chiorean, EG; Jones, S; Lee, FC; Liau, KF; Royce, M; Sweeney, CJ; Tye, L; Verschraegen, CF, 2010) |
| "To evaluate the safety and efficacy of preoperative radiotherapy (RT) in combination with cetuximab, capecitabine, and irinotecan in patients with locally advanced rectal cancer." | 2.74 | Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial. ( Barreto-Miranda, M; Dinter, D; Erben, P; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kienle, P; Mai, S; Post, S; Ströbel, P; Treschl, A; Wenz, F; Willeke, F; Woernle, C, 2009) |
| "This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients." | 2.74 | [Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. ( Lou, F; Pan, HM; Zhu, YH, 2009) |
| "Our results show that the regimen of gemcitabine combined with capecitabine is effective and well tolerated in patients with unresectable relapsed or metastatic carcinoma of the biliary tract." | 2.73 | [Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma]. ( Chen, X; Chen, ZS; Li, J; Ouyang, XN; Xie, FW; Yu, ZY, 2008) |
| " The dosage of chemotherapy was as follows: DOC 60 mg/m(2) on day 1 by infusion over 2 hours; CDGP 20-30 mg/m(2)/day on day 1 to 5 by infusion over 1 hour, and 5-FU 600 mg/m(2)/day on day 1 to 5 by 5 days continuous infusion." | 2.73 | [Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. ( Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007) |
| " This study was to evaluate the efficacy of FOLFOX6 regimen on Chinese colorectal cancer patients with liver metastasis, and observe the adverse events." | 2.73 | [Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis]. ( Chen, G; Ding, PR; Fang, YJ; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, GQ; Wu, XJ; Zhou, ZW, 2007) |
| "2005, 62 patients with stage II-III breast cancer were treated with 2 cycles of either GC regimen or FEC regimen before operation." | 2.73 | [Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer]. ( Cheng, B; Liu, K; Qiu, DB; Wang, GB, 2007) |
| " In conclusion, capecitabine can safely be combined with docetaxel (40 mg m(-2)) and mitomycin C (4 mg m(-2))." | 2.73 | Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial. ( Ernst, T; Gnad-Vogt, U; Hochhaus, A; Hofheinz, RD; Kripp, M; Lukan, N; Merx, K; Schultheis, B, 2007) |
| "There was a significant difference in adverse effect and toxicity such as naupathia,fever, swirl, asthenia observed between two groups (P < 0." | 2.73 | [Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer]. ( Li, T; Li, ZW; Wen, HC, 2007) |
| " The most frequent common adverse events were nausea, Grades 1 - 2 in 13 patients (81." | 2.72 | Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation. ( Farker, K; Hippius, M; Höffken, K; Hoffmann, A; Merkel, U; Wedding, U, 2006) |
| " Thus, the recommended dosing schedule is level 2." | 2.72 | A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer. ( Abe, S; Araki, H; Hareyama, M; Iyama, S; Kato, J; Miyanishi, K; Murase, K; Nagakura, H; Niitsu, Y; Okamoto, T; Sagawa, T; Sato, T; Sato, Y; Takayama, T; Takimoto, R, 2006) |
| " We thus conducted a phase I/II study of gemcitabine and infusional 5-FU in Japanese patients to determine a recommended dosage for this combination and clarify efficacy and toxicity." | 2.72 | A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. ( Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H, 2006) |
| " A phase I, open-label dose-escalating study was performed to determine the maximum tolerated dose (MTD) of BBR 3464 administered in combination with protracted venous infusional (PVI) 5-fluorouracil (5-FU) for up to six courses in patients with locally advanced and/or metastatic cancer." | 2.71 | A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer. ( Bisset, D; Boyle, D; Camboni, G; Cassidy, J; Edwards, C; Gourley, C; Jodrell, D; Samuel, L; Young, A, 2004) |
| "Grade 2/3 neutropenia was observed in 4 (3%) treatment cycles." | 2.71 | Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors. ( Agelaki, S; Amarantidis, K; Androulakis, N; Georgoulias, V; Kakolyris, S; Kouroussis, C; Mavroudis, D; Samonis, G; Souglakos, J; Vardakis, N; Xenidis, N, 2004) |
| "Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer." | 2.71 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. ( Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY, 2004) |
| "Patients with previously untreated esophageal cancer were eligible if they had performance status 0-1, were 75 years or younger and had adequate organ function." | 2.71 | Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2004) |
| "Advanced pancreatic cancer has limited treatment options." | 2.71 | Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer. ( Baranda, J; Garcia, AA; Leichman, CG; Leichman, L; Lenz, HJ; Pandit, L, 2003) |
| "Capecitabine was administered in twice daily divided doses, and CI-994 was given as a single daily dose." | 2.71 | A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. ( Janisch, L; Kimmel, KA; Kindler, HL; Macek, TA; Olson, SC; Ratain, MJ; Schilsky, RL; Undevia, SD; Vogelzang, NJ, 2004) |
| "Esophageal cancer has a poor prognosis." | 2.71 | [Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer]. ( Fujitani, K; Hirao, M; Tsujinaka, T, 2005) |
| "3 mg of ramosetron (RAM) combined with 8 mg of dexamethasone (DEX) and 0." | 2.71 | [A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone]. ( Horiuchi, C; Ikeda, Y; Ishitoya, J; Katori, H; Matsuda, H; Mikami, Y; Taguchi, T; Tanigaki, Y; Tsukuda, M; Yoshida, T, 2005) |
| "The prognosis of patients with hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor." | 2.70 | Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. ( Ando, E; Fukumori, K; Kuromatsu, R; Okuda, K; Sata, M; Sumie, S; Tanaka, M; Yamashita, F; Yano, Y; Yutani, S, 2002) |
| " We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma." | 2.70 | Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002) |
| "Capecitabine is a novel fluoropyrimidine carbamate, orally administered and selectively activated to fluorouracil by a sequential triple-enzyme pathway in liver and tumor cells." | 2.70 | Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy. ( Kramer, G; Locker, GJ; Mader, R; Marberger, M; Rauchenwald, M; Schmidinger, M; Steger, GG; Wenzel, C; Zielinski, CC, 2002) |
| "The subjects were patients with squamous cell carcinoma of the oral cavity who had not received any therapy, comprising 7 patients with carcinoma of the tongue, 2 with buccal carcinoma, 2 with maxillary gingival carcinoma, and 1 with carcinoma of the oral floor." | 2.70 | [Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer]. ( Ando, T; Fukada, K; Hoshino, M; Kuwazawa, T; Maruoka, Y; Nishihara, N; Ogiuchi, H; Ogiuchi, Y; Okamoto, T, 2002) |
| ", Carlsbad, CA) when administered in combination with 5-fluorouracil (5-FU) and leucovorin (LV)." | 2.70 | Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. ( Dorr, FA; Geary, RS; Holmlund, JT; Kindler, HL; Kunkel, K; Mani, S; Ratain, MJ; Rudin, CM, 2002) |
| "For patients with unresectable gastric cancer registered between July 1994 and September 1995, the following dosage regimen was examined: a drip infusion of cisplatin (CDDP) at 7 mg/m2/day for 5 consecutive days and 2-day withdrawal a week for 3 weeks with concomitant sustained drip infusion of 5-FU at 300 mg/m2/day for 21 days." | 2.69 | [A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group]. ( Ishida, T; Iwanaga, T; Katsu, K; Kobayashi, K; Narahara, H; Okajima, K; Okuno, M; Otani, T; Sowa, M; Taguchi, T; Takami, M; Yamamoto, H; Yasutake, K; Yasutomi, M, 1998) |
| "To improve survival rate in advanced head and neck cancer, we scheduled 90 patients to receive low dose cisplatin plus 5-fluorouracil regimen as neoadjuvant(NAC), concurrent(CC), adjuvant(AC), and second line chemotherapy (SC) setting." | 2.69 | The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck. ( Kawada, M; Kitahara, S; Kohno, N; Nakanoboh, M; Shirasaka, T; Tamura, E; Tanabe, T, 2000) |
| "Patients with a squamous cell carcinoma of the oropharynx for whom curative radiotherapy or surgery was considered feasible were entered in a multicentric randomized trial comparing neoadjuvant chemotherapy followed by loco-regional treatment to the same loco-regional treatment without chemotherapy." | 2.69 | Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC). ( Coche-Dequeant, B; De Raucourt, D; Domenge, C; Hill, C; Lefebvre, JL; Luboinski, B; Marandas, P; Rhein, B; Sancho-Garnier, H; Stromboni-Luboinski, M; Wibault, P, 2000) |
| "N&V and leukopenia were the major side effects." | 2.68 | Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer. ( Ichikawa, G; Inuyama, Y; Kawaida, M; Kohno, N; Ohnuma, T; Shirasaka, T, 1995) |
| " None of the patients could be administered the initially scheduled dosage of 500 mg/m2 of 5FU." | 2.68 | [Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma]. ( Hosaka, M; Kubota, Y; Masuda, M; Noguchi, S; Shuin, T; Yao, M, 1995) |
| "Eleven patients with metastatic renal cell carcinoma received combination therapy with 5-fluorouracil (5-FU), Cisplatin (CDDP) and Interferon alpha-2b (IFN alpha-2b)." | 2.68 | [Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma]. ( Fujinami, K; Ikeda, I; Kondo, I; Miura, T, 1996) |
| "Therapy for metastatic breast cancer has not improved significantly in recent years." | 2.68 | Metastatic breast cancer: treatment with fluorouracil-based combinations. ( Klaassen, U; Seeber, S, 1997) |
| " Intolerance to single dosing was clearly demonstrated, and only the split dosing was advanced to 500 mg/m2/day." | 2.68 | Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil. ( Chan, KK; Groshen, S; Jeffers, S; Leichman, CG; Leichman, L; Muggia, FM; Spicer, D; Wu, X, 1996) |
| "Vomiting was not consistently related to the excretion of either catecholamine." | 2.67 | Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline. ( Börjesson, S; Fredrikson, M; Fürst, CJ; Hursti, TJ; Peterson, C; Steineck, G, 1994) |
| "Fifty patients with advanced breast cancer were treated by high dose cisplatin (DDP) combination chemotherapy during the period of August 1984 to June 1991." | 2.67 | [High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases]. ( Zhou, JC, 1993) |
| " From the above results, THP in combination with cyclophosphamide and 5-Fluorouracil is comparable to ADR in efficacy and can be regarded as having better safety than ADR for the treatment of breast cancer." | 2.66 | [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer]. ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tanaka, T; Tominaga, T, 1986) |
| "Mitoxantrone (Novantrone), is an anthracenedione which in preclinical studies demonstrated a spectrum of antitumor activity similar to the anthracyclines, but with less cardiotoxicity." | 2.66 | Mitoxantrone: an overview of safety and toxicity. ( Bernstein, T; Cartwright, K; Dukart, G; Goldberg, J; Posner, LE, 1985) |
| "Stomatitis was more frequent on the infusion arm but it was mild and reversible." | 2.66 | A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. ( Al-Sarraf, M; Cummings, G; Ensley, JF; Jacobs, J; Kish, JA; Weaver, A, 1985) |
| "Women with breast carcinoma and four or more involved ipsilateral axillary lymph nodes were randomly assigned to receive an induction course and 2 yr of maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil (CMF, 150 patients), CMF plus vincristine and prednisone (CMFVP, 166 patients), or chemoimmunotherapy with CMF plus the methanol extraction residue of BCG (CMF-MER, 85 patients)." | 2.65 | A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer. ( Falkson, G; Falkson, HC; Glidewell, OJ; Henry, PH; Holland, JF; Leone, LA; Perloff, M; Tormey, DC; Weinberg, VE; Weiss, RB, 1983) |
| "Oral tegafur and I." | 2.65 | A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer. ( Bedikian, AY; Bodey, GP; Karlin, D; Korinek, J; Stroehlein, J, 1983) |
| " Weekly oral 5-FU results in comparable response and survival to 5-FU given intravenously, consistent with a relatively low dose-response relationship for 5-FU in breast carcinoma." | 2.65 | Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery. ( Bateman, JR; Chlebowski, RT; Pugh, RP; Weiner, JM, 1981) |
| " With the dosage and schedule we used, and in our patient population of largely elderly adults, THC therapy resulted in an overall more unpleasant treatment experience than that noted with prochlorperazine or placebo." | 2.65 | Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo. ( Creagan, ET; Frytak, S; Moertel, CG; O'Connell, MJ; O'Fallon, JR; Rubin, J; Schutt, AJ; Schwartau, NW, 1979) |
| "FOLFIRINOX has been one of the first-line options for advanced pancreatic cancer, even though it induces significant adverse effects." | 2.58 | The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. ( Fan, Z; Liu, B; Lu, T; Tong, H, 2018) |
| "To compare the efficacy and safety of two chemotherapeutic regimens, irinotecan monotherapy or irinotecan in combination with fluoropyrimidines, for patients with advanced CRC when administered in the first or second-line settings." | 2.53 | Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. ( Repana, D; Van Hemelrijck, M; Wardhana, A; Watkins, J; Wulaningsih, W; Yoshuantari, N, 2016) |
| "Colorectal cancer is one of the most common cancers affecting men and women in the United States." | 2.43 | Advanced colorectal cancer: current treatment and nursing management with economic considerations. ( Fung, A; Viale, PH; Zitella, L, 2005) |
| " Hand-foot syndrome (HFS) is the only clinical adverse event occurring more often during capecitabine treatment." | 2.42 | Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda). ( Grothey, A; Marsé, H; Valverde, S; Van Cutsem, E, 2004) |
| "Advanced pancreatic cancer (APC) disproportionately impacts older adults." | 1.72 | Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy. ( Dawe, DE; Kim, CA; Lambert, P; McAndrew, EN; Rittberg, R; Zhang, H, 2022) |
| "Capecitabine is an oral anticancer drug which can cause some adverse reactions and the great challenge for its use is to ensure the medication adherence." | 1.72 | Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer. ( Barbosa, CR; Cobaxo, TS; de Souza, RN; Dias, LP; Duarte, NC; Lima, CS; Lima, TM; Moriel, P; Pincinato, EC; Tavares, MG; Teixeira, JC; Visacri, MB, 2022) |
| "The outbreak of coronavirus disease 2019 (COVID-19) has affected the treatment of cancer patients, with particular regard to the management of both chemotherapy and side effects." | 1.62 | NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study. ( Caputo, V; Cicero, G; De Luca, R; Ferrera, G; Mistretta, O; Paci, R; Rosati, G; Volpe, C, 2021) |
| "Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled." | 1.62 | Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk. ( Fukunaga, M; Hayashi, T; Kogawa, T; Matsui, R; Mizuki, F; Nishimura, J; Satoh, T; Shimokawa, M; Tsuji, Y, 2021) |
| " Given the known sex differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines warrants further investigation." | 1.62 | Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. ( Alberts, SR; Allegra, CJ; Andre, T; Blanke, CD; de Gramont, A; Dixon, JG; Francini, E; George, TJ; Goldberg, RM; Grothey, A; Haller, DG; Kerr, R; Marsoni, S; O'Connell, MJ; Saltz, LB; Seitz, JF; Shi, Q; Taieb, J; Twelves, C; VanCutsem, E; Wagner, AD; Wolmark, N; Yothers, G, 2021) |
| "Patients with newly diagnosed advanced pancreatic cancer in Saskatchewan, Canada, from 2011 to 2016, who received FOLFIRINOX or GnP were assessed." | 1.51 | Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study. ( Ahmed, S; Chalchal, H; Haider, K; Moser, M; Olson, C; Papneja, N; Shaw, J; Tan, K; Zaidi, A, 2019) |
| " The frequency and severity of these adverse events vary from patient to patient and are partially explained by genetic polymorphism into the dihydropyrimidine dehydrogenase (DPYD) gene." | 1.46 | Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms. ( Cergnul, M; Cheli, S; Falvella, FS; Fava, S; Luoni, M, 2017) |
| "025) in the toxic group (n = 12) compared to the non-toxic group (n = 19)." | 1.42 | Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. ( Bowen, JM; Game, PA; Hussey, DJ; Irvine, T; Karapetis, CS; Keefe, DM; Kristaly, K; Smith, L; Tan, H; Thompson, SK; Tsykin, A; Watson, DI; White, I, 2015) |
| "Although hyperammonemia is known as one of the adverse side effects of 5-FU, a disturbance of consciousness caused by hyperammonemia is not a usual finding." | 1.42 | [A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer]. ( Egawa, C; Kagawa, Y; Kato, T; Katsura, Y; Murakami, K; Naito, A; Ohmura, Y; Okishiro, M; Takeda, Y; Takeno, A; Tamura, S, 2015) |
| "Capecitabine is a complex chemotherapeutic agent with many side effects that might affect patient adherence to treatment." | 1.40 | Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia. ( Hassan, NB; Norazwany, Y; Norhayati, I; Norsa'adah, B; Roslan, MH; Wan Nazuha, WR; Zahrina, AK, 2014) |
| " Grade 3/4 adverse events were: neutropenia (54." | 1.39 | Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer. ( Maruyama, S; Takii, Y, 2013) |
| "All patients scheduled for breast cancer surgery at Danderyd Hospital, Stockholm, Sweden during 1 year (March 2003-March 2004) were asked to participate in this prospective, observational study." | 1.39 | Is there an association between PONV and chemotherapy-induced nausea and vomiting? ( Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S, 2013) |
| " Gastro-intestinal adverse events graded according to the WHO criteria were recorded after the first cycle." | 1.38 | Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity. ( Bocci, G; Ciccolini, J; Danesi, R; Di Paolo, A; Iliadis, A; Lacarelle, B; Marouani, H; Woloch, C, 2012) |
| "Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease." | 1.37 | Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011) |
| "Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications." | 1.37 | Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011) |
| "Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen." | 1.36 | [Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010) |
| "While hiccups are usually benign, severe attacks may lead to exhaustion, eating difficulties, and affect quality of life." | 1.35 | Severe hiccups during chemotherapy: corticosteroids the likely culprit. ( Gilbar, P; McPherson, I, 2009) |
| " Thus,we devised a new intermittent dosage regimen utilizing the cell cycle difference of normal GI tract, bone marrow cell and pancreatic cancer cell, making use of 5-FU (-->S-1), CDDP and paclitaxel in March 2002." | 1.34 | [The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Koito, K; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| " In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen." | 1.34 | [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| "The data of 114 breast cancer patients treated with adjuvant dose dense chemotherapy was retrospectively analyzed." | 1.34 | [Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer]. ( Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD, 2007) |
| "Pretreatment distress and posttreatment nausea, vomiting, and fatigue were assessed at the 1st, 4th, 6th and last cycles of chemotherapy." | 1.34 | Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity. ( Jensen, AB; Johansson, A; Mehlsen, M; Paulsen, K; von der Maase, H; Zachariae, R, 2007) |
| "The side effect of anticancer agents such as nausea and vomiting frequently interrupt chemotherapy." | 1.33 | [Effect of steroid on antiemetic for side effect of anticancer chemotherapy]. ( Matsumoto, T; Mikami, T; Momokawa, K; Nakamura, Y; Sakayauchi, T; Sasaki, T; Watanabe, T, 2005) |
| " This study was to explore relationship of DPD to serum concentration of 5-FU in colorectal cancer patients treated with FOLFOX6 regimen, and their correlation to treatment response and adverse events." | 1.33 | [Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients]. ( Dong, QM; He, YJ; Li, S; Li, YY; Xia, ZJ; Zhang, L; Zhou, ZM; Zhou, ZW, 2005) |
| " In patients with Grade 3 or more, leukocytopenia was observed in 7 patients and diarrhea in 1 as adverse events." | 1.33 | [Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer]. ( Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K, 2006) |
| "Irinotecan (CPT11) has established activity against advanced colorectal cancer without cross-resistance with 5-fluorouracil + leucovorin-based therapy." | 1.32 | Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan. ( Chen, PM; Chen, WS; Chiou, TJ; Lin, JK; Liu, JH; Tai, CJ; Wang, WS; Yen, CC, 2003) |
| "Ten patients with recurrent esophageal cancer were treated with the combination of docetaxel 60 mg/m2 (day 1), CDDP 10 mg/body (days 1-5) and 5-FU 500 mg/body (days 1-5) at intervals of 2-3 weeks." | 1.32 | [Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study]. ( Fujita, H; Matono, S; Sasahara, H; Shirouzu, K; Sueyoshi, S; Tanaka, T; Yamana, H, 2003) |
| "Twenty-four patients with advanced gastric cancer who had been treated by multiple chemotherapy regimens presenting poor responses were allotted." | 1.32 | [Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer]. ( Chen, YX; He, ZM; Mei, JF; Qian, J; Qin, SK; Shao, ZJ, 2004) |
| "Transient hypotension was the most common side effect occurring in association with amifostine." | 1.31 | Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. ( Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E, 2001) |
| "Patients with high risk breast carcinoma were conditioned with high dose carmustine, cisplatin, and cyclophosphamide followed by autologous PSCT." | 1.30 | Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma. ( Chap, L; Hecht, JR; Lembo, T, 1997) |
| "Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5." | 1.28 | Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991) |
| "Forty-one patients with bladder cancer and 12 patients with prostatic cancer were evaluated." | 1.28 | [Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991) |
| "Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer." | 1.28 | [Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. ( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989) |
| "Tegafur was administered orally in two or three divided doses." | 1.27 | Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983) |
| " Pharmacokinetic study after single oral administration of 300 to 1200 mg of UFT-E was carried out in cancer patients measuring tagafur, uracil and 5-FU levels in serum, normal tissue and tumor tissue using HPLC and GC-mass." | 1.27 | [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients]. ( Fujii, S; Hoshino, A; Kamiya, O; Kimura, K; Kojima, T; Nagata, K; Ohara, K; Sugihara, T; Suzuki, M; Yamada, M, 1983) |
| " Reduced clearance of FU by MISO was associated with an earlier onset of the period of nonlinearity of FU pharmacokinetics and an increased half-life of elimination." | 1.27 | Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans. ( Martin, WM; McDermott, BJ; Murphy, RF; Van den Berg, HW, 1983) |
| "Diphenhydramine was administered intramuscularly 30 minutes before and 5 hours after chemotherapy." | 1.27 | [The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine]. ( Arihiro, T; Dozono, H; Morimoto, O; Ochiai, K; Sasaki, H; Takahashi, S; Terashima, Y; Tsuruoka, M; Yasuda, M; Yokoyama, S, 1987) |
| "Six patients with an upper gastrointestinal hemorrhage or a small bowel obstruction all had local recurrence." | 1.27 | Results in the management of locally unresectable pancreatic carcinoma. ( Parker, RG; Selch, MT, 1986) |
| "Thirty-six patients with advanced colorectal cancer with unequivocal evidence of progression while treated with fluoropyrimidines were treated with a six-day continuous infusion of 500 mg/m2/d of folinic acid initiated 24 hours before a five-day course of 5-FU administered as an intravenous (IV) bolus of 370 mg/m2/d." | 1.27 | High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study. ( Bertrand, M; Blayney, DW; Carr, BI; Cecchi, G; Doroshow, JH; Goldberg, D; Leong, L; Margolin, K; Metter, G; Multhauf, P, 1986) |
| "Thyroid cancer, nasal cancer and paranasal sinus cancer gave the best results." | 1.27 | [Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture]. ( Hattori, Y; Horiuchi, M; Miyake, H; Murakami, T; Otake, H; Sawaki, S; Takahashi, H; Takeyama, I; Tamamushi, N; Yao, K, 1985) |
| " Susceptibility to motion sickness appears to be a determinant of the side effects of cancer chemotherapy that may prove useful as a clinical marker of those patients who may require more intensive side effect management." | 1.27 | The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy. ( Morrow, GR, 1985) |
| "Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)." | 1.26 | [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 87 (23.71) | 18.7374 |
| 1990's | 70 (19.07) | 18.2507 |
| 2000's | 101 (27.52) | 29.6817 |
| 2010's | 93 (25.34) | 24.3611 |
| 2020's | 16 (4.36) | 2.80 |
| Authors | Studies |
|---|---|
| De Luca, R | 1 |
| Volpe, C | 1 |
| Mistretta, O | 1 |
| Paci, R | 1 |
| Ferrera, G | 1 |
| Caputo, V | 1 |
| Rosati, G | 1 |
| Cicero, G | 1 |
| Shimokawa, M | 1 |
| Hayashi, T | 2 |
| Nishimura, J | 2 |
| Satoh, T | 2 |
| Fukunaga, M | 2 |
| Matsui, R | 1 |
| Tsuji, Y | 1 |
| Mizuki, F | 1 |
| Kogawa, T | 1 |
| McAndrew, EN | 1 |
| Zhang, H | 1 |
| Lambert, P | 1 |
| Rittberg, R | 1 |
| Dawe, DE | 1 |
| Kim, CA | 1 |
| De Francia, S | 1 |
| Berchialla, P | 1 |
| Armando, T | 1 |
| Storto, S | 1 |
| Allegra, S | 1 |
| Sciannameo, V | 1 |
| Soave, G | 1 |
| Sprio, AE | 1 |
| Racca, S | 1 |
| Caiaffa, MR | 1 |
| Ciuffreda, L | 1 |
| Mussa, MV | 1 |
| Kim, G | 1 |
| Cockrum, P | 1 |
| Surinach, A | 1 |
| Wang, S | 1 |
| Wainberg, Z | 1 |
| Oliva, D | 1 |
| Andersson, BÅ | 1 |
| Shamoun, L | 1 |
| Lewin, N | 1 |
| Nilsson, MP | 1 |
| Schildt, EB | 1 |
| Fust, L | 1 |
| Åsenlund, U | 1 |
| Sellerstam, G | 1 |
| Elinder, E | 1 |
| Sharp, L | 1 |
| Lewin, F | 1 |
| Marmorino, F | 1 |
| Rossini, D | 1 |
| Lonardi, S | 1 |
| Moretto, R | 1 |
| Zucchelli, G | 1 |
| Aprile, G | 1 |
| Dell'Aquila, E | 1 |
| Ratti, M | 1 |
| Bergamo, F | 1 |
| Masi, G | 2 |
| Urbano, F | 1 |
| Ronzoni, M | 1 |
| Libertini, M | 1 |
| Borelli, B | 1 |
| Randon, G | 1 |
| Buonadonna, A | 1 |
| Allegrini, G | 2 |
| Pella, N | 1 |
| Ricci, V | 1 |
| Boccaccino, A | 1 |
| Latiano, TP | 2 |
| Cordio, S | 2 |
| Passardi, A | 1 |
| Tamburini, E | 1 |
| Boni, L | 1 |
| Falcone, A | 2 |
| Cremolini, C | 1 |
| Maiello, E | 2 |
| Di Maggio, G | 1 |
| Cinieri, S | 1 |
| Giuliani, F | 1 |
| Pisconti, S | 1 |
| Rinaldi, A | 1 |
| Febbraro, A | 1 |
| Aieta, M | 1 |
| Rossi, A | 1 |
| Rizzi, D | 1 |
| Di Maio, M | 1 |
| Colucci, G | 1 |
| Bordonaro, R | 2 |
| Matsumoto, K | 1 |
| Takahashi, M | 2 |
| Sato, K | 1 |
| Osaki, A | 1 |
| Takano, T | 1 |
| Naito, Y | 1 |
| Matsuura, K | 1 |
| Aogi, K | 2 |
| Fujiwara, K | 1 |
| Tamura, K | 1 |
| Baba, M | 1 |
| Tokunaga, S | 3 |
| Hirano, G | 1 |
| Imoto, S | 2 |
| Miyazaki, C | 1 |
| Yanagihara, K | 1 |
| Imamura, CK | 1 |
| Chiba, Y | 1 |
| Saeki, T | 2 |
| Loi, M | 1 |
| Magallon-Baro, A | 1 |
| Suker, M | 1 |
| Van Eijck, C | 1 |
| Hoogeman, M | 1 |
| Nuyttens, JJ | 1 |
| Park, H | 1 |
| Jin, RU | 1 |
| Wang-Gillam, A | 1 |
| Suresh, R | 1 |
| Rigden, C | 1 |
| Amin, M | 1 |
| Tan, BR | 1 |
| Pedersen, KS | 1 |
| Lim, KH | 1 |
| Trikalinos, NA | 1 |
| Acharya, A | 1 |
| Copsey, ML | 1 |
| Navo, KA | 1 |
| Morton, AE | 1 |
| Gao, F | 1 |
| Lockhart, AC | 1 |
| Wagner, AD | 1 |
| Grothey, A | 2 |
| Andre, T | 2 |
| Dixon, JG | 1 |
| Wolmark, N | 1 |
| Haller, DG | 1 |
| Allegra, CJ | 1 |
| de Gramont, A | 3 |
| VanCutsem, E | 1 |
| Alberts, SR | 2 |
| George, TJ | 1 |
| O'Connell, MJ | 3 |
| Twelves, C | 1 |
| Taieb, J | 1 |
| Saltz, LB | 1 |
| Blanke, CD | 2 |
| Francini, E | 1 |
| Kerr, R | 1 |
| Yothers, G | 1 |
| Seitz, JF | 1 |
| Marsoni, S | 2 |
| Goldberg, RM | 3 |
| Shi, Q | 2 |
| Visacri, MB | 1 |
| Duarte, NC | 1 |
| Lima, TM | 1 |
| de Souza, RN | 1 |
| Cobaxo, TS | 1 |
| Teixeira, JC | 1 |
| Barbosa, CR | 1 |
| Dias, LP | 1 |
| Tavares, MG | 1 |
| Pincinato, EC | 1 |
| Lima, CS | 1 |
| Moriel, P | 1 |
| Wang, DS | 1 |
| Hu, MT | 1 |
| Wang, ZQ | 2 |
| Ren, C | 1 |
| Qiu, MZ | 1 |
| Luo, HY | 2 |
| Jin, Y | 1 |
| Fong, WP | 1 |
| Wang, SB | 1 |
| Peng, JW | 1 |
| Zou, QF | 1 |
| Tan, Q | 1 |
| Wang, FH | 2 |
| Li, YH | 4 |
| Mie, T | 1 |
| Sasaki, T | 3 |
| Takeda, T | 1 |
| Fukuda, K | 1 |
| Furukawa, T | 2 |
| Yamada, Y | 5 |
| Kasuga, A | 1 |
| Matsuyama, M | 1 |
| Ozaka, M | 1 |
| Sasahira, N | 1 |
| Chang, TK | 1 |
| Yin, TC | 1 |
| Su, WC | 1 |
| Tsai, HL | 1 |
| Huang, CW | 1 |
| Chen, YC | 1 |
| Li, CC | 1 |
| Chen, PJ | 1 |
| Ma, CJ | 1 |
| Chuang, KH | 1 |
| Cheng, TL | 1 |
| Wang, JY | 1 |
| Caron, B | 1 |
| Reimund, JM | 1 |
| Ben Abdelghani, M | 1 |
| Sondag, D | 1 |
| Noirclerc, M | 1 |
| Duclos, B | 1 |
| Kurtz, JE | 1 |
| Nguimpi-Tambou, M | 1 |
| Fang, M | 1 |
| Song, T | 1 |
| Liang, X | 1 |
| Lv, S | 1 |
| Li, J | 7 |
| Xu, H | 1 |
| Luo, L | 1 |
| Jia, Y | 1 |
| Falvella, FS | 1 |
| Luoni, M | 1 |
| Cheli, S | 1 |
| Fava, S | 1 |
| Cergnul, M | 1 |
| Uchiyama, K | 3 |
| Yamada, M | 3 |
| Shiiba, Y | 1 |
| Kasazaki, S | 1 |
| Suga, K | 1 |
| Iwabuchi, H | 3 |
| Asoda, S | 1 |
| Uehara, K | 1 |
| Chao, YL | 1 |
| Anders, CK | 1 |
| Bubalo, JS | 1 |
| Herrington, JD | 1 |
| Takemoto, M | 1 |
| Willman, P | 1 |
| Edwards, MS | 1 |
| Williams, C | 1 |
| Fisher, A | 1 |
| Palumbo, A | 1 |
| Chen, E | 1 |
| Blanke, C | 1 |
| Lopez, CD | 1 |
| Liu, GY | 1 |
| Lv, X | 1 |
| Wu, YS | 1 |
| Mao, MJ | 1 |
| Ye, YF | 1 |
| Yu, YH | 1 |
| Liang, H | 1 |
| Yang, J | 1 |
| Ke, LR | 1 |
| Qiu, WZ | 1 |
| Huang, XJ | 1 |
| Li, WZ | 1 |
| Guo, X | 1 |
| Xiang, YQ | 1 |
| Xia, WX | 2 |
| Tong, H | 1 |
| Fan, Z | 1 |
| Liu, B | 1 |
| Lu, T | 1 |
| Deng, B | 1 |
| Jia, L | 1 |
| Tan, H | 2 |
| Lou, Y | 1 |
| Li, X | 1 |
| Li, Y | 3 |
| Yu, L | 1 |
| Narjoux, G | 1 |
| Clarenne, J | 1 |
| Azzouz, B | 1 |
| Zeller, PS | 1 |
| Slimano, F | 1 |
| Bouché, O | 1 |
| Abdel-Rahman, O | 1 |
| Papneja, N | 1 |
| Zaidi, A | 1 |
| Chalchal, H | 1 |
| Moser, M | 1 |
| Tan, K | 1 |
| Olson, C | 1 |
| Haider, K | 1 |
| Shaw, J | 1 |
| Ahmed, S | 1 |
| Riechelmann, RP | 1 |
| Srimuninnimit, V | 1 |
| Kavan, P | 1 |
| Di Bartolomeo, M | 1 |
| Cicin, I | 1 |
| García-Alfonso, P | 2 |
| Chau, I | 2 |
| Fedyanin, MY | 1 |
| Martos, CF | 1 |
| Ter-Ovanesov, M | 1 |
| Peeters, M | 1 |
| Ko, YJ | 1 |
| Yalcin, S | 1 |
| Karthaus, M | 1 |
| Aparicio, J | 1 |
| Heinemann, V | 1 |
| Picard, P | 1 |
| Bury, D | 1 |
| Drea, E | 1 |
| Sobrero, A | 2 |
| Neely, D | 1 |
| Ong, J | 1 |
| Patterson, J | 1 |
| Kirkpatrick, D | 1 |
| Skelly, R | 1 |
| Pacetti, U | 1 |
| Veltri, E | 1 |
| Fattoruso, SI | 1 |
| Cardillo, FD | 1 |
| Evangelista, S | 1 |
| Cognetti, F | 1 |
| Fabi, A | 1 |
| Koch, S | 1 |
| Wein, A | 2 |
| Siebler, J | 2 |
| Boxberger, F | 1 |
| Neurath, MF | 1 |
| Harich, HD | 1 |
| Hohenberger, W | 2 |
| Dörje, F | 1 |
| Meng, J | 2 |
| Gu, QP | 1 |
| Meng, QF | 1 |
| Zhang, J | 1 |
| Li, ZP | 1 |
| Si, YM | 1 |
| Guo, W | 2 |
| Zhuang, QW | 1 |
| Ejlertsen, B | 1 |
| Jensen, MB | 1 |
| Elversang, J | 1 |
| Rasmussen, BB | 1 |
| Andersson, M | 1 |
| Andersen, J | 1 |
| Nielsen, DL | 1 |
| Cold, S | 1 |
| Mouridsen, HT | 2 |
| Huang, D | 1 |
| Ba, Y | 1 |
| Xiong, J | 1 |
| Xu, N | 4 |
| Yan, Z | 1 |
| Zhuang, Z | 1 |
| Yu, Z | 2 |
| Wan, H | 1 |
| Zhang, Y | 2 |
| Deng, T | 1 |
| Zheng, R | 1 |
| Guo, Z | 1 |
| Hu, C | 1 |
| Wang, M | 1 |
| Yao, Y | 2 |
| Takii, Y | 1 |
| Maruyama, S | 3 |
| Martin, M | 2 |
| Bonneterre, J | 4 |
| Geyer, CE | 2 |
| Ito, Y | 1 |
| Ro, J | 1 |
| Lang, I | 1 |
| Kim, SB | 1 |
| Germa, C | 1 |
| Vermette, J | 1 |
| Wang, K | 2 |
| Awada, A | 2 |
| Silvestris, N | 1 |
| Brunetti, AE | 1 |
| Russano, M | 1 |
| Nardulli, P | 1 |
| Shen, L | 2 |
| Xu, JM | 1 |
| Feng, FY | 2 |
| Jiao, SC | 1 |
| Wang, LW | 1 |
| Guan, ZZ | 3 |
| Qin, SK | 2 |
| Wang, JJ | 1 |
| Yu, SY | 1 |
| Wang, YJ | 1 |
| Jin, YN | 1 |
| Tao, M | 1 |
| Zheng, LZ | 1 |
| Pan, LX | 2 |
| Yamashita, H | 2 |
| Omori, M | 1 |
| Okuma, K | 2 |
| Kobayashi, R | 1 |
| Igaki, H | 1 |
| Nakagawa, K | 1 |
| Likhacheva, A | 1 |
| Jhingran, A | 1 |
| Bodurka, DC | 1 |
| Sun, C | 1 |
| Sam, M | 1 |
| Eifel, PJ | 1 |
| Tomasello, G | 1 |
| Liguigli, W | 1 |
| Poli, R | 1 |
| Lazzarelli, S | 1 |
| Brighenti, M | 1 |
| Negri, F | 1 |
| Curti, A | 1 |
| Martinotti, M | 1 |
| Olivetti, L | 1 |
| Rovatti, M | 1 |
| Donati, G | 1 |
| Passalacqua, R | 1 |
| Kajiura, S | 1 |
| Hosokawa, A | 2 |
| Yoshita, H | 1 |
| Ueda, Y | 1 |
| Ueda, A | 1 |
| Mihara, H | 1 |
| Ando, T | 3 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Ogawa, K | 1 |
| Minemura, M | 1 |
| Sugiyama, T | 1 |
| Gozzo, Tde O | 1 |
| Moysés, AM | 1 |
| da Silva, PR | 1 |
| de Almeida, AM | 1 |
| Woo, SM | 1 |
| Lee, WJ | 1 |
| Kim, JH | 3 |
| Kim, DH | 1 |
| Han, SS | 1 |
| Park, SJ | 2 |
| Kim, TH | 1 |
| Lee, JH | 2 |
| Koh, YH | 1 |
| Hong, EK | 1 |
| Suenaga, M | 1 |
| Fuse, N | 1 |
| Yamaguchi, T | 1 |
| Yamanaka, Y | 1 |
| Motomura, S | 1 |
| Matsumoto, H | 1 |
| Hamamoto, Y | 2 |
| Mizunuma, N | 2 |
| Doi, T | 3 |
| Hatake, K | 1 |
| Iwasaki, J | 1 |
| Ohtsu, A | 2 |
| Liu, Y | 1 |
| Wu, W | 2 |
| Hong, W | 1 |
| Sun, X | 1 |
| Wu, J | 1 |
| Huang, Q | 1 |
| Roxburgh, P | 1 |
| Lumsden, GR | 1 |
| Paul, J | 1 |
| Harden, S | 1 |
| Sweeting, L | 1 |
| James, A | 1 |
| Crellin, A | 1 |
| Morrison, R | 1 |
| Evans, TR | 1 |
| McDonald, AC | 1 |
| Bayoglu, IV | 1 |
| Varol, U | 1 |
| Yildiz, I | 1 |
| Muslu, U | 1 |
| Alacacioglu, A | 1 |
| Kucukzeybek, Y | 1 |
| Akyol, M | 1 |
| Demir, L | 1 |
| Dirican, A | 1 |
| Cokmert, S | 1 |
| Yildiz, Y | 1 |
| Karabulut, B | 1 |
| Uslu, R | 1 |
| Tarhan, MO | 1 |
| Soveri, LM | 1 |
| Hermunen, K | 1 |
| Poussa, T | 1 |
| Quinaux, E | 2 |
| Bono, P | 1 |
| Österlund, P | 1 |
| Lee, AM | 1 |
| Pavey, E | 1 |
| Sargent, DJ | 2 |
| Sinicrope, FA | 1 |
| Berenberg, JL | 1 |
| Diasio, RB | 1 |
| Zahrina, AK | 1 |
| Norsa'adah, B | 1 |
| Hassan, NB | 1 |
| Norazwany, Y | 1 |
| Norhayati, I | 1 |
| Roslan, MH | 1 |
| Wan Nazuha, WR | 1 |
| Kim, JE | 2 |
| Hong, YS | 3 |
| Lee, JL | 1 |
| Kim, KP | 2 |
| Sym, SJ | 1 |
| Shin, DB | 2 |
| Lee, J | 3 |
| Park, YS | 2 |
| Ahn, JS | 1 |
| Kim, TW | 2 |
| Namikawa, T | 1 |
| Munekage, E | 1 |
| Maeda, H | 1 |
| Kitagawa, H | 1 |
| Kobayashi, M | 1 |
| Hanazaki, K | 1 |
| Ishimaru, K | 1 |
| Takano, A | 1 |
| Katsura, M | 1 |
| Yamaguchi, N | 1 |
| Kaneko, K | 1 |
| Takahashi, H | 2 |
| Krop, IE | 1 |
| Suter, TM | 1 |
| Dang, CT | 1 |
| Dirix, L | 1 |
| Romieu, G | 1 |
| Zamagni, C | 1 |
| Citron, ML | 1 |
| Campone, M | 1 |
| Smitt, M | 1 |
| Gianni, L | 1 |
| Bowen, JM | 1 |
| White, I | 1 |
| Smith, L | 1 |
| Tsykin, A | 1 |
| Kristaly, K | 1 |
| Thompson, SK | 1 |
| Karapetis, CS | 1 |
| Game, PA | 1 |
| Irvine, T | 1 |
| Hussey, DJ | 1 |
| Watson, DI | 1 |
| Keefe, DM | 1 |
| Takemoto, H | 1 |
| Nakata, K | 1 |
| Ide, Y | 1 |
| Fukuzaki, T | 1 |
| Kudo, T | 1 |
| Miyake, Y | 2 |
| Yasui, M | 1 |
| Morita, S | 2 |
| Sakai, D | 1 |
| Uemura, M | 1 |
| Hata, T | 1 |
| Takemasa, I | 1 |
| Mizushima, T | 1 |
| Ohno, Y | 3 |
| Yamamoto, H | 3 |
| Sekimoto, M | 1 |
| Nezu, R | 1 |
| Doki, Y | 1 |
| Mori, M | 2 |
| Miwa, K | 1 |
| Oki, E | 2 |
| Emi, Y | 2 |
| Saeki, H | 2 |
| Kusumoto, T | 1 |
| Akagi, Y | 2 |
| Ogata, Y | 2 |
| Samura, H | 1 |
| Ishikawa, H | 2 |
| Tanaka, T | 5 |
| Sueyoshi, S | 2 |
| Higashi, H | 1 |
| Matsuda, H | 3 |
| Touyama, T | 1 |
| Maehara, Y | 3 |
| Ko, AH | 1 |
| LoConte, N | 1 |
| Tempero, MA | 1 |
| Walker, EJ | 1 |
| Kate Kelley, R | 1 |
| Lewis, S | 1 |
| Chang, WC | 1 |
| Kantoff, E | 1 |
| Vannier, MW | 1 |
| Catenacci, DV | 1 |
| Venook, AP | 1 |
| Kindler, HL | 3 |
| Arslan, M | 1 |
| Ozdemir, L | 1 |
| Komatsu, S | 1 |
| Souma, T | 1 |
| Onizawa, K | 1 |
| Yasui, T | 1 |
| Nakayama, S | 2 |
| McRee, AJ | 1 |
| Sanoff, HK | 1 |
| Carlson, C | 1 |
| Ivanova, A | 1 |
| O'Neil, BH | 1 |
| Kagawa, Y | 1 |
| Kato, T | 1 |
| Naito, A | 1 |
| Murakami, K | 1 |
| Katsura, Y | 1 |
| Ohmura, Y | 1 |
| Okishiro, M | 1 |
| Takeno, A | 1 |
| Egawa, C | 1 |
| Takeda, Y | 1 |
| Tamura, S | 1 |
| Bi, T | 1 |
| Jin, F | 1 |
| Long, J | 1 |
| Gong, X | 1 |
| Luo, X | 1 |
| Li, Z | 1 |
| He, Q | 1 |
| Qu, B | 1 |
| Tebbutt, NC | 1 |
| Price, TJ | 1 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 1 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Cooray, P | 1 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 1 |
| Ganju, V | 1 |
| Gebski, V | 1 |
| Wulaningsih, W | 1 |
| Wardhana, A | 1 |
| Watkins, J | 1 |
| Yoshuantari, N | 1 |
| Repana, D | 1 |
| Van Hemelrijck, M | 1 |
| Zhao, L | 1 |
| Liu, R | 1 |
| Zhang, Z | 1 |
| Li, T | 2 |
| Li, F | 1 |
| Liu, H | 1 |
| Li, G | 1 |
| Nakata, Y | 1 |
| Ijichi, K | 1 |
| Hanai, N | 1 |
| Nishikawa, D | 1 |
| Suzuki, H | 1 |
| Hirakawa, H | 1 |
| Kodaira, T | 1 |
| Fujimoto, Y | 1 |
| Fujii, T | 1 |
| Miyazaki, T | 1 |
| Shimizu, T | 2 |
| Hasegawa, Y | 1 |
| Kim, JW | 1 |
| Lee, KW | 1 |
| Kim, SY | 1 |
| Park, SR | 1 |
| Nam, BH | 1 |
| Cho, SH | 2 |
| Chung, IJ | 2 |
| Oh, HS | 1 |
| Lee, MA | 1 |
| Kang, HJ | 1 |
| Park, YI | 1 |
| Song, EK | 1 |
| Han, HS | 1 |
| Lee, KT | 1 |
| Kang, JH | 2 |
| Zang, DY | 1 |
| Nomura, H | 1 |
| Kawakami, H | 1 |
| Nagai, S | 1 |
| Shinohara, T | 1 |
| Isaka, H | 1 |
| Yu, ZY | 1 |
| Ouyang, XN | 1 |
| Chen, ZS | 1 |
| Chen, X | 1 |
| Xie, FW | 1 |
| Huang, HQ | 1 |
| Cai, QQ | 1 |
| Lin, XB | 1 |
| Wang, AL | 1 |
| Bu, Q | 1 |
| Hu, XH | 2 |
| Pan, ZH | 1 |
| Shuang, YR | 1 |
| Kim, K | 2 |
| Chie, EK | 1 |
| Jang, JY | 1 |
| Kim, SW | 1 |
| Oh, DY | 1 |
| Im, SA | 1 |
| Kim, TY | 1 |
| Bang, YJ | 1 |
| Ha, SW | 1 |
| Horisberger, K | 1 |
| Treschl, A | 1 |
| Mai, S | 1 |
| Barreto-Miranda, M | 1 |
| Kienle, P | 1 |
| Ströbel, P | 1 |
| Erben, P | 1 |
| Woernle, C | 1 |
| Dinter, D | 1 |
| Kähler, G | 1 |
| Hochhaus, A | 2 |
| Post, S | 1 |
| Willeke, F | 1 |
| Wenz, F | 1 |
| Hofheinz, RD | 2 |
| Kiba, T | 1 |
| Oikawa, M | 1 |
| Hokkoku, K | 1 |
| Watanabe, Y | 1 |
| Nakagawa, T | 1 |
| Shintaku, K | 1 |
| Yoshimitsu, Y | 1 |
| Sakuma, H | 1 |
| Ueda, H | 1 |
| Nakai, M | 1 |
| Gilbar, P | 1 |
| McPherson, I | 1 |
| Skof, E | 1 |
| Rebersek, M | 1 |
| Hlebanja, Z | 1 |
| Ocvirk, J | 1 |
| Lou, F | 1 |
| Zhu, YH | 1 |
| Pan, HM | 1 |
| Lorenzen, S | 1 |
| Schuster, T | 1 |
| Porschen, R | 1 |
| Al-Batran, SE | 1 |
| Hofheinz, R | 1 |
| Thuss-Patience, P | 1 |
| Moehler, M | 2 |
| Grabowski, P | 1 |
| Arnold, D | 1 |
| Greten, T | 1 |
| Müller, L | 1 |
| Röthling, N | 1 |
| Peschel, C | 1 |
| Langer, R | 1 |
| Lordick, F | 1 |
| Orphanos, G | 1 |
| Alexopoulos, A | 1 |
| Malliou, S | 1 |
| Ioannidis, G | 1 |
| Ardavanis, A | 1 |
| Kandylis, C | 1 |
| Stavrakakis, J | 1 |
| Rigatos, G | 1 |
| Zhang, DS | 1 |
| Feng, F | 1 |
| Zhang, L | 4 |
| Xu, RH | 3 |
| Jiang, WQ | 3 |
| He, YJ | 3 |
| Bae, WK | 1 |
| Hwang, JE | 1 |
| Shim, HJ | 1 |
| Lee, JK | 1 |
| Lim, SC | 1 |
| Chung, WK | 1 |
| Lu, M | 1 |
| Zhang, XD | 1 |
| Bao, HY | 1 |
| Fang, WJ | 1 |
| Zhang, XC | 1 |
| Shi, GM | 1 |
| Huang, S | 1 |
| Yu, LF | 1 |
| Chen, J | 1 |
| Mou, HB | 1 |
| Deng, J | 1 |
| Shen, P | 1 |
| Kong, L | 1 |
| Zhang, YW | 1 |
| Hu, CS | 1 |
| Guo, Y | 1 |
| Wu, F | 1 |
| Chen, SC | 1 |
| Lu, ZH | 2 |
| Xiong, JP | 2 |
| Boku, N | 3 |
| Kato, K | 2 |
| Komatsu, Y | 2 |
| Yamaguchi, K | 1 |
| Muro, K | 5 |
| Sato, A | 1 |
| Koizumi, W | 1 |
| Takiuchi, H | 1 |
| Schneiders, FL | 1 |
| van den Berg, HP | 1 |
| Peters, GJ | 1 |
| Verheul, HM | 1 |
| van der Vliet, HJ | 1 |
| Rades, D | 1 |
| Kronemann, S | 1 |
| Meyners, T | 1 |
| Bohlen, G | 1 |
| Tribius, S | 1 |
| Kazic, N | 1 |
| Schroeder, U | 1 |
| Hakim, SG | 1 |
| Schild, SE | 1 |
| Dunst, J | 1 |
| Sweeney, CJ | 1 |
| Chiorean, EG | 1 |
| Verschraegen, CF | 1 |
| Lee, FC | 1 |
| Jones, S | 1 |
| Royce, M | 2 |
| Tye, L | 1 |
| Liau, KF | 1 |
| Bello, A | 1 |
| Chao, R | 1 |
| Burris, HA | 1 |
| Malik, I | 1 |
| Bernal, P | 1 |
| Byrd, J | 1 |
| Chon, YE | 1 |
| Seong, J | 1 |
| Kim, BK | 1 |
| Cha, J | 1 |
| Kim, SU | 1 |
| Park, JY | 2 |
| Ahn, SH | 2 |
| Han, KH | 2 |
| Chon, CY | 2 |
| Shin, SK | 1 |
| Kim, DY | 1 |
| Bastani, P | 1 |
| Ahmad Kiadaliri, A | 1 |
| Thukral, A | 1 |
| Metz, J | 1 |
| Hwang, WT | 1 |
| O'Dwyer, P | 1 |
| Plastaras, J | 1 |
| Both, S | 1 |
| Bar-Ad, V | 1 |
| Ad, VB | 1 |
| Abe, T | 2 |
| Hachiro, Y | 1 |
| Kunimoto, M | 1 |
| Gallerani, E | 1 |
| Bauer, J | 2 |
| Hess, D | 1 |
| Boehm, S | 1 |
| Droege, C | 1 |
| Jeckelmann, S | 1 |
| Miani, M | 1 |
| Herrmann, R | 1 |
| Sperka, S | 1 |
| Sessa, C | 2 |
| Hesketh, PJ | 1 |
| Sanz-Altamira, P | 1 |
| Bushey, J | 1 |
| Hesketh, AM | 1 |
| Cao, KJ | 1 |
| Zhang, AL | 1 |
| Ma, WJ | 1 |
| Huang, PY | 1 |
| Luo, DH | 1 |
| Li, JH | 1 |
| Li, B | 1 |
| Jiang, HR | 1 |
| Zhong, MZ | 1 |
| Winterhalder, R | 1 |
| Hoesli, P | 1 |
| Delmore, G | 1 |
| Pederiva, S | 1 |
| Bressoud, A | 1 |
| Hermann, F | 1 |
| von Moos, R | 1 |
| Bot, BM | 1 |
| Thomas, DM | 1 |
| Bleyer, A | 1 |
| Kohne, CH | 2 |
| Seymour, MT | 1 |
| Tagashira, H | 1 |
| Matsuhisa, T | 1 |
| Oze, I | 1 |
| Kiyoto, S | 1 |
| Hara, F | 1 |
| Takabatake, D | 1 |
| Takashima, S | 3 |
| Osumi, S | 1 |
| Eguchi, H | 1 |
| Sato, Y | 3 |
| Tatematsu, M | 2 |
| Ishikawa, K | 1 |
| Okamoto, H | 2 |
| Noma, H | 3 |
| Chakravarty, T | 1 |
| Crane, CH | 1 |
| Ajani, JA | 2 |
| Mansfield, PF | 1 |
| Briere, TM | 1 |
| Beddar, AS | 1 |
| Mok, H | 1 |
| Reed, VK | 1 |
| Krishnan, S | 1 |
| Delclos, ME | 1 |
| Das, P | 1 |
| Kim, YJ | 1 |
| Goh, PG | 1 |
| Kim, ES | 1 |
| Lee, SY | 1 |
| Moon, HS | 1 |
| Lee, ES | 1 |
| Sung, JK | 1 |
| Kim, SH | 3 |
| Lee, BS | 1 |
| Jeong, HY | 1 |
| Kadoyama, K | 1 |
| Miki, I | 1 |
| Tamura, T | 1 |
| Brown, JB | 1 |
| Sakaeda, T | 1 |
| Okuno, Y | 1 |
| Xiang, XJ | 1 |
| Qiu, F | 1 |
| Yu, F | 1 |
| Zhan, ZY | 1 |
| Feng, M | 1 |
| Yan, J | 1 |
| Zhao, JG | 1 |
| Oshiro, C | 1 |
| Kamigaki, S | 1 |
| Nakamura, Y | 2 |
| Arai, T | 2 |
| Kanai, Y | 1 |
| Fujino, M | 1 |
| Fujii, C | 1 |
| Hamaguchi, Y | 1 |
| Iseki, C | 1 |
| Hachino, Y | 1 |
| Furukawa, H | 1 |
| Chang, KJ | 1 |
| Reid, T | 1 |
| Senzer, N | 1 |
| Swisher, S | 1 |
| Pinto, H | 1 |
| Hanna, N | 1 |
| Chak, A | 1 |
| Soetikno, R | 1 |
| Blazer, M | 1 |
| Phillips, G | 1 |
| Reardon, J | 1 |
| Efries, D | 1 |
| Smith, Y | 1 |
| Weatherby, L | 1 |
| Juergens, K | 1 |
| Rose, J | 1 |
| Griffith, N | 1 |
| Bekaii-Saab, T | 1 |
| Qi, WX | 1 |
| Tang, LN | 1 |
| He, AN | 1 |
| Shen, Z | 1 |
| Hayakawa, Y | 1 |
| Flaherty, AM | 1 |
| Woloch, C | 1 |
| Di Paolo, A | 2 |
| Marouani, H | 1 |
| Bocci, G | 1 |
| Ciccolini, J | 1 |
| Lacarelle, B | 1 |
| Danesi, R | 2 |
| Iliadis, A | 1 |
| Schwartzman, AD | 1 |
| Sethi, R | 1 |
| Smith, R | 1 |
| Zhong, LP | 1 |
| Zhang, CP | 1 |
| Ren, GX | 1 |
| William, WN | 1 |
| Sun, J | 1 |
| Zhu, HG | 1 |
| Tu, WY | 1 |
| Cai, YL | 1 |
| Wang, LZ | 1 |
| Fan, XD | 1 |
| Wang, ZH | 1 |
| Hu, YJ | 1 |
| Ji, T | 1 |
| Yang, WJ | 1 |
| Ye, WM | 1 |
| He, Y | 1 |
| Wang, YA | 1 |
| Xu, LQ | 1 |
| Wang, BS | 1 |
| Kies, MS | 1 |
| Lee, JJ | 1 |
| Myers, JN | 1 |
| Zhang, ZY | 1 |
| Oddby-Muhrbeck, E | 1 |
| Öbrink, E | 1 |
| Eksborg, S | 1 |
| Rotstein, S | 2 |
| Lönnqvist, PA | 1 |
| Nakatsumi, H | 1 |
| Yuki, S | 1 |
| Sogabe, S | 1 |
| Tateyama, M | 1 |
| Muto, S | 1 |
| Kudo, M | 1 |
| Miyagishima, T | 1 |
| Uebayashi, M | 1 |
| Meguro, T | 1 |
| Oba, K | 1 |
| Asaka, M | 1 |
| Sadanaga, N | 1 |
| Kakeji, Y | 1 |
| Baba, H | 1 |
| Nishimaki, T | 1 |
| Natsugoe, S | 1 |
| Shirouzu, K | 2 |
| Uncu, D | 1 |
| Aksoy, S | 1 |
| Çetin, B | 1 |
| Yetişyiğit, T | 1 |
| Özdemir, N | 1 |
| Berk, V | 1 |
| Dane, F | 1 |
| Inal, A | 1 |
| Harputluoğlu, H | 1 |
| Budakoğlu, B | 1 |
| Koca, D | 1 |
| Sevinç, A | 1 |
| Cihan, S | 1 |
| Durnalı, AG | 1 |
| Özkan, M | 1 |
| Öztürk, MA | 1 |
| Işıkdoğan, A | 1 |
| Büyükberber, S | 1 |
| Benekli, M | 1 |
| Köş, T | 1 |
| Alkış, N | 1 |
| Karaca, H | 1 |
| Turhal, NS | 1 |
| Zengin, N | 1 |
| Ando, E | 3 |
| Tanaka, M | 3 |
| Yamashita, F | 3 |
| Kuromatsu, R | 1 |
| Yutani, S | 1 |
| Fukumori, K | 2 |
| Sumie, S | 1 |
| Yano, Y | 2 |
| Okuda, K | 1 |
| Sata, M | 2 |
| Francini, G | 1 |
| Petrioli, R | 1 |
| Messinese, S | 1 |
| Pozzessere, D | 1 |
| Marsili, S | 1 |
| Correale, P | 1 |
| Sabatino, M | 1 |
| Fiaschi, AI | 1 |
| Carlomagno, C | 1 |
| Lauria, R | 1 |
| De Laurentiis, M | 1 |
| Arpino, G | 1 |
| Massarelli, E | 1 |
| Ferrara, C | 1 |
| Milano, A | 1 |
| Vernaglia Lombardi, A | 1 |
| Costanzo, R | 1 |
| Catalano, G | 1 |
| Bianco, AR | 1 |
| De Placido, S | 1 |
| Calvo, E | 1 |
| Cortés, J | 1 |
| González-Cao, M | 1 |
| Rodríguez, J | 1 |
| Aramendía, JM | 1 |
| Fernández-Hidalgo, O | 1 |
| Martín-Algarra, S | 1 |
| Salgado, JE | 1 |
| Martínez-Monge, R | 1 |
| de Irala, J | 1 |
| Brugarolas, A | 1 |
| Liaw, CC | 1 |
| Chang, HK | 1 |
| Liau, CT | 1 |
| Huang, JS | 1 |
| Lin, YC | 2 |
| Chen, JS | 1 |
| Okabe, S | 1 |
| Ishikawa, T | 1 |
| Tanami, H | 1 |
| Kuwabara, H | 1 |
| Fukahara, T | 1 |
| Udagawa, M | 1 |
| Ootsukasa, S | 1 |
| Murase, N | 1 |
| Iwai, T | 1 |
| Shimada, Y | 2 |
| Matsumura, Y | 2 |
| Fujita, S | 1 |
| Akasu, T | 1 |
| Moriya, Y | 1 |
| Shirao, K | 3 |
| Tai, CJ | 1 |
| Liu, JH | 1 |
| Chen, WS | 1 |
| Lin, JK | 1 |
| Wang, WS | 1 |
| Yen, CC | 1 |
| Chiou, TJ | 1 |
| Chen, PM | 1 |
| HARTMANN, JR | 1 |
| ORIGENES, ML | 1 |
| MURPHY, ML | 1 |
| SITARZ, A | 1 |
| ERLANDSON, M | 1 |
| CUDMORE, JT | 1 |
| GROESBECK, HP | 1 |
| SCHELL, HW | 1 |
| MOERTEL, CG | 7 |
| REITEMEIER, RJ | 4 |
| HAHN, RG | 4 |
| TOURNEUR, R | 1 |
| GRIVAUX, M | 1 |
| LAMOTTE-BARRILLON, S | 1 |
| MCCAFFERY, JF | 1 |
| Stickel, F | 1 |
| Jüngert, B | 1 |
| Brueckl, V | 1 |
| Schirner, I | 1 |
| Brueckl, WM | 1 |
| Männlein, G | 1 |
| Hegewald, J | 1 |
| Mühldorfer, S | 1 |
| Bittorf, B | 1 |
| Hahn, EG | 1 |
| Ura, T | 1 |
| Gourley, C | 1 |
| Cassidy, J | 1 |
| Edwards, C | 1 |
| Samuel, L | 1 |
| Bisset, D | 1 |
| Camboni, G | 1 |
| Young, A | 1 |
| Boyle, D | 1 |
| Jodrell, D | 1 |
| Sasahara, H | 1 |
| Matono, S | 1 |
| Yamana, H | 1 |
| Fujita, H | 1 |
| Pusztai, L | 1 |
| Mendoza, TR | 1 |
| Reuben, JM | 1 |
| Martinez, MM | 1 |
| Willey, JS | 1 |
| Lara, J | 1 |
| Syed, A | 1 |
| Fritsche, HA | 1 |
| Bruera, E | 1 |
| Booser, D | 1 |
| Valero, V | 2 |
| Arun, B | 2 |
| Ibrahim, N | 1 |
| Rivera, E | 2 |
| Cleeland, CS | 1 |
| Hortobagyi, GN | 5 |
| Barbara, C | 1 |
| Cupini, S | 1 |
| Del Tacca, M | 1 |
| Schrijvers, D | 1 |
| Van Herpen, C | 1 |
| Kerger, J | 1 |
| Joosens, E | 1 |
| Van Laer, C | 1 |
| Van den Weyngaert, D | 1 |
| Nguyen, H | 1 |
| Le Bouder, C | 1 |
| Castelijns, JA | 1 |
| Kaanders, J | 1 |
| De Mulder, P | 1 |
| Vermorken, JB | 1 |
| Cals, L | 1 |
| Rixe, O | 1 |
| François, E | 1 |
| Favre, R | 1 |
| Merad, L | 1 |
| Deplanque, G | 1 |
| Laadem, A | 1 |
| Juin, P | 1 |
| Bereder, JM | 1 |
| Bernardini, D | 1 |
| Herait, P | 1 |
| Kakolyris, S | 2 |
| Souglakos, J | 1 |
| Kouroussis, C | 2 |
| Androulakis, N | 1 |
| Samonis, G | 1 |
| Vardakis, N | 1 |
| Amarantidis, K | 1 |
| Agelaki, S | 1 |
| Mavroudis, D | 1 |
| Xenidis, N | 1 |
| Georgoulias, V | 2 |
| Kuehr, T | 1 |
| Ruff, P | 1 |
| Rapoport, BL | 1 |
| Falk, S | 1 |
| Daniel, F | 1 |
| Jacobs, C | 1 |
| Davidson, N | 1 |
| Thaler, J | 1 |
| Boussard, B | 1 |
| Carmichael, J | 1 |
| Teufel, A | 1 |
| Steinmann, S | 1 |
| Zanke, C | 1 |
| Hohl, H | 1 |
| Adami, B | 1 |
| Schroeder, M | 1 |
| Klein, O | 1 |
| Höhler, T | 1 |
| Galle, PR | 1 |
| Heike, M | 1 |
| Lu, JW | 1 |
| Gao, CM | 1 |
| Wu, JZ | 1 |
| Sun, XF | 1 |
| Wang, L | 1 |
| Feng, JF | 1 |
| Song, SY | 1 |
| Lee, SI | 1 |
| Chung, HC | 1 |
| Choi, SH | 1 |
| Noh, SH | 1 |
| Park, JN | 1 |
| Han, JY | 1 |
| Lee, KS | 1 |
| Cho, JY | 1 |
| Marsé, H | 1 |
| Van Cutsem, E | 1 |
| Valverde, S | 1 |
| Hirao, M | 2 |
| Fujitani, K | 2 |
| Tsujinaka, T | 2 |
| Garcia, AA | 1 |
| Leichman, L | 2 |
| Baranda, J | 1 |
| Pandit, L | 1 |
| Lenz, HJ | 1 |
| Leichman, CG | 2 |
| Undevia, SD | 1 |
| Janisch, L | 1 |
| Olson, SC | 1 |
| Schilsky, RL | 1 |
| Vogelzang, NJ | 1 |
| Kimmel, KA | 1 |
| Macek, TA | 1 |
| Ratain, MJ | 2 |
| Ishida, K | 1 |
| Ando, N | 1 |
| Yamamoto, S | 1 |
| Ide, H | 1 |
| Shinoda, M | 1 |
| Schena, M | 1 |
| Barone, C | 1 |
| Birocco, N | 1 |
| Dongiovanni, D | 1 |
| Numico, G | 1 |
| Colantonio, I | 1 |
| Bertetto, O | 1 |
| Qian, J | 1 |
| Mei, JF | 1 |
| Chen, YX | 1 |
| Shao, ZJ | 1 |
| He, ZM | 1 |
| Momokawa, K | 1 |
| Sakayauchi, T | 1 |
| Watanabe, T | 2 |
| Mikami, T | 1 |
| Matsumoto, T | 1 |
| Dong, QM | 1 |
| Li, S | 1 |
| Zhou, ZM | 1 |
| Zhou, ZW | 2 |
| Xia, ZJ | 1 |
| Li, YY | 1 |
| Steiner, M | 1 |
| Seule, M | 1 |
| Steiner, B | 1 |
| Bauer, I | 1 |
| Freund, M | 1 |
| Schuff-Werner, P | 1 |
| Kotake, K | 1 |
| Ohashi, Y | 1 |
| Kodaira, S | 1 |
| Koyama, Y | 1 |
| Suzuki, S | 1 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Tanaka, S | 1 |
| Suzuki, M | 2 |
| Hanyu, F | 1 |
| Tsai, JY | 1 |
| Iannitti, D | 1 |
| Berkenblit, A | 1 |
| Akerman, P | 1 |
| Nadeem, A | 1 |
| Rathore, R | 1 |
| Harrington, D | 1 |
| Roye, D | 1 |
| Miner, T | 1 |
| Barnett, JM | 1 |
| Maia, C | 1 |
| Stuart, K | 1 |
| Safran, H | 1 |
| Lee, KE | 1 |
| Im, YH | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Shim, YM | 1 |
| Ito, T | 1 |
| Hata, Y | 1 |
| Matsuoka, S | 1 |
| Nakajima, N | 1 |
| Yokoyama, R | 1 |
| Honda, S | 1 |
| Sano, F | 1 |
| Akasaka, Y | 1 |
| Ohmori, K | 1 |
| Viale, PH | 1 |
| Fung, A | 1 |
| Zitella, L | 1 |
| Ferrari, V | 1 |
| Valcamonico, F | 1 |
| Amoroso, V | 1 |
| Simoncini, E | 1 |
| Vassalli, L | 1 |
| Marpicati, P | 1 |
| Rangoni, G | 1 |
| Grisanti, S | 1 |
| Pasinetti, N | 1 |
| Marini, G | 1 |
| Tanigaki, Y | 1 |
| Mikami, Y | 1 |
| Horiuchi, C | 1 |
| Taguchi, T | 4 |
| Yoshida, T | 1 |
| Ishitoya, J | 1 |
| Katori, H | 1 |
| Ikeda, Y | 1 |
| Tsukuda, M | 2 |
| Farker, K | 1 |
| Merkel, U | 1 |
| Wedding, U | 1 |
| Hippius, M | 1 |
| Höffken, K | 1 |
| Hoffmann, A | 1 |
| Takayama, T | 1 |
| Sagawa, T | 1 |
| Okamoto, T | 2 |
| Miyanishi, K | 1 |
| Sato, T | 1 |
| Araki, H | 1 |
| Iyama, S | 1 |
| Abe, S | 1 |
| Murase, K | 1 |
| Takimoto, R | 1 |
| Nagakura, H | 1 |
| Hareyama, M | 1 |
| Kato, J | 1 |
| Niitsu, Y | 1 |
| Ohta, K | 1 |
| Dohden, K | 1 |
| Morishita, M | 1 |
| Hayashi, H | 1 |
| Hattori, M | 1 |
| Hosokawa, O | 1 |
| Morita, M | 1 |
| Kaizaki, Y | 1 |
| Kiya, T | 1 |
| Miyata, Y | 1 |
| Muto, M | 1 |
| Hamaguchi, T | 1 |
| Mera, K | 1 |
| Yano, T | 1 |
| Tanigawara, Y | 1 |
| Okusaka, T | 1 |
| Ishii, H | 1 |
| Funakoshi, A | 1 |
| Ueno, H | 1 |
| Furuse, J | 1 |
| Sumii, T | 1 |
| Zhang, P | 1 |
| Wu, LY | 1 |
| Hu, Y | 1 |
| Liu, JW | 1 |
| Gao, YJ | 1 |
| Guan, XQ | 1 |
| Nan, KJ | 1 |
| Suo, AL | 1 |
| Wang, XW | 1 |
| Zhang, MH | 1 |
| Zhang, WD | 1 |
| Li, CW | 1 |
| Zhao, JB | 1 |
| Meyers, C | 1 |
| Groves, M | 1 |
| Francis, D | 1 |
| Broglio, K | 1 |
| Yin, G | 1 |
| Buchholz, T | 1 |
| Berg, DT | 1 |
| Jiang, Y | 1 |
| Qiu, XH | 1 |
| Yang, YX | 1 |
| Zhang, SQ | 1 |
| Chen, ZM | 1 |
| Shi, YX | 2 |
| Huang, H | 1 |
| Ma, ZY | 1 |
| Wang, JH | 1 |
| Xie, WM | 1 |
| Li, XG | 1 |
| Liu, YL | 1 |
| Dai, AD | 1 |
| Zhuang, W | 1 |
| Zhang, C | 1 |
| Zhang, W | 1 |
| Zhao, ZY | 1 |
| Wu, Q | 1 |
| Cheng, J | 1 |
| Wu, CP | 1 |
| Xu, LG | 1 |
| Wang, GQ | 1 |
| Wan, DS | 1 |
| Pan, ZZ | 1 |
| Chen, G | 1 |
| Fang, YJ | 1 |
| Wu, XJ | 1 |
| Li, LR | 1 |
| Ding, PR | 1 |
| Liu, K | 1 |
| Wang, GB | 1 |
| Cheng, B | 1 |
| Qiu, DB | 1 |
| Iwasaki, Y | 1 |
| Shiraha, H | 1 |
| Sakaguchi, K | 1 |
| Shiratori, Y | 1 |
| Maruoka, Y | 2 |
| Ogiuchi, Y | 2 |
| Ogiuchi, H | 2 |
| Yoon, YJ | 1 |
| Kim, JK | 1 |
| Lee, HW | 1 |
| Lee, DY | 1 |
| Moon, YM | 1 |
| Yamamitsu, S | 2 |
| Kimura, H | 2 |
| Inui, N | 2 |
| Hiyama, S | 2 |
| Hirata, K | 2 |
| Kimura, Y | 2 |
| Koito, K | 1 |
| Shirasaka, T | 5 |
| Wang, F | 1 |
| Yoshino, T | 1 |
| Onozawa, Y | 1 |
| Hironaka, S | 1 |
| Fukutomi, A | 1 |
| Yamaguchi, Y | 2 |
| Hasuike, N | 1 |
| Yamazaki, K | 1 |
| Machida, N | 1 |
| Ono, H | 2 |
| Zhou, YD | 1 |
| Sun, Q | 1 |
| Huan, HY | 1 |
| Mao, F | 1 |
| Guan, JH | 1 |
| Zachariae, R | 1 |
| Paulsen, K | 1 |
| Mehlsen, M | 1 |
| Jensen, AB | 1 |
| Johansson, A | 1 |
| von der Maase, H | 1 |
| Kim, SG | 1 |
| Oh, SY | 2 |
| Kwon, HC | 2 |
| Lee, S | 2 |
| Kim, HJ | 2 |
| Ernst, T | 1 |
| Merx, K | 1 |
| Gnad-Vogt, U | 1 |
| Lukan, N | 1 |
| Kripp, M | 1 |
| Schultheis, B | 1 |
| Lee, DM | 1 |
| Yoo, HS | 1 |
| Jang, JS | 1 |
| Kim, MC | 1 |
| Jeong, JS | 1 |
| Li, ZW | 1 |
| Wen, HC | 1 |
| Benz, C | 1 |
| Tillis, T | 1 |
| Tattelman, E | 1 |
| Cadman, E | 1 |
| Habeshaw, T | 1 |
| Adam, JS | 1 |
| Kirk, J | 1 |
| Kemeny, NE | 1 |
| Ahmed, T | 1 |
| Michaelson, RA | 1 |
| Harper, HD | 1 |
| Yip, LC | 1 |
| Togni, P | 1 |
| Varini, M | 1 |
| Cavalli, F | 2 |
| Legha, SS | 2 |
| Blumenschein, GR | 4 |
| Buzdar, AU | 4 |
| Tormey, DC | 4 |
| Weinberg, VE | 1 |
| Holland, JF | 1 |
| Weiss, RB | 1 |
| Glidewell, OJ | 1 |
| Perloff, M | 1 |
| Falkson, G | 3 |
| Falkson, HC | 2 |
| Henry, PH | 1 |
| Leone, LA | 1 |
| Vogel, CL | 1 |
| Smalley, RV | 1 |
| Raney, M | 1 |
| Krauss, S | 1 |
| Carpenter, J | 1 |
| Velez-Garcia, E | 1 |
| Fishkin, E | 1 |
| Raab, S | 1 |
| Moore, MR | 1 |
| Stagg, M | 1 |
| Bedikian, AY | 2 |
| Stroehlein, J | 1 |
| Korinek, J | 1 |
| Karlin, D | 1 |
| Bodey, GP | 3 |
| Valdivieso, M | 2 |
| Burgess, MA | 1 |
| Kamiya, O | 1 |
| Hoshino, A | 1 |
| Ohara, K | 1 |
| Nagata, K | 1 |
| Kojima, T | 1 |
| Sugihara, T | 1 |
| Kimura, K | 1 |
| Fujii, S | 1 |
| Ansfield, FJ | 2 |
| Kallas, GJ | 1 |
| Singson, JP | 1 |
| Logothetis, CJ | 1 |
| Samuels, ML | 1 |
| von Eschenbach, AC | 1 |
| Trindade, A | 1 |
| Ogden, S | 1 |
| Grant, C | 1 |
| Johnson, DE | 1 |
| Bukowski, RM | 2 |
| Abderhalden, RT | 1 |
| Hewlett, JS | 1 |
| Weick, JK | 1 |
| Groppe, CW | 1 |
| Pinnamaneni, K | 1 |
| Yap, HY | 3 |
| Distefano, A | 1 |
| David, M | 1 |
| Durand, M | 1 |
| Chauvergne, J | 1 |
| Mauriac, L | 1 |
| Bui, BN | 1 |
| Hoerni, B | 1 |
| Aboud, A | 1 |
| Shildt, RA | 1 |
| Kennedy, PS | 1 |
| Chen, TT | 1 |
| Athens, JW | 1 |
| O'Bryan, RM | 1 |
| Balcerzak, SP | 1 |
| McDermott, BJ | 1 |
| Van den Berg, HW | 1 |
| Martin, WM | 2 |
| Murphy, RF | 1 |
| Windschitl, H | 1 |
| Scott, M | 1 |
| Schutt, A | 1 |
| McCormack, G | 1 |
| Everson, L | 1 |
| Cullinan, S | 1 |
| Gerstner, J | 1 |
| Krook, J | 1 |
| Laurie, J | 1 |
| Shreck, R | 1 |
| Kotake, T | 1 |
| Usami, M | 1 |
| Miki, T | 1 |
| Kuroda, M | 1 |
| Obata, K | 1 |
| Osafune, M | 1 |
| Fujioka, H | 1 |
| Takasugi, Y | 1 |
| Israel, L | 1 |
| Breau, JL | 1 |
| Aguilera, J | 1 |
| Chang, YC | 1 |
| Crowley, J | 1 |
| Lee, YT | 1 |
| Chlebowski, RT | 2 |
| Silverberg, I | 1 |
| Pajak, T | 1 |
| Weiner, J | 1 |
| Kardinal, C | 1 |
| Bateman, JR | 2 |
| Wiseman, CL | 1 |
| Gutterman, JU | 1 |
| Hersh, EM | 1 |
| McCracken, JD | 1 |
| Ray, P | 1 |
| Heilbrun, LK | 1 |
| Vaitkevicius, VK | 1 |
| Saiki, JH | 1 |
| Rivkin, SE | 2 |
| Rossof, AH | 1 |
| Moore, TN | 1 |
| Vogl, SE | 1 |
| Lanham, R | 1 |
| Kaplan, BH | 1 |
| Engstrom, PF | 1 |
| MacIntyre, JM | 1 |
| Douglass, HO | 2 |
| Muggia, F | 2 |
| Mittelman, A | 2 |
| Wilcox, PM | 2 |
| Fetting, JH | 2 |
| Nettesheim, KM | 1 |
| Abeloff, MD | 1 |
| Sorbe, B | 1 |
| Frankendal, B | 1 |
| Boesen, E | 1 |
| Pugh, RP | 1 |
| Weiner, JM | 1 |
| Frytak, S | 2 |
| Rubin, J | 2 |
| Schutt, AJ | 3 |
| Weiland, LH | 1 |
| Childs, DS | 1 |
| Holbrook, MA | 1 |
| Lavin, PT | 1 |
| Livstone, E | 1 |
| Spiro, H | 1 |
| Knowlton, A | 1 |
| Kalser, M | 1 |
| Barkin, J | 1 |
| Lessner, H | 1 |
| Mann-Kaplan, R | 1 |
| Ramming, K | 1 |
| Douglas, HO | 2 |
| Thomas, P | 1 |
| Nave, H | 1 |
| Bateman, J | 1 |
| Lokich, J | 2 |
| Brooks, J | 1 |
| Chaffey, J | 1 |
| Corson, JM | 1 |
| Zamcheck, N | 1 |
| Novak, JW | 1 |
| Kohno, N | 2 |
| Ichikawa, G | 1 |
| Inuyama, Y | 1 |
| Kawaida, M | 1 |
| Ohnuma, T | 1 |
| Noguchi, S | 2 |
| Shuin, T | 1 |
| Kubota, Y | 1 |
| Masuda, M | 1 |
| Yao, M | 1 |
| Hosaka, M | 1 |
| Kohno, H | 1 |
| Enomoto, H | 1 |
| Kawai, S | 1 |
| Yago, T | 1 |
| Ikema, Y | 1 |
| Makino, Y | 1 |
| Kubota, A | 1 |
| Furukawa, M | 1 |
| Hebbar, M | 1 |
| Hecquet, B | 1 |
| Vanlemmens, L | 1 |
| Lecomte, S | 1 |
| Pion, JM | 1 |
| Adenis, A | 1 |
| Konishi, K | 1 |
| Yabushita, K | 1 |
| Ota, J | 1 |
| Kikkawa, N | 1 |
| Yasutomi, M | 2 |
| Sowa, M | 2 |
| Kusama, M | 1 |
| Tominaga, T | 3 |
| Enomoto, K | 2 |
| Yoshida, M | 1 |
| Koyama, H | 2 |
| Sonoo, H | 1 |
| Abe, R | 2 |
| Nishi, T | 1 |
| Yamaguchi, S | 1 |
| Huber, MH | 1 |
| Shirinian, M | 1 |
| Lippman, SM | 1 |
| Dimery, IW | 1 |
| Frankenthaler, RA | 1 |
| Hong, WK | 1 |
| Nakazato, H | 1 |
| Koike, A | 1 |
| Saji, S | 1 |
| Ogawa, N | 1 |
| Sakamoto, J | 1 |
| Nakai, Y | 1 |
| Furuse, K | 1 |
| Ohta, M | 1 |
| Fujii, M | 3 |
| Asakawa, M | 1 |
| Fukuoka, M | 1 |
| Yoshida, K | 1 |
| Niitani, H | 1 |
| Fredrikson, M | 2 |
| Hursti, TJ | 1 |
| Steineck, G | 1 |
| Fürst, CJ | 2 |
| Börjesson, S | 1 |
| Peterson, C | 1 |
| Domaradzka-Woźniak, A | 1 |
| Wojtacki, J | 1 |
| Dziewulska-Bokiniec, A | 1 |
| Stöger, H | 2 |
| Bauernhofer, T | 1 |
| Schmid, M | 2 |
| Ploner, F | 1 |
| Moser, R | 1 |
| Derstvenscheg, E | 1 |
| Steindorfer, P | 2 |
| Wilders-Truschnig, M | 1 |
| Kuss, I | 1 |
| Samonigg, H | 2 |
| Tan, EH | 1 |
| Ang, PT | 1 |
| Khoo, KS | 1 |
| Zhou, JC | 1 |
| Tomio, L | 1 |
| Zorat, PL | 1 |
| Paccagnella, A | 1 |
| Segati, R | 1 |
| Loreggian, L | 1 |
| Lora, O | 1 |
| Friso, ML | 1 |
| Chiarion-Sileni, V | 1 |
| Favaretto, A | 1 |
| Fede, A | 1 |
| Buser, KS | 1 |
| Joss, RA | 1 |
| Piquet, D | 1 |
| Aapro, MS | 1 |
| Haefliger, JM | 1 |
| Jungi, WF | 1 |
| Obrist, R | 1 |
| Brunner, KW | 1 |
| Arai, Y | 1 |
| Sone, Y | 1 |
| Inaba, Y | 1 |
| Mukaijo, T | 1 |
| Nakatsuka, A | 1 |
| Nagashima, K | 1 |
| Kido, C | 1 |
| Ariyoshi, Y | 1 |
| Levitt, M | 1 |
| Warr, D | 1 |
| Yelle, L | 1 |
| Rayner, HL | 1 |
| Lofters, WS | 1 |
| Perrault, DJ | 1 |
| Wilson, KS | 1 |
| Latreille, J | 1 |
| Potvin, M | 1 |
| Warner, E | 1 |
| Lekander, M | 1 |
| Blomgren, H | 1 |
| Williamson, SK | 1 |
| Tangen, CM | 1 |
| Maddox, AM | 1 |
| Spiridonidis, CH | 1 |
| Macdonald, JS | 2 |
| Singh, G | 1 |
| Singh, DP | 1 |
| Gupta, D | 1 |
| Muralikrishna, BV | 1 |
| Coombes, RC | 1 |
| Bliss, JM | 1 |
| Wils, J | 1 |
| Morvan, F | 1 |
| Espié, M | 1 |
| Amadori, D | 1 |
| Gambrosier, P | 1 |
| Richards, M | 1 |
| Aapro, M | 1 |
| Villar-Grimalt, A | 1 |
| McArdle, C | 1 |
| Pérez-López, FR | 1 |
| Vassilopoulos, P | 1 |
| Ferreira, EP | 1 |
| Chilvers, CE | 1 |
| Coombes, G | 1 |
| Woods, EM | 1 |
| Marty, M | 1 |
| Feliu, J | 2 |
| González Barón, M | 2 |
| García-Girón, C | 1 |
| Espinosa, E | 2 |
| Belón, J | 1 |
| Blanco, E | 1 |
| Garrido, P | 1 |
| Ordónez, A | 2 |
| Gómez-Navarro, J | 1 |
| Zamora, P | 1 |
| Wang, R | 1 |
| Fan, Q | 1 |
| Wang, Z | 1 |
| Hisano, C | 1 |
| Nakano, S | 1 |
| Masumoto, N | 1 |
| Fujishima, H | 1 |
| Nakamura, M | 1 |
| Niho, Y | 1 |
| Bosnjak, SM | 1 |
| Neskovic-Konstantinovic, ZB | 1 |
| Jovanovic-Micic, DJ | 1 |
| Mitrovic, LB | 1 |
| Radulovic, SS | 1 |
| Fujinami, K | 1 |
| Ikeda, I | 1 |
| Miura, T | 1 |
| Kondo, I | 1 |
| García Girón, C | 1 |
| Vicent, JM | 1 |
| Gómez Navarro, J | 1 |
| Berrocal, A | 1 |
| Vilches, Y | 1 |
| de Castro, J | 1 |
| Díaz, J | 1 |
| Park, Y | 1 |
| Hatano, Y | 1 |
| Sasamoto, S | 1 |
| Kato, N | 1 |
| Okuyama, N | 1 |
| Yamazaki, S | 1 |
| Kobayashi, F | 1 |
| Yamanouchi, T | 1 |
| Sato, H | 1 |
| Adachi, I | 1 |
| Sakamoto, T | 1 |
| Fujimaki, M | 1 |
| Horikoshi, I | 1 |
| Hecht, JR | 1 |
| Lembo, T | 1 |
| Chap, L | 1 |
| Tanikawa, K | 2 |
| Kimura, E | 1 |
| Niimi, S | 1 |
| Watanabe, A | 1 |
| Tokumaru, Y | 2 |
| Imanishi, Y | 2 |
| Kanke, M | 2 |
| Kanzaki, J | 2 |
| Iop, A | 1 |
| Cartei, G | 1 |
| Vigevani, E | 1 |
| Clocchiatti, L | 1 |
| Mansutti, M | 1 |
| Sibau, AM | 1 |
| Klaassen, U | 1 |
| Seeber, S | 1 |
| Fujii, K | 1 |
| Nakashima, K | 1 |
| Ohno, T | 1 |
| Anai, H | 1 |
| Hoshino, K | 1 |
| Ono, K | 1 |
| Kimura, O | 1 |
| Kawaguchi, H | 1 |
| Fukui, H | 1 |
| Ikeda, M | 1 |
| Shinohara, H | 1 |
| Yonekawa, H | 1 |
| Machimura, T | 1 |
| Nishihori, H | 1 |
| Kurihara, N | 1 |
| Urakami, H | 1 |
| Nemoto, Y | 1 |
| Ollivier, S | 1 |
| Fonck, M | 1 |
| Bécouarn, Y | 1 |
| Brunet, R | 1 |
| Narahara, H | 1 |
| Otani, T | 1 |
| Iwanaga, T | 1 |
| Okajima, K | 1 |
| Katsu, K | 1 |
| Kobayashi, K | 1 |
| Okuno, M | 1 |
| Takami, M | 1 |
| Ishida, T | 2 |
| Yasutake, K | 1 |
| Kato, O | 1 |
| Fukuda, H | 1 |
| Kusaba, T | 2 |
| Steyn, RS | 1 |
| Vijeyasingam, R | 1 |
| Darnton, SJ | 1 |
| Cullen, MH | 1 |
| Matthews, HR | 1 |
| Chiara, S | 1 |
| Nobile, MT | 1 |
| Vincenti, M | 1 |
| Lionetto, R | 1 |
| Gozza, A | 1 |
| Barzacchi, MC | 1 |
| Sanguineti, O | 1 |
| Repetto, L | 1 |
| Rosso, R | 1 |
| Muggia, FM | 1 |
| Wu, X | 1 |
| Spicer, D | 1 |
| Groshen, S | 1 |
| Jeffers, S | 1 |
| Chan, KK | 1 |
| Marshall, JL | 1 |
| Richmond, E | 1 |
| DeLap, RJ | 1 |
| Lévy, E | 1 |
| Piedbois, P | 1 |
| Buyse, M | 1 |
| Pignon, JP | 1 |
| Rougier, P | 2 |
| Ryan, L | 1 |
| Hansen, R | 1 |
| Zee, B | 1 |
| Weinerman, B | 1 |
| Pater, J | 1 |
| Leichman, C | 1 |
| Macdonald, J | 1 |
| Benedetti, J | 1 |
| Fryer, J | 1 |
| Brufman, G | 2 |
| Isacson, R | 1 |
| Laplanche, A | 1 |
| Thirion, P | 1 |
| Dikken, C | 1 |
| Sitzia, J | 1 |
| Rothenberg, ML | 1 |
| Cox, JV | 1 |
| DeVore, RF | 1 |
| Hainsworth, JD | 1 |
| Pazdur, R | 1 |
| Sandbach, J | 1 |
| Wolf, DL | 1 |
| Mohrland, JS | 1 |
| Elfring, GL | 1 |
| Miller, LL | 1 |
| Von Hoff, DD | 1 |
| Asato, Y | 1 |
| Yoshimi, F | 1 |
| Amemiya, R | 1 |
| Koizumi, S | 1 |
| Hasegawa, H | 1 |
| Miya, T | 1 |
| Goya, T | 1 |
| Sigsgaard, T | 1 |
| Herrstedt, J | 1 |
| Andersen, LJ | 1 |
| Havsteen, H | 2 |
| Langer, SW | 1 |
| Kjaerbøl, AG | 1 |
| Lund, H | 1 |
| Kjaer, M | 3 |
| Dombernowsky, P | 1 |
| Tsukamoto, F | 1 |
| Yoneda, K | 1 |
| Takamura, Y | 1 |
| Hojo, S | 1 |
| Shiba, E | 1 |
| Colevas, AD | 1 |
| Norris, CM | 1 |
| Tishler, RB | 1 |
| Fried, MP | 1 |
| Gomolin, HI | 1 |
| Amrein, P | 1 |
| Nixon, A | 1 |
| Lamb, C | 1 |
| Costello, R | 1 |
| Barton, J | 1 |
| Read, R | 1 |
| Adak, S | 1 |
| Posner, MR | 1 |
| Miyashita, M | 1 |
| Onda, M | 1 |
| Ikeda, K | 1 |
| Bando, K | 1 |
| Hagiwara, N | 1 |
| Tsuchiya, Y | 1 |
| Yoshiyuki, T | 1 |
| Kiyama, T | 1 |
| Saito, T | 1 |
| Sasajima, K | 1 |
| Yamashita, K | 1 |
| Faivre, C | 1 |
| Ducreux, M | 1 |
| Mitry, E | 1 |
| Lusinchi, A | 1 |
| Lasser, P | 1 |
| Elias, D | 1 |
| Eschwege, F | 1 |
| Sasaki, K | 1 |
| Yanagida, T | 1 |
| Ohya, M | 1 |
| Tsuji, A | 1 |
| Horimi, T | 1 |
| Takasaki, M | 1 |
| Takahashi, I | 2 |
| Kitahara, S | 1 |
| Tamura, E | 1 |
| Tanabe, T | 1 |
| Nakanoboh, M | 1 |
| Kawada, M | 1 |
| Domenge, C | 1 |
| Hill, C | 1 |
| Lefebvre, JL | 1 |
| De Raucourt, D | 1 |
| Rhein, B | 1 |
| Wibault, P | 1 |
| Marandas, P | 1 |
| Coche-Dequeant, B | 1 |
| Stromboni-Luboinski, M | 1 |
| Sancho-Garnier, H | 1 |
| Luboinski, B | 1 |
| Santini, D | 1 |
| Tonini, G | 1 |
| Salerno, A | 1 |
| Vincenzi, B | 1 |
| Patti, G | 1 |
| Battistoni, F | 1 |
| Dicuonzo, G | 1 |
| Labianca, R | 2 |
| Hoff, PM | 1 |
| Ansari, R | 1 |
| Batist, G | 1 |
| Cox, J | 1 |
| Kocha, W | 1 |
| Kuperminc, M | 1 |
| Maroun, J | 1 |
| Walde, D | 1 |
| Weaver, C | 1 |
| Harrison, E | 1 |
| Burger, HU | 1 |
| Osterwalder, B | 1 |
| Wong, AO | 1 |
| Wong, R | 1 |
| Guglielmi, A | 1 |
| Cirillo, M | 1 |
| Recaldin, E | 1 |
| Frassineti, GL | 1 |
| Aschele, C | 1 |
| Ravaioli, A | 1 |
| Testore, P | 1 |
| Caroti, C | 1 |
| Gallo, L | 1 |
| Pessi, MA | 1 |
| Cortesi, E | 1 |
| Turci, D | 1 |
| Grossi, F | 1 |
| Genvresse, I | 1 |
| Lange, C | 1 |
| Schanz, J | 1 |
| Schweigert, M | 1 |
| Harder, H | 1 |
| Possinger, K | 1 |
| Späth-Schwalbe, E | 1 |
| Olencki, T | 1 |
| Peereboom, D | 1 |
| Wood, L | 1 |
| Budd, GT | 1 |
| Novick, A | 1 |
| Finke, J | 1 |
| McLain, D | 1 |
| Elson, P | 1 |
| Tomita, T | 1 |
| Patt, YZ | 1 |
| Hassan, MM | 1 |
| Lozano, RD | 1 |
| Waugh, KA | 1 |
| Hoque, AM | 1 |
| Frome, AI | 1 |
| Lahoti, S | 1 |
| Ellis, L | 1 |
| Vauthey, JN | 1 |
| Curley, SA | 1 |
| Schnirer, II | 1 |
| Raijman, I | 1 |
| Webb, A | 1 |
| Cunningham, D | 1 |
| Hill, M | 1 |
| Waters, JS | 1 |
| Norman, A | 1 |
| Massey, A | 1 |
| Wenzel, C | 1 |
| Locker, GJ | 1 |
| Schmidinger, M | 1 |
| Mader, R | 1 |
| Kramer, G | 1 |
| Marberger, M | 1 |
| Rauchenwald, M | 1 |
| Zielinski, CC | 1 |
| Steger, GG | 1 |
| Koukourakis, MI | 1 |
| Giatromanolaki, A | 1 |
| Sivridis, E | 1 |
| Frangiadaki, C | 1 |
| Retalis, G | 1 |
| Yang, TS | 1 |
| Hsu, KC | 1 |
| Wang, HM | 1 |
| Hoshino, M | 1 |
| Nishihara, N | 1 |
| Fukada, K | 1 |
| Kuwazawa, T | 1 |
| Mani, S | 1 |
| Rudin, CM | 1 |
| Kunkel, K | 1 |
| Holmlund, JT | 1 |
| Geary, RS | 1 |
| Dorr, FA | 1 |
| Luoma, ML | 1 |
| Hakamies-Blomqvist, L | 1 |
| Sjöström, J | 1 |
| Mouridsen, H | 1 |
| Pluzanska, A | 1 |
| Malmström, P | 1 |
| Bengtsson, NO | 1 |
| Hultborn, R | 1 |
| Ostenstaad, B | 1 |
| Mjaaland, I | 1 |
| Valvere, V | 1 |
| Wist, E | 1 |
| Baldursson, G | 1 |
| Ahigren, J | 1 |
| Blomqvist, C | 1 |
| Shinchi, H | 1 |
| Takao, S | 1 |
| Matsuo, Y | 1 |
| Mataki, Y | 1 |
| Mori, S | 1 |
| Aikou, T | 1 |
| Hayakawa, H | 1 |
| Adimi, P | 1 |
| Hansen, F | 1 |
| Aabo, K | 1 |
| Keldsen, N | 1 |
| Pfeiffer, P | 1 |
| Sandberg, E | 1 |
| Jakobsen, A | 1 |
| Hanley, J | 1 |
| Carbone, PP | 1 |
| Jones, KD | 1 |
| Hughes, LE | 1 |
| Lundbeck, F | 1 |
| Christophersen, IS | 1 |
| Hartman, HA | 1 |
| Kessinger, A | 1 |
| Lemon, HM | 1 |
| Foley, JF | 1 |
| O'Fallon, JR | 2 |
| Creagan, ET | 1 |
| Schwartau, NW | 1 |
| Cedermark, BJ | 1 |
| Kaufman, JH | 1 |
| Amrein, PC | 1 |
| Fabian, RL | 1 |
| Mohapatro, SK | 1 |
| Dandapat, MC | 1 |
| Padhi, NC | 1 |
| Diaz-Rubio, E | 1 |
| Casado, A | 1 |
| Dominguez, S | 1 |
| Sastre, J | 1 |
| Gez, E | 2 |
| Strauss, N | 1 |
| Vitzhaki, N | 1 |
| Cass, Y | 1 |
| Edelmann, DZ | 1 |
| Flaherty, L | 1 |
| Wozniak, A | 1 |
| Redman, B | 1 |
| Kraut, M | 1 |
| Martino, S | 1 |
| Heilbrun, L | 1 |
| Tohnai, I | 1 |
| Kawabe, Y | 1 |
| Nakashima, T | 1 |
| Yamagiwa, M | 1 |
| Suzuki, T | 1 |
| Mizuno, A | 1 |
| Mineda, H | 1 |
| De Besi, P | 1 |
| Busnardo, B | 1 |
| Toso, S | 1 |
| Girelli, ME | 1 |
| Nacamulli, D | 1 |
| Simioni, N | 1 |
| Casara, D | 1 |
| Zorat, P | 1 |
| Fiorentino, MV | 1 |
| Ohmori, H | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Akebi, N | 1 |
| Saika, T | 1 |
| Nanba, K | 1 |
| Tanahashi, T | 1 |
| Josen, T | 1 |
| Nasu, Y | 1 |
| Kerbrat, P | 1 |
| Fargeot, P | 2 |
| Metz, R | 3 |
| Roche, H | 1 |
| Bastit, P | 1 |
| Chevrier, A | 1 |
| Tubiana-Hulin, M | 2 |
| Geyer, G | 1 |
| Cappelaere, P | 2 |
| Kasparek, AK | 1 |
| Dusleag, J | 1 |
| Pfeiffer, K | 1 |
| Smola, M | 1 |
| Lechner, P | 1 |
| Chevallier, B | 1 |
| Pujade-Lauraine, E | 1 |
| Spielmann, M | 1 |
| Paes, D | 1 |
| Bons, J | 1 |
| Evans, WK | 1 |
| Wierzbicki, R | 1 |
| Shepherd, FA | 1 |
| Rusthoven, J | 1 |
| Stewart, DJ | 1 |
| Aitken, SE | 1 |
| Maroun, JA | 1 |
| Ezzat, A | 1 |
| Nakao, I | 1 |
| Ota, K | 1 |
| Ibayashi, J | 1 |
| Sakata, Y | 1 |
| Matsuoka, T | 1 |
| Ishikawa, M | 1 |
| Wakui, A | 1 |
| Ogoshi, K | 1 |
| Akazawa, S | 1 |
| Sakai, Y | 1 |
| Jinushi, K | 1 |
| Kim, R | 1 |
| Toi, M | 1 |
| Saeki, K | 1 |
| Yoshinaka, K | 1 |
| Yanagawa, E | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
| Gordon, W | 1 |
| Stansberry, PK | 1 |
| Weiss, GB | 1 |
| Silvey, L | 1 |
| Carpenter, JT | 1 |
| Wheeler, RH | 1 |
| Conolley, C | 1 |
| Martoni, A | 1 |
| Rani, P | 1 |
| Ercolino, L | 1 |
| Canova, N | 1 |
| Pannuti, F | 1 |
| Roila, F | 2 |
| Tonato, M | 2 |
| Basurto, C | 2 |
| Minotti, V | 2 |
| Ballatori, E | 2 |
| del Favero, A | 2 |
| Shiu, W | 1 |
| Tsang, V | 1 |
| Lam, YM | 1 |
| Zacharia, A | 1 |
| Zhao, TP | 1 |
| He, GF | 1 |
| Dozono, H | 1 |
| Yasuda, M | 1 |
| Yokoyama, S | 1 |
| Takahashi, S | 1 |
| Ochiai, K | 1 |
| Tsuruoka, M | 1 |
| Morimoto, O | 1 |
| Sasaki, H | 1 |
| Arihiro, T | 1 |
| Terashima, Y | 1 |
| Selch, MT | 1 |
| Parker, RG | 1 |
| Bertrand, M | 1 |
| Doroshow, JH | 1 |
| Multhauf, P | 1 |
| Blayney, DW | 1 |
| Carr, BI | 1 |
| Cecchi, G | 1 |
| Goldberg, D | 1 |
| Leong, L | 1 |
| Margolin, K | 1 |
| Metter, G | 1 |
| Greene, PG | 1 |
| Seime, RJ | 1 |
| Merlano, M | 1 |
| Grimaldi, A | 1 |
| Brunetti, I | 1 |
| Modenesi, M | 1 |
| Scala, M | 1 |
| Margarino, G | 1 |
| Scasso, F | 1 |
| Santelli, A | 1 |
| Castiglia, G | 1 |
| Pallestrini, E | 1 |
| Warner-Efraty, E | 1 |
| Ben-Yosef, R | 1 |
| Ben-Baruch, N | 1 |
| Yitzhaki, N | 1 |
| Uziely, B | 1 |
| Biran, S | 1 |
| Abe, O | 1 |
| Iino, Y | 1 |
| Fujimoto, M | 1 |
| Nomura, Y | 1 |
| Sheidler, VR | 1 |
| Enterline, JP | 1 |
| Donehower, RC | 1 |
| Grochow, LB | 1 |
| Page, JP | 1 |
| Levi, JA | 1 |
| Woods, RL | 1 |
| Tattersall, MN | 1 |
| Fox, RM | 1 |
| Coates, AS | 1 |
| Posner, LE | 1 |
| Dukart, G | 1 |
| Goldberg, J | 1 |
| Bernstein, T | 1 |
| Cartwright, K | 1 |
| Bennett, JM | 1 |
| Byrne, P | 1 |
| Desai, A | 1 |
| White, C | 1 |
| DeConti, R | 1 |
| Vogel, C | 1 |
| Krementz, E | 1 |
| Doroshow, J | 1 |
| Plotkin, D | 1 |
| Kish, JA | 1 |
| Ensley, JF | 1 |
| Jacobs, J | 1 |
| Weaver, A | 1 |
| Cummings, G | 1 |
| Al-Sarraf, M | 1 |
| Kitamura, M | 1 |
| Hayashi, K | 1 |
| Kosaki, G | 1 |
| Sawaki, S | 1 |
| Tamamushi, N | 1 |
| Yao, K | 1 |
| Takeyama, I | 1 |
| Otake, H | 1 |
| Miyake, H | 1 |
| Horiuchi, M | 1 |
| Hattori, Y | 1 |
| Murakami, T | 1 |
| Morrow, GR | 1 |
| Delgado, M | 1 |
| Keiling, R | 1 |
| Armand, JP | 1 |
| Prevot, G | 1 |
| Misset, JL | 1 |
| Grimbert, J | 1 |
| Mathe, G | 1 |
| Furue, H | 1 |
| Byfield, JE | 1 |
| Frankel, SS | 1 |
| Hornbeck, CL | 1 |
| Sharp, TR | 1 |
| Callipari, FB | 1 |
| Floyd, RA | 1 |
| Bounous, G | 1 |
| Gentile, JM | 1 |
| Hugon, J | 1 |
| Gailani, S | 1 |
| Leone, L | 1 |
| Stutz, FH | 1 |
| Blom, J | 1 |
| van Eden, EB | 1 |
| Cichy, A | 1 |
| Jurga, L | 1 |
| Klvana, M | 1 |
| Priestman, TJ | 1 |
| Nadler, SH | 2 |
| Moore, GE | 1 |
| Piro, AJ | 1 |
| Wilson, RE | 1 |
| Hall, TC | 1 |
| Aliapoulios, MA | 1 |
| Nevinny, HB | 1 |
| Moore, FD | 1 |
| Hill, GJ | 1 |
| Grage, TB | 1 |
| Wilson, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of Breast Cancer Chemotherapy-induced Nausea and Vomiting: a Single-center, Randomized Controlled Clinical Trial[NCT05841849] | Phase 4 | 1,028 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | ||
| Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290] | Phase 2 | 67 participants (Actual) | Interventional | 2013-11-08 | Completed | ||
| Efficacy of Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting in Nondrinking Women Younger Than 50 Years Who Received Moderately Emetogenic Chemotherapy: A Randomized, Double-blind, Phase Ⅲ Trial[NCT03674294] | Phase 3 | 248 participants (Actual) | Interventional | 2015-08-04 | Completed | ||
| A Multicenter Randomized Dble-Blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin and 5-FU/LV Combination in First-Line Treatment of Patients With Metastatic Colorectal Carcinoma(MCRC)[NCT00272051] | Phase 3 | 620 participants | Interventional | 2002-07-31 | Completed | ||
| A Multicenter, Randomized Double-blind Placebo Controlled Phase III Study of the Efficacy of Xaliproden in Preventing the Neurotoxicity of Oxaliplatin in First-line Treatment of Patients With Metastatic Colorectal Cancer Treated With Oxaliplatin / 5-FU/LV[NCT00305188] | Phase 3 | 879 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| PACCE: A Randomized, Open-Label, Controlled, Clinical Trial of Chemotherapy and Bevacizumab With and Without Panitumumab in the First-Line Treatment of Subjects With Metastatic Colorectal Cancer[NCT00115765] | Phase 3 | 1,053 participants (Actual) | Interventional | 2005-06-01 | Completed | ||
| A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Pat[NCT00384176] | Phase 2/Phase 3 | 1,814 participants (Actual) | Interventional | 2006-08-30 | Completed | ||
| A Randomized, Multicenter, Phase 3 Study to Compare the Efficacy of Panitumumab in Combination With Oxaliplatin/ 5-fluorouracil/ Leucovorin to the Efficacy of Oxaliplatin/ 5-fluorouracil/ Leucovorin Alone in Patients With Previously Untreated Metastatic C[NCT00364013] | Phase 3 | 1,183 participants (Actual) | Interventional | 2006-08-01 | Completed | ||
| A Multicenter, Single Arm, Open Label Clinical Trial to Evaluate the Safety and Health-Related Quality of Life of Aflibercept in Patients With Metastatic Colorectal Cancer (mCRC) Previously Treated With an Oxaliplatin-Containing Regimen[NCT01571284] | Phase 3 | 781 participants (Actual) | Interventional | 2012-05-30 | Completed | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer[NCT00777101] | Phase 2 | 233 participants (Actual) | Interventional | 2009-02-04 | Completed | ||
| An Open Label Study to Characterize the Incidence and Severity of Diarrhea in Patients With HER2+ Breast Cancer Treated With Neratinib With or Without Trastuzumab[NCT03094052] | Phase 2 | 11 participants (Actual) | Interventional | 2018-10-09 | Completed | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| Randomized Study of the Efficacy and Safety of Transdermal Granisetron Compared With Intravenous and Oral Agent in the Control of Nausea and Vomiting Induced by Moderately Emetogenic Chemotherapy[NCT01662687] | Phase 4 | 276 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Ca[NCT01196052] | Phase 2 | 153 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Phase III Prospective Randomized Trial Comparing Ramosetron Versus Ondansetron for Radiotherapy Induced Nausea and Vomiting in the Treatment of Gastrointestinal Cancer[NCT00971399] | Phase 3 | 172 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| An Open-label, Randomized Phase III Trial of Cisplatin and 5-fluorouracil With or Without Panitumumab for Patients With Nonresectable, Advanced or Metastatic Esophageal Squamous Cell Cancer[NCT01627379] | Phase 3 | 300 participants (Anticipated) | Interventional | 2012-05-31 | Terminated (stopped due to Sponsor decision due to recommendation of the IDMC.) | ||
| A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480] | Phase 2 | 0 participants | Interventional | Completed | |||
| A Prospective, Single-arm, Phase II Study of Adelbelimab Combined With Carboplatin and Nab-paclitaxel in Neoadjuvant Therapy for Patients With Resectable Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT06016413] | Phase 2 | 30 participants (Anticipated) | Interventional | 2023-09-01 | Not yet recruiting | ||
| Study of TPF (Docetaxel, Cisplatin, 5-fluorouracil) Induction Chemotherapy Followed by Surgery and Radiotherapy in Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma[NCT01542931] | Phase 2/Phase 3 | 256 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333] | Phase 1 | 9 participants (Anticipated) | Interventional | 2008-02-29 | Recruiting | ||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449] | Phase 2 | 58 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916] | Phase 2 | 42 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926] | Phase 2 | 50 participants | Interventional | 2000-06-30 | Completed | ||
| 09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248] | Phase 1 | 0 participants (Actual) | Interventional | 2014-03-31 | Withdrawn (stopped due to The study closed prior to enrolling any participants.) | ||
| Randomized Multicenter Controlled Phase III Study of Postoperative Adjuvant Therapy for Stage II/IIIA Gastric Cancer Using TS-1 Alone or TS-1+PSK Combined Therapy[NCT00216034] | Phase 3 | 255 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Phase III Randomized Controlled Study of Postoperative Adjuvant Therapy Using TS-1 or TS-1+PSK for Stage II or III Gastric Cancer Patients[NCT00687843] | Phase 3 | 480 participants (Anticipated) | Interventional | 2008-06-30 | Active, not recruiting | ||
| Randomized Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Unresectable Advanced Gastric Carcinoma and Recurrent Gastric Carcinoma[NCT00503321] | Phase 2/Phase 3 | 13 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Patients' enrollment was not sufficient.) | ||
| A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer[NCT01685489] | Phase 1 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to funding sequestered) | ||
| Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial[NCT02774187] | Phase 3 | 247 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma[NCT02981498] | Phase 2 | 35 participants (Anticipated) | Interventional | 2015-06-30 | Completed | ||
| The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer[NCT00943137] | Phase 2 | 55 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641] | Phase 2 | 100 participants (Anticipated) | Interventional | 2019-01-28 | Recruiting | ||
| Phase I Study of Cabazitaxel - Platinum Fluorouracil Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck[NCT01379339] | Phase 1 | 40 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943] | Phase 1 | 18 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516] | 8 participants (Actual) | Interventional | 2009-02-28 | Completed | |||
| Randomized Trial to Evaluate Therapeutic Gain by Changing Chemoradiotherapy From Concurrent-adjuvant to Induction-concurrent Sequence, and Radiotherapy From Conventional to Accelerated Fractionation for Advanced Nasopharyngeal Carcinoma[NCT00379262] | Phase 3 | 803 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763] | 13 participants (Actual) | Interventional | 2008-03-31 | Completed | |||
| A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628] | 10 participants (Anticipated) | Interventional | 2012-01-31 | Not yet recruiting | |||
| Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544] | Phase 1 | 24 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 33 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 5.8 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 10.5 |
"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 25 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 22 |
Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 15.5 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 19.6 |
Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.4 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.8 |
Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)
| Intervention | months (Median) |
|---|---|
| Arm A: FOLFIRINOX (HER2-negative) | 8.0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 13.9 |
(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)
| Intervention | participants (Number) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anemia | Febrile neutropenia | Anal Fistula | Diarrhea | Hematemesis | Nausea | Peripheral ischemia | Vomiting | Fatigue | Laparoscopy surgery | Pain | Sepsis | Lung infection | Pneumonia | Hypernatremia | Neutrophil count decreased | Platelet count decreased | Anorexia | Dehydration | Hypokalemia | Back pain | Peripheral sensory neuropathy | Syncope | Dyspnea | Pleural embolism | Skin infection | Thromboembolic event | Abdominal pain | Enterocolitis | Hemorrhoids | G-tube infection | Neutropenic entercolitis | Alkaline phosphatase increased | |
| Arm A: FOLFIRINOX (HER2-negative) | 1 | 2 | 1 | 4 | 1 | 2 | 1 | 3 | 4 | 1 | 1 | 1 | 1 | 1 | 1 | 19 | 3 | 3 | 4 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Arm B: FOLFIRINOX & Trastuzumab (HER2-positive) | 0 | 0 | 0 | 5 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Best overall response of complete or partial response within irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 49 |
| Irinotecan and Bevacizumab Without Panitumumab | 46 |
Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 14 |
| Irinotecan and Bevacizumab Without Panitumumab | 15 |
Best overall response of complete or partial response within oxaliplatin stratum (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 190 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 196 |
Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 31 |
| Irinotecan and Bevacizumab Without Panitumumab | 28 |
Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 29 |
| Irinotecan and Bevacizumab Without Panitumumab | 27 |
Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm. (NCT00115765)
Timeframe: Overall study
| Intervention | Participant (Number) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 26 |
| Irinotecan and Bevacizumab Without Panitumumab | 18 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median. (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 47 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 45 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 19.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 24.5 |
Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median (NCT00115765)
Timeframe: Overall Study
| Intervention | Participant (Number) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 71 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 46 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 10.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.7 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.4 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.0 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.0 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS) (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 9.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.5 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 11.1 |
| Irinotecan and Bevacizumab Without Panitumumab | 11.9 |
Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 10.8 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 11.4 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum (NCT00115765)
Timeframe: Overall Study
| Intervention | Month (Median) |
|---|---|
| Irinotecan and Bevacizumab Plus Panitumumab | 6.6 |
| Irinotecan and Bevacizumab Without Panitumumab | 6.0 |
Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum. (NCT00115765)
Timeframe: Overall study
| Intervention | Month (Median) |
|---|---|
| Oxaliplatin and Bevacizumab Plus Panitumumab | 5.7 |
| Oxaliplatin and Bevacizumab Without Panitumumab | 5.9 |
Duration of Response is calculated as the time from the first recording of CR/PR until the patient progresses, regardless of whether the patient was still taking study medication. Only confirmed responses are included in the calculation. For patients who had not progressed, the end date used in the calculation of duration of response is the data cut-off date of 15th November 2009. (NCT00384176)
Timeframe: Up until data cut-off date of 15/11/2007
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 8.6 |
| Bevacizumab 5 mg/kg | 9.6 |
"Objective response rate is Complete Response (CR) + Partial Response (PR) as defined below:~CR = Disappearance of all target lesions. PR = At least a 30% decrease in the sum of longest diameters (LDs) of target lesions, taking as reference the baseline sum of LDs." (NCT00384176)
Timeframe: Up until data cut-off
| Intervention | Participants (Number) |
|---|---|
| Cediranib 20 mg | 328 |
| Bevacizumab 5 mg/kg | 337 |
Number of months from randomisation to the date of death from any cause (NCT00384176)
Timeframe: Randomisation until data cut-off
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 22.8 |
| Bevacizumab 5 mg/kg | 21.3 |
Percentage change in tumour size from baseline to first RECIST assessment (Week 8) ((Week 8 - baseline)/baseline)*100 (NCT00384176)
Timeframe: Baseline to Week 8
| Intervention | Percentage change in tumour size (Mean) |
|---|---|
| Cediranib 20 mg | -23.2 |
| Bevacizumab 5 mg/kg | -22.1 |
Progression is defined as the number of months from randomisation until progressive disease based on RECIST (progression of target lesions, clear progression of existing non-target lesions or the appearance of one or more new lesions) or death in the absence of progression. (NCT00384176)
Timeframe: Baseline then at Weeks 8, 16, 24 and then every 12 weeks until progression
| Intervention | Months (Median) |
|---|---|
| Cediranib 20 mg | 9.9 |
| Bevacizumab 5 mg/kg | 10.3 |
Time to worsening of symptoms, as measured by the FACT colorectal symptom index (FCSI), will be defined as the time when a sustained clinically important deterioration in the total score from the FCSI has been recorded. (NCT00384176)
Timeframe: Baseline through to data cut-off
| Intervention | Days (Median) |
|---|---|
| Cediranib 20 mg | 170 |
| Bevacizumab 5 mg/kg | 245 |
Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 11.1 |
| Wild-type KRAS - FOLFOX | 8.8 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.4 |
| Mutant KRAS - FOLFOX | 8.0 |
The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 23.9 |
| Wild-type KRAS - FOLFOX | 19.7 |
| Mutant KRAS - FOLFOX + Panitumumab | 15.5 |
| Mutant KRAS - FOLFOX | 19.3 |
Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders. (NCT00364013)
Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | percentage of participants (Number) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 55.21 |
| Wild-type KRAS - FOLFOX | 47.68 |
| Mutant KRAS - FOLFOX + Panitumumab | 39.53 |
| Mutant KRAS - FOLFOX | 40.28 |
Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions. (NCT00364013)
Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 9.6 |
| Wild-type KRAS - FOLFOX | 8.0 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.3 |
| Mutant KRAS - FOLFOX | 8.8 |
Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria. (NCT00364013)
Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.
| Intervention | months (Median) |
|---|---|
| Wild-type KRAS - FOLFOX + Panitumumab | 10.8 |
| Wild-type KRAS - FOLFOX | 9.2 |
| Mutant KRAS - FOLFOX + Panitumumab | 7.5 |
| Mutant KRAS - FOLFOX | 9.0 |
"A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: Is there a reasonable possibility that the event may have been caused by the study treatment?" (NCT00364013)
Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Any adverse event | Serious adverse event | Leading to discontinuation of any study drug | Treatment-related adverse event (TRAE) | Serious treatment-related adverse event | TRAE leading to discontinuation of any study drug | |
| FOLFOX + Panitumumab | 583 | 262 | 136 | 581 | 162 | 117 |
| FOLFOX Alone | 579 | 198 | 84 | 565 | 89 | 63 |
Creatinine clearance is a measure of kidney function. Creatinine clearance rate is the volume of blood plasma that is cleared of creatinine by the kidneys per unit time. Creatinine clearance can be measured directly or estimated using established formulas. For this study, the creatinine clearance was calculated using the Cockroft-Gault or Modification of Diet in Renal Disease (MDRD). (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | mL/min (Mean) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 71.4 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | participants (Number) |
|---|---|
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 182 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favorable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fatigue - Baseline | Fatigue - Change at Cycle 3 | Fatigue - Change at Cycle 5 | Fatigue - Change at Cycle 7 | Fatigue - Change at Cycle 9 | Fatigue - Change at Cycle 11 | Fatigue - Change at Cycle 13 | Fatigue - Change at Cycle 15 | Fatigue - Change at Cycle 17 | Fatigue - Change at Cycle 19 | Fatigue - Change at Cycle 21 | Fatigue - Change at Cycle 23 | Fatigue - Change at Cycle 25 | Fatigue - Change at Cycle 27 | Fatigue - Change at Cycle 29 | Fatigue - Change at Cycle 31 | Fatigue - Change at Cycle 33 | Fatigue - Change at Cycle 35 | Fatigue - Change at EOT | Nausea and Vomiting - Baseline | Nausea and Vomiting - Change at Cycle 3 | Nausea and Vomiting - Change at Cycle 5 | Nausea and Vomiting - Change at Cycle 7 | Nausea and Vomiting - Change at Cycle 9 | Nausea and Vomiting - Change at Cycle 11 | Nausea and Vomiting - Change at Cycle 13 | Nausea and Vomiting - Change at Cycle 15 | Nausea and Vomiting - Change at Cycle 17 | Nausea and Vomiting - Change at Cycle 19 | Nausea and Vomiting - Change at Cycle 21 | Nausea and Vomiting - Change at Cycle 23 | Nausea and Vomiting - Change at Cycle 25 | Nausea and Vomiting - Change at Cycle 27 | Nausea and Vomiting - Change at Cycle 29 | Nausea and Vomiting - Change at Cycle 31 | Nausea and Vomiting - Change at Cycle 33 | Nausea and Vomiting - Change at Cycle 35 | Nausea and Vomiting - Change at EOT | Pain - Baseline | Pain - Change at Cycle 3 | Pain - Change at Cycle 5 | Pain - Change at Cycle 7 | Pain - Change at Cycle 9 | Pain - Change at Cycle 11 | Pain - Change at Cycle 13 | Pain - Change at Cycle 15 | Pain - Change at Cycle 17 | Pain - Change at Cycle 19 | Pain - Change at Cycle 21 | Pain - Change at Cycle 23 | Pain - Change at Cycle 25 | Pain - Change at Cycle 27 | Pain - Change at Cycle 29 | Pain - Change at Cycle 31 | Pain - Change at Cycle 33 | Pain - Change at Cycle 35 | Pain - Change at EOT | Dyspnoea - Baseline | Dyspnoea - Change at Cycle 3 | Dyspnoea - Change at Cycle 5 | Dyspnoea - Change at Cycle 7 | Dyspnoea - Change at Cycle 9 | Dyspnoea - Change at Cycle 11 | Dyspnoea - Change at Cycle 13 | Dyspnoea - Change at Cycle 15 | Dyspnoea - Change at Cycle 17 | Dyspnoea - Change at Cycle 19 | Dyspnoea - Change at Cycle 21 | Dyspnoea - Change at Cycle 23 | Dyspnoea - Change at Cycle 25 | Dyspnoea - Change at Cycle 27 | Dyspnoea - Change at Cycle 29 | Dyspnoea - Change at Cycle 31 | Dyspnoea - Change at Cycle 33 | Dyspnoea - Change at Cycle 35 | Dyspnoea - Change at EOT | Insomnia - Baseline | Insomnia - Change at Cycle 3 | Insomnia - Change at Cycle 5 | Insomnia - Change at Cycle 7 | Insomnia - Change at Cycle 9 | Insomnia - Change at Cycle 11 | Insomnia - Change at Cycle 13 | Insomnia - Change at Cycle 15 | Insomnia - Change at Cycle 17 | Insomnia - Change at Cycle 19 | Insomnia - Change at Cycle 21 | Insomnia - Change at Cycle 23 | Insomnia - Change at Cycle 25 | Insomnia - Change at Cycle 27 | Insomnia - Change at Cycle 29 | Insomnia - Change at Cycle 31 | Insomnia - Change at Cycle 33 | Insomnia - Change at Cycle 35 | Insomnia - Change at EOT | Appetite loss - Baseline | Appetite loss - Change at Cycle 3 | Appetite loss - Change at Cycle 5 | Appetite loss - Change at Cycle 7 | Appetite loss - Change at Cycle 9 | Appetite loss - Change at Cycle 11 | Appetite loss - Change at Cycle 13 | Appetite loss - Change at Cycle 15 | Appetite loss - Change at Cycle 17 | Appetite loss - Change at Cycle 19 | Appetite loss - Change at Cycle 21 | Appetite loss - Change at Cycle 23 | Appetite loss - Change at Cycle 25 | Appetite loss - Change at Cycle 27 | Appetite loss - Change at Cycle 29 | Appetite loss - Change at Cycle 31 | Appetite loss - Change at Cycle 33 | Appetite loss - Change at Cycle 35 | Appetite loss - Change at EOT | Constipation - Baseline | Constipation - Change at Cycle 3 | Constipation - Change at Cycle 5 | Constipation - Change at Cycle 7 | Constipation - Change at Cycle 9 | Constipation - Change at Cycle 11 | Constipation - Change at Cycle 13 | Constipation - Change at Cycle 15 | Constipation - Change at Cycle 17 | Constipation - Change at Cycle 19 | Constipation - Change at Cycle 21 | Constipation - Change at Cycle 23 | Constipation - Change at Cycle 25 | Constipation - Change at Cycle 27 | Constipation - Change at Cycle 29 | Constipation - Change at Cycle 31 | Constipation - Change at Cycle 33 | Constipation - Change at Cycle 35 | Constipation - Change at EOT | Diarrhoea - Baseline | Diarrhoea - Change at Cycle 3 | Diarrhoea - Change at Cycle 5 | Diarrhoea - Change at Cycle 7 | Diarrhoea - Change at Cycle 9 | Diarrhoea - Change at Cycle 11 | Diarrhoea - Change at Cycle 13 | Diarrhoea - Change at Cycle 15 | Diarrhoea - Change at Cycle 17 | Diarrhoea - Change at Cycle 19 | Diarrhoea - Change at Cycle 21 | Diarrhoea - Change at Cycle 23 | Diarrhoea - Change at Cycle 25 | Diarrhoea - Change at Cycle 27 | Diarrhoea - Change at Cycle 29 | Diarrhoea - Change at Cycle 31 | Diarrhoea - Change at Cycle 33 | Diarrhoea - Change at Cycle 35 | Diarrhoea - Change at EOT | Financial difficulties - Baseline | Financial difficulties - Change at Cycle 3 | Financial difficulties - Change at Cycle 5 | Financial difficulties - Change at Cycle 7 | Financial difficulties - Change at Cycle 9 | Financial difficulties - Change at Cycle 11 | Financial difficulties - Change at Cycle 13 | Financial difficulties - Change at Cycle 15 | Financial difficulties - Change at Cycle 17 | Financial difficulties - Change at Cycle 19 | Financial difficulties - Change at Cycle 21 | Financial difficulties - Change at Cycle 23 | Financial difficulties - Change at Cycle 25 | Financial difficulties - Change at Cycle 27 | Financial difficulties - Change at Cycle 29 | Financial difficulties - Change at Cycle 31 | Financial difficulties - Change at Cycle 33 | Financial difficulties - Change at Cycle 35 | Financial difficulties - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 29.16 | 7.35 | 8.40 | 9.54 | 7.89 | 11.30 | 8.33 | 7.41 | 6.70 | 8.93 | 10.39 | 10.80 | 7.66 | 9.66 | 11.67 | 14.07 | 15.15 | 14.44 | 12.31 | 5.88 | 6.68 | 6.98 | 6.61 | 6.20 | 8.97 | 6.82 | 6.85 | 3.45 | 6.56 | 3.99 | 7.87 | 4.02 | 7.25 | 1.67 | 13.33 | 3.03 | 3.33 | 6.64 | 20.47 | 2.68 | 2.52 | 3.00 | 2.72 | 6.64 | 5.16 | 7.26 | 9.39 | 8.74 | 7.25 | 8.33 | 5.75 | 5.07 | 4.17 | 10.00 | 7.58 | 6.67 | 10.85 | 13.45 | 3.63 | 5.75 | 6.98 | 6.89 | 8.19 | 6.36 | 3.58 | 5.16 | 6.78 | 3.79 | 4.04 | 1.23 | 3.03 | -1.75 | 16.67 | 16.67 | 16.67 | 6.53 | 24.15 | 0.37 | -0.08 | -2.37 | -0.24 | 2.56 | 0.65 | -2.19 | -1.92 | 1.64 | 0.74 | -0.93 | -0.00 | -1.52 | -3.33 | -4.44 | -6.06 | -3.33 | 5.31 | 17.38 | 9.10 | 9.02 | 9.84 | 9.98 | 14.53 | 10.67 | 10.74 | 8.91 | 9.84 | 13.04 | 12.38 | 11.49 | 15.94 | 15.00 | 15.56 | 15.15 | 16.67 | 12.03 | 12.71 | 2.42 | 3.77 | 2.63 | 5.35 | 4.42 | 4.58 | 4.92 | 5.43 | 8.33 | 6.06 | 9.26 | 5.75 | 1.45 | 6.67 | 22.22 | 12.12 | 10.00 | 3.78 | 10.37 | 11.72 | 10.85 | 14.63 | 11.44 | 15.46 | 11.26 | 11.02 | 10.34 | 15.25 | 14.07 | 18.52 | 10.34 | 13.64 | 16.67 | 20.00 | 18.18 | 30.00 | 7.31 | 20.12 | -1.83 | -1.32 | -0.99 | -0.49 | 3.30 | 1.11 | -0.27 | 0.77 | 1.67 | 4.44 | 2.94 | -4.60 | -2.90 | 0.00 | -2.22 | -3.03 | 0.00 | 2.97 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and Visual Analogue Scale (VAS). EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. Possible values for single index utility score ranged from -0.594 (severe problems in all dimensions) to 1.0 (no problem in all dimensions) on scale where 1 represented best possible health state. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 0.77 | -0.02 | -0.03 | -0.04 | -0.05 | -0.07 | -0.05 | -0.06 | -0.05 | -0.05 | -0.09 | -0.14 | -0.08 | -0.08 | -0.08 | -0.12 | 0.02 | -0.05 | -0.11 |
EQ-5D was a standardized HRQL questionnaire consisting of EQ-5D descriptive system and VAS. EQ-5D descriptive system comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression measured on 3 levels (no problem, some problems & severe problems) within a particular EQ-5D dimension. 5 dimensional 3-level system was converted into single index utility score. The VAS recorded the respondent's self-rated health on a vertical visual analogue scale. The VAS 'thermometer' has endpoints of 100 (Best imaginable health state) at the top and 0 (Worst imaginable health state) at the bottom. This information can be used as a quantitative measure of health outcome as judged by the individual respondents. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72.81 | -1.85 | -2.15 | -2.20 | -2.74 | -3.10 | -2.36 | -1.05 | -1.91 | -3.06 | -2.13 | -5.77 | -7.28 | -4.94 | -8.80 | -6.69 | -7.90 | -8.88 | -6.67 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent).EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28). Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at the end of treatment (EOT) (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change at Cycle 3 | Change at Cycle 5 | Change at Cycle 7 | Change at Cycle 9 | Change at Cycle 11 | Change at Cycle 13 | Change at Cycle 15 | Change at Cycle 17 | Change at Cycle 19 | Change at Cycle 21 | Change at Cycle 23 | Change at Cycle 25 | Change at Cycle 27 | Change at Cycle 29 | Change at Cycle 31 | Change at Cycle 33 | Change at Cycle 35 | Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 68.61 | -3.34 | -4.70 | -3.63 | -3.97 | -5.85 | -2.26 | -3.05 | -1.18 | -2.36 | -5.56 | -6.86 | -8.05 | -10.14 | -8.33 | -9.44 | -11.36 | -5.83 | -8.82 |
EORTC-QLQ-C30 is a cancer-specific instrument with 30 questions for evaluation of new chemotherapy and provides an assessment of participant reported outcome dimensions. First 28 questions used 4-point scale (1=not at all,2=a little,3=quite a bit,4=very much) for evaluating 5 functional scales (physical,role,emotional,cognitive,social), 3 symptom scales (fatigue,nausea/vomiting,pain) & other single items. For each item,high score represented high level of symptomatology/problem. Last 2 questions represented participant's assessment of overall health & quality of life, coded on 7-point scale (1=very poor to 7=excellent). EORTC QLQ-C30 observed values and change from baseline for global health status (scoring of questions 29 & 30) and 5 functional scales, 3 symptom scales and other single items (scoring of questions 1 to 28).Answers were converted into grading scale, with values between 0 and 100. A high score represented a favourable outcome with a best quality of life for participant. (NCT01571284)
Timeframe: Pre-dose at Baseline, Day 1 of every odd cycle (from Cycle 3 to 35); at EOT (within 30 days of last treatment) (maximum exposure: 214 weeks)
| Intervention | units on a scale (Mean) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical - Baseline | Physical - Change at Cycle 3 | Physical - Change at Cycle 5 | Physical - Change at Cycle 7 | Physical - Change at Cycle 9 | Physical - Change at Cycle 11 | Physical - Change at Cycle 13 | Physical - Change at Cycle 15 | Physical - Change at Cycle 17 | Physical - Change at Cycle 19 | Physical - Change at Cycle 21 | Physical - Change at Cycle 23 | Physical - Change at Cycle 25 | Physical - Change at Cycle 27 | Physical - Change at Cycle 29 | Physical - Change at Cycle 31 | Physical - Change at Cycle 33 | Physical - Change at Cycle 35 | Physical - Change at EOT | Role - Baseline | Role - Change at Cycle 3 | Role - Change at Cycle 5 | Role - Change at Cycle 7 | Role - Change at Cycle 9 | Role - Change at Cycle 11 | Role - Change at Cycle 13 | Role - Change at Cycle 15 | Role - Change at Cycle 17 | Role - Change at Cycle 19 | Role - Change at Cycle 21 | Role - Change at Cycle 23 | Role - Change at Cycle 25 | Role - Change at Cycle 27 | Role - Change at Cycle 29 | Role - Change at Cycle 31 | Role - Change at Cycle 33 | Role - Change at Cycle 35 | Role - Change at EOT | Emotional - Baseline | Emotional - Change at Cycle 3 | Emotional - Change at Cycle 5 | Emotional - Change at Cycle 7 | Emotional - Change at Cycle 9 | Emotional - Change at Cycle 11 | Emotional - Change at Cycle 13 | Emotional - Change at Cycle 15 | Emotional - Change at Cycle 17 | Emotional - Change at Cycle 19 | Emotional - Change at Cycle 21 | Emotional - Change at Cycle 23 | Emotional - Change at Cycle 25 | Emotional - Change at Cycle 27 | Emotional - Change at Cycle 29 | Emotional - Change at Cycle 31 | Emotional - Change at Cycle 33 | Emotional - Change at Cycle 35 | Emotional - Change at EOT | Cognitive - Baseline | Cognitive - Change at Cycle 3 | Cognitive - Change at Cycle 5 | Cognitive - Change at Cycle 7 | Cognitive - Change at Cycle 9 | Cognitive - Change at Cycle 11 | Cognitive - Change at Cycle 13 | Cognitive - Change at Cycle 15 | Cognitive - Change at Cycle 17 | Cognitive - Change at Cycle 19 | Cognitive - Change at Cycle 21 | Cognitive - Change at Cycle 23 | Cognitive - Change at Cycle 25 | Cognitive - Change at Cycle 27 | Cognitive - Change at Cycle 29 | Cognitive - Change at Cycle 31 | Cognitive - Change at Cycle 33 | Cognitive - Change at Cycle 35 | Cognitive- Change at EOT | Social - Baseline | Social - Change at Cycle 3 | Social - Change at Cycle 5 | Social - Change at Cycle 7 | Social - Change at Cycle 9 | Social - Change at Cycle 11 | Social - Change at Cycle 13 | Social - Change at Cycle 15 | Social - Change at Cycle 17 | Social - Change at Cycle 19 | Social - Change at Cycle 21 | Social - Change at Cycle 23 | Social - Change at Cycle 25 | Social - Change at Cycle 27 | Social - Change at Cycle 29 | Social - Change at Cycle 31 | Social - Change at Cycle 33 | Social - Change at Cycle 35 | Social - Change at EOT | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 81.79 | -3.73 | -3.95 | -4.62 | -4.36 | -6.99 | -4.99 | -3.54 | -5.10 | -5.68 | -5.70 | -7.87 | -5.75 | -6.59 | -7.67 | -9.33 | -5.45 | -10.00 | -11.16 | 79.91 | -6.26 | -5.66 | -6.68 | -6.55 | -8.76 | -7.36 | -7.18 | -9.58 | -9.84 | -9.78 | -10.65 | -10.92 | -10.14 | -10.83 | -14.44 | -15.15 | -15.00 | -12.11 | 78.96 | 1.14 | 0.74 | 1.58 | 1.69 | 0.08 | 0.93 | 2.51 | 2.91 | 1.39 | 0.06 | 1.75 | 4.98 | 1.57 | 2.64 | 1.30 | 0.25 | -0.00 | -2.87 | 86.90 | -1.77 | -1.87 | -1.99 | -2.18 | -4.27 | -2.83 | -2.28 | -3.45 | -5.00 | -5.56 | -5.71 | -6.90 | -5.80 | -6.67 | -5.56 | -10.61 | -11.67 | -4.98 | 80.57 | -2.05 | -2.86 | -4.78 | -4.56 | -7.09 | -5.56 | -6.18 | -5.56 | -5.28 | -5.56 | -7.62 | -4.60 | -2.17 | -5.00 | -7.78 | -1.52 | -1.67 | -9.01 |
Abnormal electrolytes parameters included: hyponatremia, hypernatremia, hypocalcemia, hypercalcemia, hypokalemia, and hyperkalemia. Number of participants with each of these parameters were analyzed by grades ( All Grades and Grades 3-4 as per NCI CTCAE Version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hyponatremia: All Grades | Hyponatremia: Grades 3-4 | Hypernatremia: All Grades | Hypernatremia: Grades 3-4 | Hypocalcemia: All Grades | Hypocalcemia: Grades 3-4 | Hypercalcemia: All Grades | Hypercalcemia: Grades 3-4 | Hypokalemia: All Grades | Hypokalemia: Grades 3-4 | Hyperkalemia: All Grades | Hyperkalemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 181 | 32 | 75 | 1 | 213 | 5 | 52 | 2 | 121 | 16 | 166 | 10 |
Abnormal hematological parameters included: anaemia, thrombocytopenia, leukopenia and neutropenia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4 as per NCI CTCAE (Version 4.03), where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Anaemia: All Grades | Anaemia: Grades 3-4 | Thrombocytopenia: All Grades | Thrombocytopenia: Grades 3-4 | Leukopenia: All Grades | Leukopenia: Grades 3-4 | Neutropenia: All Grades | Neutropenia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 535 | 14 | 293 | 13 | 532 | 72 | 450 | 227 |
Non-gradeable biochemistry parameters included; chloride, urea, total protein, blood urea nitrogen (BUN) and lactate dehydrogenase (LDH). Number of participants with
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
Chloride| Chloride>ULN | BUN | BUN>ULN | UREA | UREA>ULN | LDH | LDH>ULN | Total proteins | Total proteins>ULN | | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 135 | 217 | 41 | 83 | 60 | 250 | 79 | 423 | 162 | 77 |
Renal and liver function parameters included: creatinine, hyperbilirubinemia, aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE version 4.03, where Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Creatinine: All Grades | Creatinine: Grades 3-4 | Hyperbilirubinemia: All Grades | Hyperbilirubinemia: Grades 3-4 | AST: All Grades | AST: Grades 3-4 | ALT: All Grades | ALT: Grades 3-4 | Alkaline phosphatase: All Grades | Alkaline phosphatase: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 161 | 2 | 130 | 9 | 342 | 12 | 270 | 10 | 465 | 23 |
A theoretical cycle is a 2 week period i.e. 14 days. A cycle is delayed if duration of previous cycle is greater than 14+2 days ; dose modification includes dose reduction and dose omission. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| No delay and no dose modification | Any delay and/or dose modification | Delay only | Delay and Aflibercept modified | Delay and FOLFIRI modified | Delay and Aflibercept and Folfiri modified | Only Aflibercept modified | Only FOLFIRI modified | Both Aflibercept and FOLFIRI modified | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 119 | 660 | 163 | 39 | 308 | 97 | 5 | 43 | 5 |
The INR is a derived measure of the prothrombin time. The INR is the ratio of a participant's prothrombin time to a normal control sample. Normal range (without anti coagulation therapy): 0.8-1.2; Targeted range (with anti coagulation therapy) 2.0-3.0. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| INR<1.5 | INR>=1.5 to <3 | INR>=3 to <5 | INR>=5 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 106 | 0 | 2 | 2 |
Other abnormal biochemistry parameters included: hypoglycemia, hyperglycemia and hypoalbuminemia. Number of participants with each of these parameters were analyzed by grades (All Grades and Grades 3-4) as per NCI CTCAE Version 4.03, where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. All Grades included Grades 1-4. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Hypoglycemia: All Grades | Hypoglycemia: Grades 3-4 | Hyperglycemia: All Grades | Hyperglycemia: Grades 3-4 | Hypoalbuminemia: All Grades | Hypoalbuminemia: Grades 3-4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 90 | 6 | 403 | 30 | 241 | 6 |
Proteinuria is defined as the presence of excess proteins in the urine (assessed either by spot sample, dipstick/ urine protein or 24 hour urine collection). Hematuria is defined as the presence of blood in urine (positive dipstick for RBC or reported AE). Number of participants with proteinuria grade >=2 (graded as per NCI CTCAE Version 4.03), where Grade>=2 represents moderate to life-threatening/disabling event. Hypertension (high blood pressure) is defined as having a blood pressure reading of more than 140/90 mmHg over a number of weeks. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Proteinuria with hematuria | Proteinuria with hypertension | Proteinuria with hematuria and hypertension | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 72 | 4 | 3 |
Proteinuria is defined as the ratio of protein to creatinine. Number of participants with proteinuria were analyzed by grades (Grades 1, 2, 3 ,4) as per NCI CTCAE Version 4.03 where Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 286 | 123 | 54 | 5 |
Any untoward medical occurrence in a participant who received investigational medicinal product (IMP) was considered an adverse event (AE) without regard to possibility of causal relationship with this treatment. A serious AE (SAE): Any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. Any TEAE included participants with both serious and non-serious AEs. National Cancer Institute Common Terminology Criteria (NCI-CTCAE) Version 4.03 was used to assess severity (Grade 1=mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening/disabling) of AEs. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Any TEAE (All Grades) | Any TEAEs (Grades 3-4) | Any serious TEAE | Any serious related TEAE | Any TEAE leading to death | Any TEAE (permanent treatment discontinuation) | Any TEAE (premature treatment discontinuation) | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 769 | 609 | 272 | 159 | 47 | 208 | 104 |
Urinary protein creatinine ratio (UPCR) corresponds to the ratio of the urinary protein and urinary creatinine concentration (expressed in mg/dL). This ratio provides an accurate quantification of 24-hours urinary protein excretion. There is a high correlation between morning UPCR and 24-hour proteinuria in participants with normal or reduced renal functions. Normal ratio is < or = 1. (NCT01571284)
Timeframe: Baseline up to 30 days after the last treatment administration (either Aflibercept or FOLFIRI whichever comes last) (maximum exposure: 214 weeks)
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| UPCR<=1 | UPCR>=1 to <=2 | UPCR>=2 to <=3 | UPCR>3 | |
| Aflibercept + FOLFIRI (Irinotecan, 5-FU & Leucovorin) | 265 | 51 | 24 | 27 |
"Clinical benefit rate (CR, PR, or SD = 24 weeks) for women For ErbB2 Positive Advanced Breast Cancer. Clinical benefit rate was the percentage of subjects who achieved overall tumor response per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.~Clinical Benefit (CB) = CR + PR + SD >= 24 weeks." (NCT00777101)
Timeframe: From randomization date to progression or last tumor assessment, assessed up to 69 months
| Intervention | percentage of participants (Median) |
|---|---|
| Neratinib | 44.4 |
| Lapatinib+Capecitabine | 63.8 |
Duration of response was measured from the time at which response criteria were met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the first date of recurrence or progressive disease (PD) or death. For subjects without death or progression, censorship was at the last valid tumor assessment per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.0: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. (NCT00777101)
Timeframe: From start date of response to first PD, assessed up to 69 months after the first subject was randomized.
| Intervention | months (Median) |
|---|---|
| Neratinib | 12.48 |
| Lapatinib+Capecitabine | 7.98 |
The percent of patients with symptomatic or progressive CNS lesions was the proportion of subjects who had PD considering CNS lesions only, according to RECIST criteria. (NCT00777101)
Timeframe: From randomization date to first CNS symptom or lesions
| Intervention | percentage of participants (Number) |
|---|---|
| Neratinib | 9.4 |
| Lapatinib+Capecitabine | 12.9 |
Objective Response Rate, investigator assessment. The ORR was defined as the percentage of participants demonstrating a confirmed objective response, either Complete Response (CR) or Partial Response (PR) during the study per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v.1.0: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; and Non-PD for non-target lesions, and no new lesions. (NCT00777101)
Timeframe: From randomization date to progression or last tumor assessment, assessed up to 69 months
| Intervention | percentage of participants (Number) |
|---|---|
| Neratinib | 29.1 |
| Lapatinib+Capecitabine | 40.5 |
Overall Survival (OS) was defined as the time from randomization to death due to any cause. Subjects last known to be alive were censored at the last date of last contact or the data cutoff employed for the analysis, whichever was earlier. (NCT00777101)
Timeframe: From randomization date to death, assessed up to 69 months
| Intervention | months (Median) |
|---|---|
| Neratinib | 19.74 |
| Lapatinib+Capecitabine | 23.62 |
Progression Free Survival, Measured in Months, for Subjects Randomized. Investigator assessment. The time interval from the date of randomization until the earliest date of progression per Response Evaluation Criteria In Solid Tumors Criteria (RECIST) or death due to any cause. For subjects without death or progression, censorship was at the last valid tumor assessment. (NCT00777101)
Timeframe: From randomization date to progression or death, assessed up to 69 months
| Intervention | months (Median) |
|---|---|
| Neratinib | 4.53 |
| Lapatinib+Capecitabine | 6.83 |
Time to symptomatic or progressive Central nervous system (CNS) lesions. Time to symptomatic or progressive CNS lesions was the time from the date of randomization until the date of progressive disease (PD) considering CNS lesions only (ie, appearance of newly diagnosed CNS lesions or progressive CNS lesions). (NCT00777101)
Timeframe: From randomization date to first CNS symptom or lesions
| Intervention | months (Median) |
|---|---|
| Neratinib | 19.68 |
| Lapatinib+Capecitabine | NA |
The number of participants who discontinued neratinib earlier than expected during the course of study therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 1 |
The number of participants who experienced a dose hold of neratinib during the course of study therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 0 |
The number of participants whose dose was reduced at any time during the course of therapy will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 5 |
Percentage of participants with clinically assessed grade 3 or greater diarrhea reported within the first 2 cycles (each cycle is 21 days) of neratinib while using anti-diarrheal strategies. Reports of diarrhea will be graded according to NCI CTCAE version 4.0. (NCT03094052)
Timeframe: Up to 6 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Treatment (Neratinib) | 36.3 |
Percentage of patients requiring multiple anti-diarrheal medications will be reported (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment (Neratinib) | 7 |
Percentage of participants with reported serious adverse events and adverse events of interest of any grade that have been determined to be related to the anti-diarrhea treatment will be reported by worst grade and associated toxicity. (NCT03094052)
Timeframe: Up to 55 weeks
| Intervention | participants (Number) |
|---|---|
| Treatment (Neratinib) | 100 |
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
(NCT01196052)
Timeframe: From the start to the end of radiotherapy treatment (up to 51 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 94.7 |
Participants were to receive up to a total of 17 cycles of trastuzumab emtansine. If trastuzumab was given concurrently with either the optional docetaxel or optional radiation, then the number of 3-week cycles of trastuzumab therapy was subtracted from the planned 17 cycles of trastuzumab emtansine therapy. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 82.4 |
(NCT01196052)
Timeframe: From the start to the end of concurrent hormonal therapy (up to 51 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 69.4 |
(NCT01196052)
Timeframe: From the start to the end of concurrent radiotherapy (up to 51 weeks)
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 94.9 |
A cardiac event was defined as death from a cardiac cause or severe congestive failure (New York Heart Association [NYHA] Class III or IV) with a decrease in left ventricular ejection fraction (LVEF) of ≥ 10% from Baseline to an LVEF of < 50%. (NCT01196052)
Timeframe: Baseline to 12 weeks after the start of trastuzumab emtansine treatment
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 0 |
Pathological complete response was defined as the absence of invasive neoplastic cells at microscopic examination of the primary tumor and lymph nodes after surgery following primary systemic therapy. Pathological complete response was evaluated in participants treated with neoadjuvant therapy doxorubicin/cyclophosphamide-5-fluorouracil/epirubicin/cyclophosphamide followed by 1 or more doses of trastuzumab emtansine and who underwent surgery. (NCT01196052)
Timeframe: Day of surgery
| Intervention | Percentage of participants (Number) |
|---|---|
| Trastuzumab Emtansine | 56.0 |
The following percentages of participants are reported: At least 1 adverse event while receiving T-DM1; at least 1 serious adverse event while receiving T-DM1; an adverse event leading to discontinuation, dose delay, or dose reduction of trastuzumab emtansine treatment; symptomatic cardiac dysfunction; and asymptomatic decline in left ventricular ejection fraction (LVEF). An asymptomatic LVEF decline was defined as a LVEF < 50% and a maximum decrease ≥ 10% from Baseline. The percentage of participants who died is reported. (NCT01196052)
Timeframe: From the start to the end of trastuzumab emtansine treatment (up to 51 weeks)
| Intervention | Percentage of participants (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| At least 1 adverse event (AE) | At least 1 serious adverse event | An AE leading to treatment discontinuation | An AE leading to dose delay | An AE leading to dose reduction | Symptomatic cardiac dysfunction | An asymptomatic decline in LVEF | Deaths | |
| Trastuzumab Emtansine | 98.6 | 10.1 | 13.5 | 29.1 | 21.6 | 0.0 | 2.7 | 0 |
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks
| Intervention | event (Number) |
|---|---|
| 1000mg | 1 |
| 1200mg | 0 |
| 1400mg | 0 |
| 1500mg | 3 |
(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy
| Intervention | participants (Number) |
|---|---|
| Proton Radiation and Chemotherapy | 0 |
Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment
| Intervention | participants (Number) |
|---|---|
| 1000mg | 0 |
| 1200mg | 1 |
| 1350mg | 1 |
| 1500mg | 0 |
| 1650mg | 1 |
15 reviews available for fluorouracil and Nausea
| Article | Year |
|---|---|
The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Fatigue; Fluorouracil; Humans | 2018 |
Small intestinal adenocarcinoma: rarely considered, often missed?
Topics: Adenocarcinoma; Aged; Capsule Endoscopy; Celiac Disease; Chemotherapy, Adjuvant; Cystic Fibrosis; Do | 2013 |
Raltitrexed-based chemotherapy for advanced colorectal cancer.
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Chemical and Drug Induce | 2014 |
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer.
Topics: Alopecia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combine | 2016 |
Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: a systematic review and meta-analysis of randomized controlled trials.
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy, Adjuvant; D | 2016 |
Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials.
Topics: Adolescent; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo | 2011 |
Comparison between doublet agents versus single agent in metastatic breast cancer patients previously treated with an anthracycline and a taxane: a meta-analysis of four phase III trials.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Management of diabetes and pancreatic cancer.
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2012 |
Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Duodenal Neoplasms; Fe | 2013 |
[Toxicities associated with chemotherapy in colorectal cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Clinical Trials a | 2003 |
[Complications of hepatic artery chemotherapy for liver metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cholangitis, Sclerosing | 2003 |
Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Topics: Alopecia; Ambulatory Care; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Colonic | 2004 |
Advanced colorectal cancer: current treatment and nursing management with economic considerations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Campt | 2005 |
Capecitabine: a new adjuvant option for colorectal cancer.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Capecitabine; Cause of Death; Colorectal Neop | 2006 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors.
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Hematologic Diseases; Huma | 1998 |
203 trials available for fluorouracil and Nausea
| Article | Year |
|---|---|
Single Nucleotide Polymorphism Directed Antiemetic Treatment in Women With Breast Cancer Treated With Neo- or Adjuvant Chemotherapy: A Randomised Multicentre Phase II Study. (EudraCT: 2015-000658-39).
Topics: Antiemetics; Antineoplastic Agents; Breast Neoplasms; Female; Fluorouracil; Humans; Nausea; Polymorp | 2023 |
Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; C | 2019 |
Bevacizumab in Combination With Either FOLFOX-4 or XELOX-2 in First-line Treatment of Patients With Metastatic Colorectal Cancer: A Multicenter Randomized Phase II Trial of the Gruppo Oncologico dell'Italia Meridionale (GOIM 2802).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Colorectal N | 2020 |
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast | 2020 |
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; | 2020 |
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne | 2020 |
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitan | 2021 |
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptot | 2021 |
Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplat | 2017 |
Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepit | 2018 |
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Camptothecin; Diarrhea; Drugs, Chinese Herbal; Femal | 2017 |
Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colore | 2019 |
Efficacy of nimotuzumab combined with docetaxel-cisplatin-fluorouracil regimen in treatment of advanced oral carcinoma.
Topics: Aged; Aged, 80 and over; Alopecia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemot | 2014 |
One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap | 2013 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Ca | 2013 |
Optimal control of nausea and vomiting with a three-drug antiemetic regimen with aprepitant in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Benztropine; Camptoth | 2013 |
[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2013 |
Efficacy and tolerability of chemotherapy with modified dose-dense TCF regimen (TCF-dd) in locally advanced or metastatic gastric cancer: final results of a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Docet | 2014 |
Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisp | 2016 |
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2014 |
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; De | 2014 |
Association of adverse events and survival in colorectal cancer patients treated with adjuvant 5-fluorouracil and leucovorin: Is efficacy an impact of toxicity?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal Neop | 2014 |
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients.
Topics: Administration, Cutaneous; Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined | 2015 |
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic | 2014 |
Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Topics: Adolescent; Adult; Aged; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined | 2015 |
Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Capecitabine; Colorectal Ne | 2015 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2016 |
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; | 2016 |
Oral intake of ginger for chemotherapy-induced nausea and vomiting among women with breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; | 2015 |
A phase I trial of mFOLFOX6 combined with the oral PI3K inhibitor BKM120 in patients with advanced refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; D | 2015 |
[Phase II clinical trial of two different modes of administration of the induction chemotherapy for locally advanced nasopharyngeal carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemoradiotherapy; Cisplatin; Docetaxel; | 2015 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Treatment results of alternating chemoradiotherapy with early assessment for advanced laryngeal cancer: A multi-institutional phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; C | 2017 |
[Gemcitabine combined with capecitabine in the treatment for 41 patients with relapsed or metastatic biliary tract carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrah | 2008 |
[Preliminary result of multi-center clinical trial on the docetaxel, 5-Fu and DDP in the treatment of advanced, recurrent or metastatic nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; C | 2008 |
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopl | 2009 |
Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Colorectal Neoplas | 2009 |
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro | 2009 |
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chem | 2009 |
A Phase II trial of the combination of vinorelbine and capecitabine as second-line treatment in metastatic breast cancer previously treated with taxanes and/or anthracyclines.
Topics: Adult; Aged; Anemia; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasm | 2010 |
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2009 |
Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Docetax | 2010 |
Phase II study of FOLFIRI regimen in patients with advanced colorectal cancer refractory to fluoropyrimidine and oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Colorectal Neoplas | 2011 |
Neoadjuvant chemotherapy followed by concurrent chemoradiation for locally advanced nasopharyngeal carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherapy | 2010 |
[Comparison of the therapeutic effects of paclitaxel liposome-5-Fu versus paclitaxel-5-Fu on 67 patients with advanced gastric cancer].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Pr | 2010 |
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2010 |
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 2010 |
A phase I study of the oral platinum agent satraplatin in sequential combination with capecitabine in the treatment of patients with advanced solid malignancies.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Dia | 2011 |
[Nedaplatin or cisplatin combined with 5-fluorouracil for treatment of stage III-IVa nasopharyngeal carcinoma: a randomized controlled study].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Humans; Lymp | 2011 |
A phase II study of capecitabine plus oxaliplatin as first-line chemotherapy in elderly patients with advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine | 2012 |
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 2012 |
Antiemetic control with palonosetron in patients with gastrointestinal cancer receiving a fluoropyrimidine-based regimen in addition to either irinotecan or oxaliplatin: a retrospective study.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidi | 2012 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis | 2013 |
Optimal dose period for indisetron tablets for preventing chemotherapy-induced nausea and vomiting with modified FOLFOX6: a randomized pilot study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bridged | 2012 |
Phase II trial of alternating mFOLFOX6 and FOLFIRI regimens in the first-line treatment for unresectable or metastatic colorectal cancer (KSCC0701).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dis | 2013 |
Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; | 2013 |
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Female; | 2002 |
Folinic acid, 5-fluorouracil and mitomycin C in metastatic breast cancer patients previously treated with at least two chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; | 2002 |
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D | 2002 |
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta | 2002 |
Reduced maintenance of complete protection from emesis for women during chemotherapy cycles.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 2003 |
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp | 2002 |
A phase I study of the trinuclear platinum compound, BBR 3464, in combination with protracted venous infusional 5-fluorouracil in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Fatigu | 2004 |
Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Blood; | 2004 |
A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metastatic colorectal cancer patients pretreated with 5-fluorouracil or raltitrexed.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch | 2004 |
Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docet | 2004 |
Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; | 2004 |
Dose escalation study on oxaliplatin and capecitabine (Xeloda) in patients with advanced solid tumors.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Cap | 2004 |
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; | 2004 |
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
Phase I study of the combination of nedaplatin, adriamycin and 5-fluorouracil for treatment of advanced esophageal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Doxorubici | 2004 |
Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Female; Fluoro | 2003 |
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined | 2004 |
Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2005 |
[Phase I study of the combination of nedaplatin (NED), adriamycin (ADM), and 5-fluorouracil (5-FU) (NAF) for treatment of unresectable advanced esophageal cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relati | 2005 |
A multicenter randomized study comparing 5-fluorouracil continuous infusion (ci) plus 1-hexylcarbamoyl-5-fluorouracil and 5-FU ci alone in colorectal cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Colore | 2005 |
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area | 2005 |
Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squam | 2005 |
[Clinical evaluation of chemotherapy with irinotecan (CPT-11), l-leucovorin (l-LV), 5-fluorouracil (5-FU), and UFT for metastatic or recurrent colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug A | 2005 |
An alternating regimen of irinotecan/ 5-fluorouracil/folinic acid and oxaliplatin/ 5-fluorouracil/folinic acid in metastatic colorectal cancer: a Phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2005 |
[A randomized crossover study of ramosetron plus dexamethasone for the prevention of nausea and vomiting induced by chemotherapy including cisplatin-comparison of ramosetron combined with 8 mg and 12 mg of dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, | 2005 |
Chronomodulated chemotherapy with oxaliplatin, 5-FU and sodium folinate in metastatic gastrointestinal cancer patients: original analysis of non-hematological toxicity and patient characteristics in a pilot investigation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Chronotherapy; Diarrhe | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Esop | 2006 |
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2006 |
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free S | 2006 |
[Phase II multicenter clinical trial of nedaplatin in the treatment of malignant tumors].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc | 2006 |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cape | 2006 |
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca | 2006 |
[Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Esophageal Ne | 2006 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
[Multicenter phase II study of modified FOLFIRI regimen in the advanced colorectal cancer patient refractory to fluoropyrimidine and oxaliplatin].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Co | 2006 |
[Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Disease-Free Surviva | 2007 |
[Clinical comparison of GC regimen (gemcitabine and cisplatin) versus FEC regimen (fluorouracil, epirubicin, and cyclophosphamide) as neoadjuvant chemotherapy for breast cancer].
Topics: Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cyclophosphamid | 2007 |
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisp | 2007 |
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F | 2007 |
Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Di | 2007 |
A Phase II study of oxaliplatin with low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) for gastric cancer patients with malignant ascites.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma; Disease-Fre | 2007 |
[Study on the efficacy and safety of high dose thymopentin combined with trans-artery chemoembolization for primary liver cancer].
Topics: Adjuvants, Immunologic; Adult; Aged; Asthenia; CD4-Positive T-Lymphocytes; Chemoembolization, Therap | 2007 |
Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
A randomized trial of five and three drug chemotherapy and chemoimmunotherapy in women with operable node positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; BCG Vaccine; Breast Neoplasms; | 1983 |
Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.
Topics: Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials a | 1984 |
A comparative study of oral tegafur and intravenous 5-fluorouracil in patients with metastatic colorectal cancer.
Topics: Administration, Oral; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Injections, | 1983 |
Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study.
Topics: Adenocarcinoma; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fluoroura | 1983 |
Randomized phase II studies in advanced colorectal carcinoma: a North Central Cancer Treatment Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Drug Evalu | 1983 |
Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count.
Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Diarrhea; Drug Therap | 1980 |
Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine.
Topics: Alopecia; Antineoplastic Agents; Asparaginase; Bacterial Vaccines; Blood Cell Count; Breast Neoplasm | 1980 |
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Aged; Agranulocytosis; Anorexia; Antineoplastic Agents; Clinical Trials as Topic; Do | 1980 |
Combination chemotherapy of advanced colorectal cancer with triazinate and ICRF-159 after failure of 5-Fluorouracil.
Topics: Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Drug Administration Schedule; Drug Therapy, C | 1980 |
Combination chemotherapy of advanced colorectal cancer utilizing 5-fluorouracil, semustine, dacarbazine, vincristine, and hydroxyurea: a phase III trial by the Eastern Cooperative Oncology Group (EST: 4275).
Topics: Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dacarbazine; Drug Administration | 1982 |
Anticipatory vomiting in women receiving cyclophosphamide, methotrexate, and 5-FU (CMF) adjuvant chemotherapy for breast carcinoma.
Topics: Activities of Daily Living; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1982 |
Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery.
Topics: Administration, Oral; Breast Neoplasms; Female; Fluorouracil; Humans; Injections, Intravenous; Leuko | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N | 1981 |
Salvage chemotherapy with PEM and long-CF regimen in CDDP refractory advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Admi | 1995 |
[Combination therapy with interferon-alpha and continuous infusion of 5-fluorouracil for advanced renal cell carcinoma].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Sch | 1995 |
[Comparison of granisetron alone and granisetron plus dexamethasone or hydroxyzine hydrochloride for the prevention of nausea and vomiting during chemotherapy including cisplatin].
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; | 1995 |
[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Topics: Adult; Aged; Anorexia; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorou | 1995 |
[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Dizziness; Dru | 1995 |
Phase I/II study of cisplatin, 5-fluorouracil and alpha-interferon for recurrent carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergism; Fluorouracil | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer.
Topics: Adjuvants, Immunologic; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antineoplast | 1994 |
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm | 1994 |
Delayed chemotherapy-induced nausea is augmented by high levels of endogenous noradrenaline.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circadian Rhythm; Cis | 1994 |
[Use of dexamethasone as an antiemetic in patients with breast cancer treated with the CMF regimen].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; F | 1994 |
A phase I/II study of 4'-O-tetrahydropyranyl-doxorubicin, 5-fluorouracil, and high-dose leucovorin as first-line therapy in advanced breast cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Doxorubicin | 1994 |
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Fem | 1994 |
[High dose cisplatin combination chemotherapy for advanced breast cancer--a report on 50 cases].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cisplatin; | 1993 |
Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1993 |
[Intermittent hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
Topics: Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intra-A | 1993 |
Ondansetron compared with dexamethasone and metoclopramide as antiemetics in the chemotherapy of breast cancer with cyclophosphamide, methotrexate, and fluorouracil.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha | 1993 |
Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study.
Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc | 1995 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemother | 1996 |
Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. A phase II study of the ONCOPAZ Cooperative Group.
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Anemia; Antidotes; Antimetabolites, Antineoplast | 1996 |
[Comparative trial of granisetron alone and granisetron plus methylprednisolone for prevention of nausea and vomiting during cancer chemotherapy].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Stud | 1996 |
Single 8 mg dose of oral ondansetron failed to prevent FAC chemotherapy-induced acute nausea and vomiting.
Topics: Acute Disease; Administration, Oral; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1996 |
[Combination therapy with 5-fluorouracil (5-FU), cisplatin (CDDP) and interferon alpha-2B (IFN alpha-2B) for advanced renal cell carcinoma].
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Ce | 1996 |
Phase II study of cisplatin, 5-fluorouracil, and leucovorin in inoperable squamous cell carcinoma of the esophagus. ONCOPAZ Cooperative Group, Spain.
Topics: Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combi | 1996 |
[Clinical evaluation of ondansetron suppository].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Humans; | 1997 |
[Clinical effect of two azasetron treatment methods against nausea and vomiting induced by anticancer drugs including CDDP].
Topics: Adult; Antiemetics; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cisplatin; Drug | 1997 |
[Comparison of effects between single vs five-day injection of granisetron for combination chemotherapy with cisplatin and 5-fluorouracil for head and neck cancer].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protoc | 1997 |
Metastatic breast cancer: treatment with fluorouracil-based combinations.
Topics: Adult; Aged; Anemia; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Di | 1997 |
[Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
Topics: Abdominal Pain; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Femal | 1997 |
[Efficacy of combination of ondansetron injection and tablet in CAF-induced emesis in breast cancer patients].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neop | 1998 |
Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Dacarbazine; Female; F | 1998 |
[A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1998 |
A crossover study of oral administration of UFT in chronic liver disease: comparison of continuous and intermittent schedules.
Topics: Administration, Oral; Aged; Area Under Curve; Carcinoma, Hepatocellular; Chronic Disease; Cross-Over | 1998 |
A phase II trial of cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine | 1998 |
Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe | 1998 |
Phase I and pharmacokinetic study of oral UFT, a combination of the 5-fluorouracil prodrug tegafur and uracil.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Cohor | 1996 |
A multicenter, phase II trial of weekly irinotecan (CPT-11) in patients with previously treated colorectal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 1999 |
[Treatment for advanced colorectal carcinoma with 5-fluorouracil plus low-dose leucovorin].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone | 1999 |
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1999 |
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Al | 1999 |
Phase II trial of docetaxel, cisplatin, fluorouracil, and leucovorin as induction for squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 1999 |
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp | 2000 |
The role of low dose cisplatin plus 5-fluorouracil for treatment of recurrent and/or advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, S | 2000 |
Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuv | 2000 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antimetabolites, Antineoplastic; Cap | 2001 |
5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Conjunctivitis; D | 2001 |
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chills; Combined Moda | 2001 |
Phase II trial of cisplatin, interferon alpha-2b, doxorubicin, and 5-fluorouracil for biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neopla | 2001 |
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2001 |
Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; D | 2002 |
Phase II study of a weekly 8-hour 5-fluorouracil and leucovorin infusion for patients with advanced colorectal cancer: dose adjusted according to its toxicity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Response Relati | 2001 |
[Combination chemotherapy with nedaplatin (CDGP) and 5-FU for oral cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Administ | 2002 |
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; DNA, Antise | 2002 |
Physical performance, toxicity, and quality of life as assessed by the physician and the patient.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols | 2002 |
Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; | 2002 |
Oral fluoropyrimidines in the treatment of advanced colorectal cancer--results of two consecutive phase II trials.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2002 |
Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide.
Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combina | 1977 |
Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
Topics: Adult; Aged; Antiemetics; Double-Blind Method; Dronabinol; Drug Evaluation; Fluorouracil; Gastrointe | 1979 |
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem | 1977 |
Oral benzquinamide in the treatment of nausea and vomiting.
Topics: Clinical Trials as Topic; Fluorouracil; Humans; Nausea; Prochlorperazine; Quinolizines; Vomiting | 1975 |
Treatment of recurrent head and neck cancer with cisplatin and 5-fluorouracil vs. the same plus bleomycin and methotrexate.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1992 |
Methylprednisolone as antiemetic treatment in breast-cancer patients receiving cyclophosphamide, methotrexate, and 5-fluorouracil: a prospective, crossover, randomized blind study comparing two different dose schedules.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Bl | 1992 |
5-Fluorouracil, etoposide, and cisplatin in the management of metastatic non-small cell lung cancer.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 1991 |
[Clinical effects and toxicity of chemotherapy with cisplatin for head and neck cancer--the multi-institutional joint research in Tokai district].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Female; Fluoroura | 1990 |
Double-blind randomized cross-over trial comparing methylprednisolone with placebo in chemotherapy-induced nausea and vomiting: a study with special reference to efficacy parameters.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Double-Blind Method; Female; | 1991 |
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cosyntropin; Cyclophosphamide; Epi | 1991 |
A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1991 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Brea | 1990 |
A phase III randomised trial of cistplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; F | 1990 |
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
[Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ | 1989 |
Concurrent chemotherapy and radiation therapy for limited unresectable non-small cell carcinoma of the lung. A phase I study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1988 |
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
A randomized comparison of haloperidol plus dexamethasone versus prochlorperazine plus dexamethasone in preventing nausea and vomiting in patients receiving chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclopho | 1988 |
Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with i.v. CMF.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as To | 1987 |
A randomised cross-over trial comparing low-dose metoclopramide and chlorpromazine with high-dose metoclopramide in Chinese patients with advanced cancer receiving cisplatinum and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chlorpromazine; Cisplatin; Clinical Tri | 1987 |
Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide methotrexate 5-fluorouracil: a double-blind randomized study.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1988 |
[A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxoru | 1986 |
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do | 1985 |
Mitoxantrone: an overview of safety and toxicity.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Clini | 1985 |
A randomized multicenter trial of cyclophosphamide, Novantrone and 5-fluorouracil (CNF) versus cyclophosphamide, Adriamycin and 5-fluorouracil (CAF) in patients with metastatic breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; | 1985 |
A randomized trial of cisplatin (CACP) + 5-fluorouracil (5-FU) infusion and CACP + 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials | 1985 |
[Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
Topics: Adult; Anorexia; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy | 1985 |
Controlled studies of metopimazine for the treatment of nausea and vomiting.
Topics: Antiemetics; Clinical Trials as Topic; Fluorouracil; Humans; Isonipecotic Acids; Nausea; Neoplasms; | 1973 |
Fluorouracil, imidazole carboxamide dimethyl triazeno, vincristine, and bis-chloroethyl nitrosourea in colon cancer.
Topics: Alopecia; Amides; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Colonic Neoplasms; Dr | 1974 |
Experience with furanidyl-fluorouracil in advanced tumours of the breast.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; Feeding and Eating Disorde | 1974 |
A clinical study of fluorouracil.
Topics: Adult; Aged; Clinical Trials as Topic; Diarrhea; Female; Fluorouracil; Follow-Up Studies; Humans; Le | 1968 |
149 other studies available for fluorouracil and Nausea
| Article | Year |
|---|---|
NEPA (netupitant/palonosetron) for the antiemetic prophylaxis of nausea and vomiting induced by chemotherapy (CINV) with Folfirinox and Folfoxiri even during the COVID-19 pandemic: a real-life study.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms | 2021 |
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Ph | 2021 |
Treatment Patterns, Toxicity, and Outcomes of Older Adults With Advanced Pancreatic Cancer Receiving First-line Palliative Chemotherapy.
Topics: Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Fluorouracil; | 2022 |
Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?
Topics: Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug-Related | 2022 |
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives; | 2022 |
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Camptothecin; Capecit | 2021 |
Adverse reactions and adherence to capecitabine: A prospective study in patients with gastrointestinal cancer.
Topics: Aged; Capecitabine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged; Nausea; Pro | 2022 |
Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; De | 2021 |
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H | 2021 |
Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Dihydrouracil Dehydrogenase (NADP); F | 2017 |
[Determination of the Effect of Aprepitant and Fosaprepitant for Nausea in Patients with Oral Cancer Receiving Combination Chemotherapy with TPF].
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Docetaxel; | 2017 |
TYMS Gene Polymorphisms in Breast Cancer Patients Receiving 5-Fluorouracil-Based Chemotherapy.
Topics: Adult; Antimetabolites, Antineoplastic; Breast; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, B | 2018 |
Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Chemoradiotherapy; Ci | 2018 |
Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Arthr | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials.
Topics: Aged; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile | 2019 |
Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
Topics: Aged; Albumins; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Community He | 2019 |
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast | 2013 |
Antiemetic prophylaxis and frequency of chemotherapy-induced nausea and vomiting in palliative first-line treatment of colorectal cancer patients: the Northern Bavarian IVOPAK I Project.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2013 |
Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro | 2013 |
Longitudinal assessments of quality of life and late toxicities before and after definitive chemoradiation for esophageal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Esophageal Neoplasms | 2014 |
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl | 2013 |
[Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Brea | 2013 |
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabi | 2013 |
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Adherence to capecitabine treatment and contributing factors among cancer patients in Malaysia.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cross-Sectional Studies; | 2014 |
Efficacy of aprepitant for nausea in patients with head and neck cancer receiving daily cisplatin therapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; | 2014 |
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2015 |
[Determination of the Appropriate Timing of Aprepitant Administration for Nausea in Patients with Head and Neck Cancer Receiving Combination Chemotherapy with Docetaxel, Nedaplatin（Divided Doses for 5 Days), and 5-fluorouracil].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Docetaxel; Female; Fluorouracil; H | 2015 |
[A Case of Consciousness Disturbance Caused by Hyperammonemia during a mFOLFOX6 Regimen for Metastatic Colon Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Colectomy; Consciousness; Fem | 2015 |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Ne | 2017 |
[Predictive factors of nausea/vomiting of breast cancer patients receiving FEC and AC chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dox | 2008 |
Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
Topics: Adult; Aged; Antiemetics; Benzimidazoles; Biliary Tract Neoplasms; Chemotherapy, Adjuvant; Female; F | 2009 |
[Report of a case effectively treated by appropriate therapy for severe anticipatory nausea and vomiting due to FOLFOX or FOLFIRI].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Male | 2009 |
Severe hiccups during chemotherapy: corticosteroids the likely culprit.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Antidotes; Antiemetics; Antimetabolites, Antineoplas | 2009 |
[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junctio | 2009 |
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato | 2011 |
Comparison of four cisplatin-based radiochemotherapy regimens for nonmetastatic stage III/IV squamous cell carcinoma of the head and neck.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp | 2011 |
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
Topics: Adult; Antimetabolites, Antineoplastic; Carcinoma, Hepatocellular; Chemoradiotherapy; Duodenal Ulcer | 2011 |
Health-related quality of life after chemotherapy cycle in breast cancer in Iran.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cognition Disorders; | 2011 |
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju | 2011 |
[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case].
Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Female; Flu | 2010 |
Prospective evaluation of the incidence of delayed nausea and vomiting in patients with colorectal cancer receiving oxaliplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents, Phytogenic; Colorectal Neoplasms | 2012 |
[Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo | 2011 |
Self-reported compliance with capecitabine: findings from a prospective cohort analysis.
Topics: Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine; Diarrhea; Fema | 2011 |
[Efficacy and safety of aprepitant in patients with breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophos | 2011 |
[Induced nausea and vomiting induced by mFOLFOX6 and FOLFIRI with advanced colorectal cancer: a retrospective survey].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; | 2011 |
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2012 |
[Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Ci | 2011 |
Adverse event profiles of 5-fluorouracil and capecitabine: data mining of the public version of the FDA Adverse Event Reporting System, AERS, and reproducibility of clinical observations.
Topics: Adverse Drug Reaction Reporting Systems; Capecitabine; Data Mining; Deoxycytidine; Diarrhea; Fluorou | 2012 |
[Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 2012 |
[Antiemetic effect of palonosetron in advanced colorectal cancer patients receiving mFOLFOX6 and FOLFIRI: a retrospective survey].
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptot | 2012 |
Population pharmacokinetic analysis of 5-FU and 5-FDHU in colorectal cancer patients: search for biomarkers associated with gastro-intestinal toxicity.
Topics: Aged; Biomarkers; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diarrhea; Female; Fluorouracil; Huma | 2012 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; | 2013 |
Weekly hepatic arterial infusion of 5-fluorouracil and subsequent systemic chemotherapy for liver metastases from colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; | 2003 |
Irinotecan (CPT11) plus high-dose 5-fluorouracil (5-FU) and leucovorin (LV) as salvage therapy for metastatic colorectal cancer (MCRC) after failed oxaliplatin plus 5-FU and LV: a pilot study in Taiwan.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Adminis | 2003 |
EFFECTS OF 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) AND 5-FLUOROURACIL (NSC-19893) ON CHILDHOOD LEUKEMIA.
Topics: Bone Marrow Examination; Child; Floxuridine; Fluorouracil; Leukemia; Leukopenia; Melena; Nausea; Tox | 1964 |
COMPARISON OF HIGH-DOSAGE AND LOW-DOSAGE-MAINTENANCE THERAPY WITH 5-FLUOROURACIL IN SOLID TUMORS.
Topics: Diarrhea; Fluorouracil; Humans; Nausea; Neoplasms; Stomatitis; Toxicology; Vomiting | 1964 |
CURRENT STATUS OF 5-FLUOROURACIL THERAPY IN FAR-ADVANCED NEOPLASTIC DISEASE.
Topics: Alopecia; Chlorpromazine; Diarrhea; Erythema; Fluorouracil; Leukopenia; Nausea; Neoplasms; Thrombocy | 1964 |
FLUORINATED PYRIMIDINE THERAPY OF ADVANCED GASTROINTESTINAL CANCER.
Topics: Alopecia; Colonic Neoplasms; Drug Eruptions; Esophagitis; Fluorouracil; Gallbladder Neoplasms; Human | 1964 |
[DIGESTIVE INTOLERANCE TO DIGITALIN, CYTOSTATIC DRUGS AND VARIOUS THERAPEUTIC DRUGS. THEIR TREATMENT WITH METHOCLOPRAMIDE].
Topics: Antiemetics; Antitubercular Agents; Cobalt Isotopes; Cyclophosphamide; Cytostatic Agents; Digitalis | 1964 |
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo | 1964 |
Weekly high-dose 5-fluorouracil as 24-h infusion and folinic acid (AIO) plus irinotecan as second- and third-line treatment in patients with colorectal cancer pre-treated with AIO plus oxaliplatin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2003 |
[Preliminary evaluation of chemotherapy with docetaxel, 5-FU, CDDP for recurrent esophageal cancer--a pilot study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Sche | 2003 |
[Relationship of methylenetetrahydrofolate reductase C677T polymorphism and chemosensitivity to 5-fluorouracil in gastric carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Male; Met | 2004 |
[Oxaliplatin plus capecitabine as a second line chemotherapy for patients with advanced gastric cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Admin | 2004 |
[Effect of steroid on antiemetic for side effect of anticancer chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dexamethasone; Drug Administration S | 2005 |
[Relationship of serum level of dihydropyrimidine dehydrogenase and serum concentration of 5-fluorouracil to treatment response and adverse events in colorectal cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diarrhea; Dihydroura | 2005 |
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl | 2005 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breas | 2006 |
Peritoneal dissemination of hepatocellular carcinoma treated with a combination therapy of interferon-alpha-2b and oral tegafur/uracil.
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C | 2007 |
[Nedaplatin (NDP)-combination therapy (NDP/5-FU,NDP/S-1) for oral cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols | 2007 |
[The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2007 |
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2007 |
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N | 2007 |
Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dia | 2007 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2007 |
Chemotherapy-induced nausea, vomiting, and fatigue--the role of individual differences related to sensory perception and autonomic reactivity.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Arousal; Autonomic Nervous Sys | 2007 |
Optimal schedule of methotrexate and 5-fluorouracil in human breast cancer.
Topics: Breast Neoplasms; Cell Line; Drug Administration Schedule; Drug Evaluation; Drug Interactions; Drug | 1982 |
Weekly large fraction radiotherapy and 5 fluorouracil as a palliative treatment for large bowel carcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Diarrhea; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large; | 1982 |
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu | 1982 |
Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Neoplasms; | 1984 |
Phase I evaluation of oral tegafur.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio | 1983 |
[Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Pr | 1983 |
Phase I-II studies of oral tegafur (ftorafur).
Topics: Administration, Oral; Bone Marrow; Breast Neoplasms; Colonic Neoplasms; Dose-Response Relationship, | 1983 |
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev | 1983 |
Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Nausea | 1980 |
Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neopla | 1984 |
Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration S | 1984 |
Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Breast Neoplasms; Cy | 1984 |
Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans.
Topics: Adult; Aged; Drug Evaluation; Drug Synergism; Female; Fluorouracil; Gastrointestinal Neoplasms; Huma | 1983 |
Combination chemotherapy including adriamycin for advanced transitional cell carcinoma of the urinary tract.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Transitional Ce | 1983 |
High-dose cyclophosphamide and high-dose 5-fluorouracil. A new first-line regimen for advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; | 1984 |
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; | 1981 |
Adjuvant chemotherapy (CMF) for breast carcinoma: hematological side effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Breast Neoplasms; Carcinoma; Cyclophosp | 1982 |
Combination chemotherapy in advanced carcinoma of the cervix.
Topics: Alopecia; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Hum | 1982 |
Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study.
Topics: Aged; Alopecia; Breast Neoplasms; Chlorambucil; Drug Therapy, Combination; Female; Fluorouracil; Hum | 1982 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1995 |
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S | 1993 |
Trait anxiety and anticipatory immune reactions in women receiving adjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Breast Neoplasms; Chemotherapy | 1993 |
Neoadjuvant chemotherapy in locally advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breas | 1996 |
[CF/5-FU-DDP therapy for esophageal carcinoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Es | 1995 |
[Antiemetic efficacy of granisetron in repeated CAF chemotherapy after breast cancer operation].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclopho | 1997 |
Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carmustine; Cisplatin; Comb | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
Mitomycin C, cisplatin, and 5-fluorouracil for advanced and/or recurrent head and neck squamous cell carcinomas.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; An | 1997 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
Biochemical modulation in the treatment of advanced cancer: a study of combined leucovorin, fluorouracil, and iododeoxyuridine.
Topics: Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as | 1996 |
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di | 1998 |
[Effects of intravenous and oral administration of ondansetron hydrochloride on chemotherapy-induced nausea and vomiting in patients with esophageal cancer].
Topics: Administration, Oral; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 1999 |
[5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer].
Topics: Actuarial Analysis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 1999 |
[Chronological observation of nausea and vomiting in outpatients given oral antimetabolites as chemotherapy--two patients receiving ondansetron hydrochloride tablets].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Antiemetics; Antimetabolites, Antineoplastic; Br | 2000 |
Idiosyncratic reaction after oxaliplatin infusion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chills; Fever; Fluorouracil; | 2001 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Com | 2001 |
Manifest Anxiety Scale for evaluation of effects of granisetron in chemotherapy with CDDP and 5FU for head and neck cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Prot | 2001 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breas | 2002 |
[Incidence of emesis in outpatients on chemotherapy for breast cancer and the clinical efficacy of ondansetron hydrochloride tablets].
Topics: Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cycl | 2002 |
Chemotherapy of common solid tumours in a general surgical unit.
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Interactions; Drug Syne | 1979 |
Phase II study of adriamycin, 5-fluorouracil, levamisole, and irradiation in carcinoma of the bladder.
Topics: Bone Marrow; Carcinoma, Transitional Cell; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; | 1979 |
Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infus | 1979 |
Toxicity and side-effects of combination chemohormonal therapy of advanced breast cancer.
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therap | 1992 |
Progressive loss of antiemetic efficacy during subsequent courses of chemotherapy.
Topics: Adult; Aged; Amitriptyline; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosph | 1992 |
Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.
Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethas | 1991 |
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru | 1991 |
Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chi-Square Distributi | 1991 |
[Adverse reactions to carcinostatics and countermeasures].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Chemical and Drug Indu | 1989 |
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche | 1989 |
Mitoxantrone, 5-fluorouracil and cyclophosphamide in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph | 1988 |
A phase II clinical trial of flutamide in the treatment of advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Breast Neoplasms; Cyclophospha | 1988 |
[The prevention of CDDP-induced emesis with a combination regimen including metoclopramide, dexamethasone, droperidol and diphenhydramine].
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dex | 1987 |
Results in the management of locally unresectable pancreatic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Fluo | 1986 |
High-dose continuous infusion folinic acid and bolus 5-fluorouracil in patients with advanced colorectal cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation; Fem | 1986 |
Stimulus control of anticipatory nausea in cancer chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chlorpromazine; Combined Modality | 1987 |
Simultaneous cisplatin and 5-fluorouracil as second-line treatment of head and neck cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Fe | 1987 |
High-dose metoclopramide and dexamethasone as an antiemetic in outpatients receiving chemotherapy for breast cancer. Second study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati | 1987 |
Tastes associated with parenteral chemotherapy for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; Fluorour | 1985 |
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; | 1985 |
The effect of a susceptibility to motion sickness on the side effects of cancer chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Susceptibilit | 1985 |
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Anthraquinones; Antineoplastic Agents; Bone Marrow; Breast Neoplasms; Cycloph | 1985 |
[590-S].
Topics: Administration, Oral; Adult; Animals; Anorexia; Antineoplastic Agents; Drug Administration Schedule; | 1985 |
Phase I and pharmacologic study of 72-hour infused 5-fluorouracil in man.
Topics: Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Parenteral; Male; Nausea; Neoplasms; Neutr | 1985 |
Elemental diet in the management of the intestinal lesion produced by 5-fluorouracil in man.
Topics: Aged; Amino Acids; Animals; Biopsy; Diarrhea; Diet Therapy; Dietary Proteins; Female; Fluorouracil; | 1971 |
Combination chemotherapy in gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall | 1970 |
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc | 1974 |
Combination chemotherapy in disseminated carcinoma of the breast.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Evaluation Stu | 1974 |
Results in fifty cases of advanced squamous cell carcinoma of the head and neck treated by intravenous chemotherapy.
Topics: Adult; Aged; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Combinations; Epiglottis; Female; Fluo | 1973 |
Toxicity studies of fluorouracil used with adrenalectomy in breast cancer.
Topics: Adrenalectomy; Adult; Aged; Alopecia; Ataxia; Blood Platelet Disorders; Breast Neoplasms; Diarrhea; | 1972 |
5-fluorouracil intravenous infusion for 48 hours, repeated every two weeks.
Topics: Adult; Aged; Breast Neoplasms; Diarrhea; Evaluation Studies as Topic; Female; Fluorouracil; Gastroin | 1972 |
Oral administration of fluorouracil. A preliminary trial.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci | 1968 |